id	sid	tid	token	lemma	pos
dpc-1631	1	1	dermatology	dermatology	NOUN
dpc-1631	1	2	:	:	PUNCT
dpc-1631	1	3	practical	practical	ADJ
dpc-1631	1	4	and	and	CCONJ
dpc-1631	1	5	conceptual	conceptual	ADJ
dpc-1631	1	6	dermatology	dermatology	NOUN
dpc-1631	1	7	practical	practical	ADJ
dpc-1631	1	8	&	&	CCONJ
dpc-1631	1	9	conceptual	conceptual	ADJ
dpc-1631	1	10	review	review	NOUN
dpc-1631	1	11	|	|	ADV
dpc-1631	1	12	dermatol	dermatol	ADJ
dpc-1631	1	13	pract	pract	NOUN
dpc-1631	1	14	concept	concept	NOUN
dpc-1631	1	15	.	.	PUNCT
dpc-1631	2	1	2021;11(4	2021;11(4	NUM
dpc-1631	2	2	):	):	PUNCT
dpc-1631	2	3	e2021106	e2021106	NOUN
dpc-1631	2	4	1	1	NUM
dpc-1631	2	5	body	body	NOUN
dpc-1631	2	6	mass	mass	NOUN
dpc-1631	2	7	index	index	NOUN
dpc-1631	2	8	and	and	CCONJ
dpc-1631	2	9	melanoma	melanoma	NOUN
dpc-1631	2	10	prognosis	prognosis	NOUN
dpc-1631	2	11	nicoletta	nicoletta	PROPN
dpc-1631	2	12	cassano1,2	cassano1,2	PROPN
dpc-1631	2	13	,	,	PUNCT
dpc-1631	2	14	stefano	stefano	PROPN
dpc-1631	2	15	caccavale3	caccavale3	PROPN
dpc-1631	2	16	,	,	PUNCT
dpc-1631	2	17	gino	gino	PROPN
dpc-1631	2	18	a.	a.	PROPN
dpc-1631	2	19	vena1,2	vena1,2	PROPN
dpc-1631	2	20	,	,	PUNCT
dpc-1631	2	21	giuseppe	giuseppe	PROPN
dpc-1631	2	22	argenziano3	argenziano3	PROPN
dpc-1631	2	23	1	1	NUM
dpc-1631	2	24	dermatology	dermatology	NOUN
dpc-1631	2	25	and	and	CCONJ
dpc-1631	2	26	venereology	venereology	NOUN
dpc-1631	2	27	private	private	ADJ
dpc-1631	2	28	practice	practice	NOUN
dpc-1631	2	29	,	,	PUNCT
dpc-1631	2	30	bari	bari	NOUN
dpc-1631	2	31	,	,	PUNCT
dpc-1631	2	32	italy	italy	PROPN
dpc-1631	2	33	2	2	NUM
dpc-1631	2	34	dermatology	dermatology	NOUN
dpc-1631	2	35	and	and	CCONJ
dpc-1631	2	36	venereology	venereology	NOUN
dpc-1631	2	37	private	private	ADJ
dpc-1631	2	38	practice	practice	NOUN
dpc-1631	2	39	,	,	PUNCT
dpc-1631	2	40	barletta	barletta	PROPN
dpc-1631	2	41	,	,	PUNCT
dpc-1631	2	42	italy	italy	PROPN
dpc-1631	2	43	3	3	NUM
dpc-1631	2	44	dermatology	dermatology	NOUN
dpc-1631	2	45	unit	unit	NOUN
dpc-1631	2	46	,	,	PUNCT
dpc-1631	2	47	university	university	PROPN
dpc-1631	2	48	of	of	ADP
dpc-1631	2	49	campania	campania	PROPN
dpc-1631	2	50	luigi	luigi	PROPN
dpc-1631	2	51	vanvitelli	vanvitelli	PROPN
dpc-1631	2	52	,	,	PUNCT
dpc-1631	2	53	naples	naples	PROPN
dpc-1631	2	54	,	,	PUNCT
dpc-1631	2	55	italy	italy	PROPN
dpc-1631	2	56	key	key	ADJ
dpc-1631	2	57	words	word	NOUN
dpc-1631	2	58	:	:	PUNCT
dpc-1631	2	59	cutaneous	cutaneous	ADJ
dpc-1631	2	60	melanoma	melanoma	NOUN
dpc-1631	2	61	,	,	PUNCT
dpc-1631	2	62	body	body	NOUN
dpc-1631	2	63	mass	mass	PROPN
dpc-1631	2	64	index	index	NOUN
dpc-1631	2	65	,	,	PUNCT
dpc-1631	2	66	breslow	breslow	ADJ
dpc-1631	2	67	thickness	thickness	NOUN
dpc-1631	2	68	,	,	PUNCT
dpc-1631	2	69	obesity	obesity	NOUN
dpc-1631	2	70	citation	citation	NOUN
dpc-1631	2	71	:	:	PUNCT
dpc-1631	2	72	cassano	cassano	PROPN
dpc-1631	2	73	n	n	PROPN
dpc-1631	2	74	,	,	PUNCT
dpc-1631	2	75	caccavale	caccavale	PROPN
dpc-1631	2	76	s	s	PROPN
dpc-1631	2	77	,	,	PUNCT
dpc-1631	2	78	vena	vena	PROPN
dpc-1631	2	79	ga	ga	PROPN
dpc-1631	2	80	,	,	PUNCT
dpc-1631	2	81	argenziano	argenziano	ADJ
dpc-1631	2	82	g.	g.	PROPN
dpc-1631	2	83	body	body	PROPN
dpc-1631	2	84	mass	mass	PROPN
dpc-1631	2	85	index	index	NOUN
dpc-1631	2	86	and	and	CCONJ
dpc-1631	2	87	melanoma	melanoma	NOUN
dpc-1631	2	88	prognosis	prognosis	NOUN
dpc-1631	2	89	.	.	PUNCT
dpc-1631	3	1	dermatol	dermatol	NOUN
dpc-1631	3	2	pract	pract	PROPN
dpc-1631	3	3	concept	concept	NOUN
dpc-1631	3	4	.	.	PUNCT
dpc-1631	4	1	2021;11(4	2021;11(4	NUM
dpc-1631	4	2	):	):	PUNCT
dpc-1631	4	3	e2021106	e2021106	NOUN
dpc-1631	4	4	.	.	PUNCT
dpc-1631	5	1	doi	doi	NOUN
dpc-1631	5	2	:	:	PUNCT
dpc-1631	5	3	https://doi.org/10.5826/dpc.1104a106	https://doi.org/10.5826/dpc.1104a106	NOUN
dpc-1631	5	4	accepted	accept	VERB
dpc-1631	5	5	:	:	PUNCT
dpc-1631	5	6	march	march	PROPN
dpc-1631	5	7	5	5	NUM
dpc-1631	5	8	,	,	PUNCT
dpc-1631	5	9	2021	2021	NUM
dpc-1631	5	10	;	;	PUNCT
dpc-1631	5	11	published	publish	VERB
dpc-1631	5	12	:	:	PUNCT
dpc-1631	6	1	september	september	PROPN
dpc-1631	6	2	2021	2021	NUM
dpc-1631	6	3	copyright	copyright	NOUN
dpc-1631	6	4	:	:	PUNCT
dpc-1631	6	5	©	©	PROPN
dpc-1631	6	6	2021	2021	NUM
dpc-1631	6	7	cassano	cassano	X
dpc-1631	6	8	et	et	PROPN
dpc-1631	6	9	al	al	PROPN
dpc-1631	6	10	.	.	PUNCT
dpc-1631	7	1	this	this	PRON
dpc-1631	7	2	is	be	AUX
dpc-1631	7	3	an	an	DET
dpc-1631	7	4	open	open	ADJ
dpc-1631	7	5	-	-	PUNCT
dpc-1631	7	6	access	access	NOUN
dpc-1631	7	7	article	article	NOUN
dpc-1631	7	8	distributed	distribute	VERB
dpc-1631	7	9	under	under	ADP
dpc-1631	7	10	the	the	DET
dpc-1631	7	11	terms	term	NOUN
dpc-1631	7	12	of	of	ADP
dpc-1631	7	13	the	the	DET
dpc-1631	7	14	creative	creative	ADJ
dpc-1631	7	15	commons	common	NOUN
dpc-1631	7	16	attribution	attribution	NOUN
dpc-1631	7	17	license	license	NOUN
dpc-1631	7	18	by	by	ADP
dpc-1631	7	19	-	-	PUNCT
dpc-1631	7	20	nc-4.0	nc-4.0	NOUN
dpc-1631	7	21	,	,	PUNCT
dpc-1631	7	22	which	which	PRON
dpc-1631	7	23	permits	permit	VERB
dpc-1631	7	24	unrestricted	unrestricted	ADJ
dpc-1631	7	25	noncommercial	noncommercial	ADJ
dpc-1631	7	26	use	use	NOUN
dpc-1631	7	27	,	,	PUNCT
dpc-1631	7	28	distribution	distribution	NOUN
dpc-1631	7	29	,	,	PUNCT
dpc-1631	7	30	and	and	CCONJ
dpc-1631	7	31	reproduction	reproduction	NOUN
dpc-1631	7	32	in	in	ADP
dpc-1631	7	33	any	any	DET
dpc-1631	7	34	medium	medium	NOUN
dpc-1631	7	35	,	,	PUNCT
dpc-1631	7	36	provided	provide	VERB
dpc-1631	7	37	the	the	DET
dpc-1631	7	38	original	original	ADJ
dpc-1631	7	39	authors	author	NOUN
dpc-1631	7	40	and	and	CCONJ
dpc-1631	7	41	source	source	NOUN
dpc-1631	7	42	are	be	AUX
dpc-1631	7	43	credited	credit	VERB
dpc-1631	7	44	.	.	PUNCT
dpc-1631	8	1	funding	funding	NOUN
dpc-1631	8	2	:	:	PUNCT
dpc-1631	8	3	none	none	NOUN
dpc-1631	8	4	.	.	PUNCT
dpc-1631	9	1	competing	compete	VERB
dpc-1631	9	2	interests	interest	NOUN
dpc-1631	9	3	:	:	PUNCT
dpc-1631	9	4	the	the	DET
dpc-1631	9	5	authors	author	NOUN
dpc-1631	9	6	have	have	VERB
dpc-1631	9	7	no	no	DET
dpc-1631	9	8	conflicts	conflict	NOUN
dpc-1631	9	9	of	of	ADP
dpc-1631	9	10	interest	interest	NOUN
dpc-1631	9	11	to	to	PART
dpc-1631	9	12	disclose	disclose	VERB
dpc-1631	9	13	.	.	PUNCT
dpc-1631	10	1	authorship	authorship	NOUN
dpc-1631	10	2	:	:	PUNCT
dpc-1631	10	3	all	all	DET
dpc-1631	10	4	authors	author	NOUN
dpc-1631	10	5	have	have	AUX
dpc-1631	10	6	contributed	contribute	VERB
dpc-1631	10	7	significantly	significantly	ADV
dpc-1631	10	8	to	to	ADP
dpc-1631	10	9	this	this	DET
dpc-1631	10	10	publication	publication	NOUN
dpc-1631	10	11	.	.	PUNCT
dpc-1631	11	1	corresponding	correspond	VERB
dpc-1631	11	2	author	author	NOUN
dpc-1631	11	3	:	:	PUNCT
dpc-1631	11	4	stefano	stefano	PROPN
dpc-1631	11	5	caccavale	caccavale	PROPN
dpc-1631	11	6	,	,	PUNCT
dpc-1631	11	7	md	md	PROPN
dpc-1631	11	8	,	,	PUNCT
dpc-1631	11	9	dermatology	dermatology	NOUN
dpc-1631	11	10	unit	unit	NOUN
dpc-1631	11	11	,	,	PUNCT
dpc-1631	11	12	department	department	NOUN
dpc-1631	11	13	of	of	ADP
dpc-1631	11	14	mental	mental	ADJ
dpc-1631	11	15	and	and	CCONJ
dpc-1631	11	16	physical	physical	ADJ
dpc-1631	11	17	health	health	NOUN
dpc-1631	11	18	and	and	CCONJ
dpc-1631	11	19	preventive	preventive	ADJ
dpc-1631	11	20	medicine	medicine	NOUN
dpc-1631	11	21	,	,	PUNCT
dpc-1631	11	22	university	university	PROPN
dpc-1631	11	23	of	of	ADP
dpc-1631	11	24	campania	campania	PROPN
dpc-1631	11	25	luigi	luigi	PROPN
dpc-1631	11	26	vanvitelli	vanvitelli	PROPN
dpc-1631	11	27	,	,	PUNCT
dpc-1631	11	28	via	via	ADP
dpc-1631	11	29	sergio	sergio	PROPN
dpc-1631	11	30	pansini	pansini	PROPN
dpc-1631	11	31	,	,	PUNCT
dpc-1631	11	32	5	5	NUM
dpc-1631	11	33	,	,	PUNCT
dpc-1631	11	34	80131	80131	NUM
dpc-1631	11	35	naples	naples	PROPN
dpc-1631	11	36	,	,	PUNCT
dpc-1631	11	37	italy	italy	PROPN
dpc-1631	11	38	.	.	PUNCT
dpc-1631	12	1	email	email	NOUN
dpc-1631	12	2	:	:	PUNCT
dpc-1631	13	1	stefano85med@gmail.com	stefano85med@gmail.com	X
dpc-1631	13	2	introduction	introduction	NOUN
dpc-1631	13	3	:	:	PUNCT
dpc-1631	13	4	obesity	obesity	NOUN
dpc-1631	13	5	has	have	AUX
dpc-1631	13	6	been	be	AUX
dpc-1631	13	7	suggested	suggest	VERB
dpc-1631	13	8	as	as	ADP
dpc-1631	13	9	a	a	DET
dpc-1631	13	10	risk	risk	NOUN
dpc-1631	13	11	factor	factor	NOUN
dpc-1631	13	12	in	in	ADP
dpc-1631	13	13	the	the	DET
dpc-1631	13	14	progression	progression	NOUN
dpc-1631	13	15	of	of	ADP
dpc-1631	13	16	malignancies	malignancy	NOUN
dpc-1631	13	17	,	,	PUNCT
dpc-1631	13	18	including	include	VERB
dpc-1631	13	19	melanoma	melanoma	NOUN
dpc-1631	13	20	.	.	PUNCT
dpc-1631	14	1	most	most	ADJ
dpc-1631	14	2	studies	study	NOUN
dpc-1631	14	3	defined	define	VERB
dpc-1631	14	4	obesity	obesity	NOUN
dpc-1631	14	5	using	use	VERB
dpc-1631	14	6	body	body	NOUN
dpc-1631	14	7	mass	mass	NOUN
dpc-1631	14	8	index	index	NOUN
dpc-1631	14	9	(	(	PUNCT
dpc-1631	14	10	bmi	bmi	PROPN
dpc-1631	14	11	)	)	PUNCT
dpc-1631	14	12	,	,	PUNCT
dpc-1631	14	13	although	although	SCONJ
dpc-1631	14	14	the	the	DET
dpc-1631	14	15	index	index	NOUN
dpc-1631	14	16	is	be	AUX
dpc-1631	14	17	considered	consider	VERB
dpc-1631	14	18	an	an	DET
dpc-1631	14	19	imperfect	imperfect	ADJ
dpc-1631	14	20	measure	measure	NOUN
dpc-1631	14	21	of	of	ADP
dpc-1631	14	22	body	body	NOUN
dpc-1631	14	23	composition	composition	NOUN
dpc-1631	14	24	.	.	PUNCT
dpc-1631	15	1	objective	objective	NOUN
dpc-1631	15	2	:	:	PUNCT
dpc-1631	15	3	the	the	DET
dpc-1631	15	4	aim	aim	NOUN
dpc-1631	15	5	of	of	ADP
dpc-1631	15	6	this	this	DET
dpc-1631	15	7	article	article	NOUN
dpc-1631	15	8	is	be	AUX
dpc-1631	15	9	to	to	PART
dpc-1631	15	10	examine	examine	VERB
dpc-1631	15	11	whether	whether	SCONJ
dpc-1631	15	12	bmi	bmi	NOUN
dpc-1631	15	13	can	can	AUX
dpc-1631	15	14	impact	impact	VERB
dpc-1631	15	15	on	on	ADP
dpc-1631	15	16	the	the	DET
dpc-1631	15	17	prognosis	prognosis	NOUN
dpc-1631	15	18	of	of	ADP
dpc-1631	15	19	cutaneous	cutaneous	ADJ
dpc-1631	15	20	melanoma	melanoma	NOUN
dpc-1631	15	21	,	,	PUNCT
dpc-1631	15	22	regardless	regardless	ADV
dpc-1631	15	23	of	of	ADP
dpc-1631	15	24	anti	anti	ADJ
dpc-1631	15	25	-	-	ADJ
dpc-1631	15	26	tumor	tumor	ADJ
dpc-1631	15	27	therapy	therapy	NOUN
dpc-1631	15	28	.	.	PUNCT
dpc-1631	16	1	the	the	DET
dpc-1631	16	2	relationship	relationship	NOUN
dpc-1631	16	3	between	between	ADP
dpc-1631	16	4	bmi	bmi	NOUN
dpc-1631	16	5	and	and	CCONJ
dpc-1631	16	6	specific	specific	ADJ
dpc-1631	16	7	prognostic	prognostic	ADJ
dpc-1631	16	8	factors	factor	NOUN
dpc-1631	16	9	in	in	ADP
dpc-1631	16	10	melanoma	melanoma	NOUN
dpc-1631	16	11	patients	patient	NOUN
dpc-1631	16	12	has	have	AUX
dpc-1631	16	13	been	be	AUX
dpc-1631	16	14	reviewed	review	VERB
dpc-1631	16	15	.	.	PUNCT
dpc-1631	17	1	methods	method	NOUN
dpc-1631	17	2	:	:	PUNCT
dpc-1631	17	3	literature	literature	NOUN
dpc-1631	17	4	search	search	NOUN
dpc-1631	17	5	was	be	AUX
dpc-1631	17	6	conducted	conduct	VERB
dpc-1631	17	7	on	on	ADP
dpc-1631	17	8	pubmed	pubmed	PROPN
dpc-1631	17	9	using	use	VERB
dpc-1631	17	10	the	the	DET
dpc-1631	17	11	terms	term	NOUN
dpc-1631	17	12	“	"	PUNCT
dpc-1631	17	13	melanoma	melanoma	NOUN
dpc-1631	17	14	”	"	PUNCT
dpc-1631	17	15	and	and	CCONJ
dpc-1631	17	16	“	"	PUNCT
dpc-1631	17	17	body	body	NOUN
dpc-1631	17	18	mass	mass	PROPN
dpc-1631	17	19	index	index	NOUN
dpc-1631	17	20	”	"	PUNCT
dpc-1631	17	21	or	or	CCONJ
dpc-1631	17	22	“	"	PUNCT
dpc-1631	17	23	obesity	obesity	NOUN
dpc-1631	17	24	”	"	PUNCT
dpc-1631	17	25	.	.	PUNCT
dpc-1631	18	1	we	we	PRON
dpc-1631	18	2	selected	select	VERB
dpc-1631	18	3	articles	article	NOUN
dpc-1631	18	4	,	,	PUNCT
dpc-1631	18	5	published	publish	VERB
dpc-1631	18	6	up	up	ADV
dpc-1631	18	7	to	to	PART
dpc-1631	18	8	30	30	NUM
dpc-1631	18	9	november	november	NOUN
dpc-1631	18	10	2020	2020	NUM
dpc-1631	18	11	,	,	PUNCT
dpc-1631	18	12	examining	examine	VERB
dpc-1631	18	13	the	the	DET
dpc-1631	18	14	prognostic	prognostic	ADJ
dpc-1631	18	15	aspects	aspect	NOUN
dpc-1631	18	16	of	of	ADP
dpc-1631	18	17	melanoma	melanoma	NOUN
dpc-1631	18	18	.	.	PUNCT
dpc-1631	19	1	articles	article	NOUN
dpc-1631	19	2	evaluating	evaluate	VERB
dpc-1631	19	3	the	the	DET
dpc-1631	19	4	risk	risk	NOUN
dpc-1631	19	5	and	and	CCONJ
dpc-1631	19	6	incidence	incidence	NOUN
dpc-1631	19	7	of	of	ADP
dpc-1631	19	8	melanoma	melanoma	NOUN
dpc-1631	19	9	were	be	AUX
dpc-1631	19	10	excluded	exclude	VERB
dpc-1631	19	11	as	as	ADV
dpc-1631	19	12	well	well	ADV
dpc-1631	19	13	as	as	ADP
dpc-1631	19	14	studies	study	NOUN
dpc-1631	19	15	regarding	regard	VERB
dpc-1631	19	16	morbidity	morbidity	NOUN
dpc-1631	19	17	and	and	CCONJ
dpc-1631	19	18	complications	complication	NOUN
dpc-1631	19	19	following	follow	VERB
dpc-1631	19	20	surgical	surgical	ADJ
dpc-1631	19	21	procedures	procedure	NOUN
dpc-1631	19	22	,	,	PUNCT
dpc-1631	19	23	or	or	CCONJ
dpc-1631	19	24	those	those	PRON
dpc-1631	19	25	performed	perform	VERB
dpc-1631	19	26	in	in	ADP
dpc-1631	19	27	metastatic	metastatic	ADJ
dpc-1631	19	28	melanoma	melanoma	NOUN
dpc-1631	19	29	patients	patient	NOUN
dpc-1631	19	30	treated	treat	VERB
dpc-1631	19	31	with	with	ADP
dpc-1631	19	32	anti	anti	ADJ
dpc-1631	19	33	-	-	ADJ
dpc-1631	19	34	tumor	tumor	ADJ
dpc-1631	19	35	therapies	therapy	NOUN
dpc-1631	19	36	.	.	PUNCT
dpc-1631	20	1	results	result	NOUN
dpc-1631	20	2	:	:	PUNCT
dpc-1631	20	3	mixed	mixed	ADJ
dpc-1631	20	4	results	result	NOUN
dpc-1631	20	5	have	have	AUX
dpc-1631	20	6	emerged	emerge	VERB
dpc-1631	20	7	from	from	ADP
dpc-1631	20	8	studies	study	NOUN
dpc-1631	20	9	assessing	assess	VERB
dpc-1631	20	10	the	the	DET
dpc-1631	20	11	clinical	clinical	ADJ
dpc-1631	20	12	outcomes	outcome	NOUN
dpc-1631	20	13	in	in	ADP
dpc-1631	20	14	melanoma	melanoma	NOUN
dpc-1631	20	15	patients	patient	NOUN
dpc-1631	20	16	in	in	ADP
dpc-1631	20	17	relation	relation	NOUN
dpc-1631	20	18	to	to	PART
dpc-1631	20	19	bmi	bmi	VERB
dpc-1631	20	20	.	.	PUNCT
dpc-1631	21	1	more	more	ADV
dpc-1631	21	2	consistent	consistent	ADJ
dpc-1631	21	3	data	datum	NOUN
dpc-1631	21	4	seem	seem	VERB
dpc-1631	21	5	to	to	PART
dpc-1631	21	6	support	support	VERB
dpc-1631	21	7	the	the	DET
dpc-1631	21	8	relationship	relationship	NOUN
dpc-1631	21	9	between	between	ADP
dpc-1631	21	10	bmi	bmi	NOUN
dpc-1631	21	11	and	and	CCONJ
dpc-1631	21	12	breslow	breslow	ADJ
dpc-1631	21	13	thickness	thickness	NOUN
dpc-1631	21	14	.	.	PUNCT
dpc-1631	22	1	conclusions	conclusion	NOUN
dpc-1631	22	2	:	:	PUNCT
dpc-1631	22	3	studies	study	NOUN
dpc-1631	22	4	that	that	PRON
dpc-1631	22	5	focus	focus	VERB
dpc-1631	22	6	specifically	specifically	ADV
dpc-1631	22	7	on	on	ADP
dpc-1631	22	8	the	the	DET
dpc-1631	22	9	link	link	NOUN
dpc-1631	22	10	between	between	ADP
dpc-1631	22	11	obesity	obesity	NOUN
dpc-1631	22	12	and	and	CCONJ
dpc-1631	22	13	melanoma	melanoma	NOUN
dpc-1631	22	14	prognosis	prognosis	NOUN
dpc-1631	22	15	are	be	AUX
dpc-1631	22	16	limited	limit	VERB
dpc-1631	22	17	;	;	PUNCT
dpc-1631	22	18	further	further	ADJ
dpc-1631	22	19	research	research	NOUN
dpc-1631	22	20	is	be	AUX
dpc-1631	22	21	needed	need	VERB
dpc-1631	22	22	to	to	PART
dpc-1631	22	23	deepen	deepen	VERB
dpc-1631	22	24	our	our	PRON
dpc-1631	22	25	knowledge	knowledge	NOUN
dpc-1631	22	26	on	on	ADP
dpc-1631	22	27	this	this	DET
dpc-1631	22	28	link	link	NOUN
dpc-1631	22	29	.	.	PUNCT
dpc-1631	23	1	abstract	abstract	ADJ
dpc-1631	23	2	2	2	NUM
dpc-1631	23	3	review	review	NOUN
dpc-1631	23	4	|	|	ADV
dpc-1631	23	5	dermatol	dermatol	ADJ
dpc-1631	23	6	pract	pract	NOUN
dpc-1631	23	7	concept	concept	NOUN
dpc-1631	23	8	.	.	PUNCT
dpc-1631	24	1	2021;11(4	2021;11(4	NUM
dpc-1631	24	2	):	):	PUNCT
dpc-1631	24	3	e2021106	e2021106	NOUN
dpc-1631	24	4	introduction	introduction	NOUN
dpc-1631	24	5	there	there	PRON
dpc-1631	24	6	is	be	VERB
dpc-1631	24	7	a	a	DET
dpc-1631	24	8	growing	grow	VERB
dpc-1631	24	9	interest	interest	NOUN
dpc-1631	24	10	in	in	ADP
dpc-1631	24	11	exploring	explore	VERB
dpc-1631	24	12	the	the	DET
dpc-1631	24	13	relationship	relationship	NOUN
dpc-1631	24	14	between	between	ADP
dpc-1631	24	15	cancer	cancer	NOUN
dpc-1631	24	16	and	and	CCONJ
dpc-1631	24	17	anthropometric	anthropometric	ADJ
dpc-1631	24	18	measures	measure	NOUN
dpc-1631	24	19	,	,	PUNCT
dpc-1631	24	20	including	include	VERB
dpc-1631	24	21	body	body	NOUN
dpc-1631	24	22	mass	mass	NOUN
dpc-1631	24	23	index	index	NOUN
dpc-1631	24	24	(	(	PUNCT
dpc-1631	24	25	bmi	bmi	PROPN
dpc-1631	24	26	)	)	PUNCT
dpc-1631	24	27	.	.	PUNCT
dpc-1631	25	1	excess	excess	ADJ
dpc-1631	25	2	body	body	NOUN
dpc-1631	25	3	weight	weight	NOUN
dpc-1631	25	4	,	,	PUNCT
dpc-1631	25	5	accounting	account	VERB
dpc-1631	25	6	for	for	ADP
dpc-1631	25	7	both	both	DET
dpc-1631	25	8	overweight	overweight	NOUN
dpc-1631	25	9	(	(	PUNCT
dpc-1631	25	10	bmi	bmi	NOUN
dpc-1631	25	11	within	within	ADP
dpc-1631	25	12	the	the	DET
dpc-1631	25	13	range	range	NOUN
dpc-1631	25	14	of	of	ADP
dpc-1631	25	15	25	25	NUM
dpc-1631	25	16	-	-	SYM
dpc-1631	25	17	29.9	29.9	NUM
dpc-1631	25	18	kg	kg	NOUN
dpc-1631	25	19	/	/	SYM
dpc-1631	25	20	m2	m2	PROPN
dpc-1631	25	21	)	)	PUNCT
dpc-1631	25	22	and	and	CCONJ
dpc-1631	25	23	obesity	obesity	NOUN
dpc-1631	25	24	(	(	PUNCT
dpc-1631	25	25	bmi≥30	bmi≥30	PROPN
dpc-1631	25	26	kg	kg	PROPN
dpc-1631	25	27	/	/	SYM
dpc-1631	25	28	m2	m2	PROPN
dpc-1631	25	29	)	)	PUNCT
dpc-1631	25	30	,	,	PUNCT
dpc-1631	25	31	has	have	AUX
dpc-1631	25	32	notably	notably	ADV
dpc-1631	25	33	increased	increase	VERB
dpc-1631	25	34	worldwide	worldwide	ADV
dpc-1631	25	35	over	over	ADP
dpc-1631	25	36	the	the	DET
dpc-1631	25	37	last	last	ADJ
dpc-1631	25	38	decades	decade	NOUN
dpc-1631	25	39	and	and	CCONJ
dpc-1631	25	40	has	have	AUX
dpc-1631	25	41	been	be	AUX
dpc-1631	25	42	associated	associate	VERB
dpc-1631	25	43	with	with	ADP
dpc-1631	25	44	a	a	DET
dpc-1631	25	45	higher	high	ADJ
dpc-1631	25	46	risk	risk	NOUN
dpc-1631	25	47	for	for	ADP
dpc-1631	25	48	cancer	cancer	NOUN
dpc-1631	25	49	of	of	ADP
dpc-1631	25	50	several	several	ADJ
dpc-1631	25	51	anatomic	anatomic	ADJ
dpc-1631	25	52	sites	site	NOUN
dpc-1631	25	53	[	[	X
dpc-1631	25	54	1	1	NUM
dpc-1631	25	55	]	]	PUNCT
dpc-1631	25	56	.	.	PUNCT
dpc-1631	26	1	obese	obese	ADJ
dpc-1631	26	2	status	status	NOUN
dpc-1631	26	3	is	be	AUX
dpc-1631	26	4	characterized	characterize	VERB
dpc-1631	26	5	by	by	ADP
dpc-1631	26	6	the	the	DET
dpc-1631	26	7	occurrence	occurrence	NOUN
dpc-1631	26	8	of	of	ADP
dpc-1631	26	9	systemic	systemic	ADJ
dpc-1631	26	10	and	and	CCONJ
dpc-1631	26	11	tissue	tissue	NOUN
dpc-1631	26	12	processes	process	NOUN
dpc-1631	26	13	that	that	PRON
dpc-1631	26	14	might	might	AUX
dpc-1631	26	15	influence	influence	VERB
dpc-1631	26	16	malignancies	malignancy	NOUN
dpc-1631	26	17	,	,	PUNCT
dpc-1631	26	18	such	such	ADJ
dpc-1631	26	19	as	as	ADP
dpc-1631	26	20	release	release	NOUN
dpc-1631	26	21	of	of	ADP
dpc-1631	26	22	cytokines	cytokine	NOUN
dpc-1631	26	23	and	and	CCONJ
dpc-1631	26	24	hormones	hormone	NOUN
dpc-1631	26	25	from	from	ADP
dpc-1631	26	26	adipose	adipose	ADJ
dpc-1631	26	27	tissues	tissue	NOUN
dpc-1631	26	28	,	,	PUNCT
dpc-1631	26	29	chronic	chronic	ADJ
dpc-1631	26	30	low	low	ADJ
dpc-1631	26	31	-	-	PUNCT
dpc-1631	26	32	grade	grade	NOUN
dpc-1631	26	33	inflammation	inflammation	NOUN
dpc-1631	26	34	,	,	PUNCT
dpc-1631	26	35	increased	increase	VERB
dpc-1631	26	36	estrogen	estrogen	NOUN
dpc-1631	26	37	levels	level	NOUN
dpc-1631	26	38	,	,	PUNCT
dpc-1631	26	39	insulin	insulin	NOUN
dpc-1631	26	40	resistance	resistance	NOUN
dpc-1631	26	41	and	and	CCONJ
dpc-1631	26	42	hyperinsulinemia	hyperinsulinemia	NOUN
dpc-1631	27	1	[	[	X
dpc-1631	27	2	2	2	NUM
dpc-1631	27	3	-	-	SYM
dpc-1631	27	4	4	4	NUM
dpc-1631	27	5	]	]	PUNCT
dpc-1631	27	6	.	.	PUNCT
dpc-1631	28	1	obesity	obesity	NOUN
dpc-1631	28	2	has	have	AUX
dpc-1631	28	3	also	also	ADV
dpc-1631	28	4	been	be	AUX
dpc-1631	28	5	suggested	suggest	VERB
dpc-1631	28	6	to	to	PART
dpc-1631	28	7	contribute	contribute	VERB
dpc-1631	28	8	to	to	ADP
dpc-1631	28	9	the	the	DET
dpc-1631	28	10	risk	risk	NOUN
dpc-1631	28	11	and	and	CCONJ
dpc-1631	28	12	progression	progression	NOUN
dpc-1631	28	13	of	of	ADP
dpc-1631	28	14	cutaneous	cutaneous	ADJ
dpc-1631	28	15	melanoma	melanoma	NOUN
dpc-1631	28	16	,	,	PUNCT
dpc-1631	28	17	whose	whose	DET
dpc-1631	28	18	major	major	ADJ
dpc-1631	28	19	environmental	environmental	ADJ
dpc-1631	28	20	risk	risk	NOUN
dpc-1631	28	21	factor	factor	NOUN
dpc-1631	28	22	is	be	AUX
dpc-1631	28	23	ultraviolet	ultraviolet	ADJ
dpc-1631	28	24	radiation	radiation	NOUN
dpc-1631	28	25	(	(	PUNCT
dpc-1631	28	26	uv	uv	NOUN
dpc-1631	28	27	)	)	PUNCT
dpc-1631	28	28	,	,	PUNCT
dpc-1631	28	29	especially	especially	ADV
dpc-1631	28	30	as	as	ADP
dpc-1631	28	31	intermittent	intermittent	ADJ
dpc-1631	28	32	intense	intense	ADJ
dpc-1631	28	33	exposures	exposure	NOUN
dpc-1631	28	34	.	.	PUNCT
dpc-1631	29	1	however	however	ADV
dpc-1631	29	2	,	,	PUNCT
dpc-1631	29	3	the	the	DET
dpc-1631	29	4	analysis	analysis	NOUN
dpc-1631	29	5	of	of	ADP
dpc-1631	29	6	the	the	DET
dpc-1631	29	7	association	association	NOUN
dpc-1631	29	8	between	between	ADP
dpc-1631	29	9	obesity	obesity	NOUN
dpc-1631	29	10	and	and	CCONJ
dpc-1631	29	11	risk	risk	NOUN
dpc-1631	29	12	of	of	ADP
dpc-1631	29	13	melanoma	melanoma	NOUN
dpc-1631	29	14	has	have	AUX
dpc-1631	29	15	provided	provide	VERB
dpc-1631	29	16	conflicting	conflicting	ADJ
dpc-1631	29	17	data	datum	NOUN
dpc-1631	29	18	so	so	ADV
dpc-1631	29	19	far	far	ADV
dpc-1631	29	20	[	[	X
dpc-1631	29	21	4,5	4,5	NUM
dpc-1631	29	22	]	]	PUNCT
dpc-1631	29	23	.	.	PUNCT
dpc-1631	30	1	recent	recent	ADJ
dpc-1631	30	2	studies	study	NOUN
dpc-1631	30	3	have	have	AUX
dpc-1631	30	4	shown	show	VERB
dpc-1631	30	5	that	that	SCONJ
dpc-1631	30	6	increased	increase	VERB
dpc-1631	30	7	bmi	bmi	NOUN
dpc-1631	30	8	might	might	AUX
dpc-1631	30	9	improve	improve	VERB
dpc-1631	30	10	outcomes	outcome	NOUN
dpc-1631	30	11	in	in	ADP
dpc-1631	30	12	melanoma	melanoma	NOUN
dpc-1631	30	13	patients	patient	NOUN
dpc-1631	30	14	treated	treat	VERB
dpc-1631	30	15	with	with	ADP
dpc-1631	30	16	targeted	target	VERB
dpc-1631	30	17	therapy	therapy	NOUN
dpc-1631	30	18	and	and	CCONJ
dpc-1631	30	19	immunotherapy	immunotherapy	NOUN
dpc-1631	30	20	,	,	PUNCT
dpc-1631	30	21	providing	provide	VERB
dpc-1631	30	22	further	further	ADJ
dpc-1631	30	23	hints	hint	NOUN
dpc-1631	30	24	on	on	ADP
dpc-1631	30	25	the	the	DET
dpc-1631	30	26	phenomenon	phenomenon	NOUN
dpc-1631	30	27	known	know	VERB
dpc-1631	30	28	as	as	ADP
dpc-1631	30	29	the	the	DET
dpc-1631	30	30	“	"	PUNCT
dpc-1631	30	31	obesity	obesity	NOUN
dpc-1631	30	32	paradox	paradox	NOUN
dpc-1631	30	33	”	"	PUNCT
dpc-1631	30	34	,	,	PUNCT
dpc-1631	30	35	although	although	SCONJ
dpc-1631	30	36	a	a	DET
dpc-1631	30	37	lack	lack	NOUN
dpc-1631	30	38	of	of	ADP
dpc-1631	30	39	consistency	consistency	NOUN
dpc-1631	30	40	has	have	AUX
dpc-1631	30	41	emerged	emerge	VERB
dpc-1631	30	42	from	from	ADP
dpc-1631	30	43	the	the	DET
dpc-1631	30	44	currently	currently	ADV
dpc-1631	30	45	available	available	ADJ
dpc-1631	30	46	results	result	NOUN
dpc-1631	30	47	and	and	CCONJ
dpc-1631	30	48	the	the	DET
dpc-1631	30	49	issue	issue	NOUN
dpc-1631	30	50	is	be	AUX
dpc-1631	30	51	still	still	ADV
dpc-1631	30	52	under	under	ADP
dpc-1631	30	53	debate	debate	NOUN
dpc-1631	30	54	[	[	X
dpc-1631	30	55	6	6	NUM
dpc-1631	30	56	-	-	SYM
dpc-1631	30	57	9	9	NUM
dpc-1631	30	58	]	]	PUNCT
dpc-1631	30	59	.	.	PUNCT
dpc-1631	31	1	the	the	DET
dpc-1631	31	2	aim	aim	NOUN
dpc-1631	31	3	of	of	ADP
dpc-1631	31	4	this	this	DET
dpc-1631	31	5	article	article	NOUN
dpc-1631	31	6	is	be	AUX
dpc-1631	31	7	to	to	PART
dpc-1631	31	8	examine	examine	VERB
dpc-1631	31	9	whether	whether	SCONJ
dpc-1631	31	10	bmi	bmi	NOUN
dpc-1631	31	11	can	can	AUX
dpc-1631	31	12	impact	impact	VERB
dpc-1631	31	13	on	on	ADP
dpc-1631	31	14	the	the	DET
dpc-1631	31	15	prognosis	prognosis	NOUN
dpc-1631	31	16	of	of	ADP
dpc-1631	31	17	cutaneous	cutaneous	ADJ
dpc-1631	31	18	melanoma	melanoma	NOUN
dpc-1631	31	19	,	,	PUNCT
dpc-1631	31	20	regardless	regardless	ADV
dpc-1631	31	21	of	of	ADP
dpc-1631	31	22	anti	anti	ADJ
dpc-1631	31	23	-	-	ADJ
dpc-1631	31	24	tumor	tumor	ADJ
dpc-1631	31	25	therapy	therapy	NOUN
dpc-1631	31	26	.	.	PUNCT
dpc-1631	32	1	for	for	ADP
dpc-1631	32	2	this	this	DET
dpc-1631	32	3	purpose	purpose	NOUN
dpc-1631	32	4	,	,	PUNCT
dpc-1631	32	5	the	the	DET
dpc-1631	32	6	relationship	relationship	NOUN
dpc-1631	32	7	between	between	ADP
dpc-1631	32	8	bmi	bmi	NOUN
dpc-1631	32	9	and	and	CCONJ
dpc-1631	32	10	specific	specific	ADJ
dpc-1631	32	11	prognostic	prognostic	ADJ
dpc-1631	32	12	factors	factor	NOUN
dpc-1631	32	13	in	in	ADP
dpc-1631	32	14	melanoma	melanoma	NOUN
dpc-1631	32	15	patients	patient	NOUN
dpc-1631	32	16	has	have	AUX
dpc-1631	32	17	been	be	AUX
dpc-1631	32	18	reviewed	review	VERB
dpc-1631	32	19	.	.	PUNCT
dpc-1631	33	1	methods	method	NOUN
dpc-1631	33	2	articles	article	NOUN
dpc-1631	33	3	in	in	ADP
dpc-1631	33	4	english	english	PROPN
dpc-1631	33	5	published	publish	VERB
dpc-1631	33	6	up	up	ADP
dpc-1631	33	7	to	to	PART
dpc-1631	33	8	30	30	NUM
dpc-1631	33	9	november	november	PROPN
dpc-1631	33	10	2020	2020	NUM
dpc-1631	33	11	were	be	AUX
dpc-1631	33	12	obtained	obtain	VERB
dpc-1631	33	13	from	from	ADP
dpc-1631	33	14	the	the	DET
dpc-1631	33	15	pubmed	pubmed	PROPN
dpc-1631	33	16	database	database	NOUN
dpc-1631	33	17	.	.	PUNCT
dpc-1631	34	1	a	a	DET
dpc-1631	34	2	literature	literature	NOUN
dpc-1631	34	3	search	search	NOUN
dpc-1631	34	4	was	be	AUX
dpc-1631	34	5	conducted	conduct	VERB
dpc-1631	34	6	using	use	VERB
dpc-1631	34	7	the	the	DET
dpc-1631	34	8	terms	term	NOUN
dpc-1631	34	9	“	"	PUNCT
dpc-1631	34	10	melanoma	melanoma	NOUN
dpc-1631	34	11	”	"	PUNCT
dpc-1631	34	12	and	and	CCONJ
dpc-1631	34	13	“	"	PUNCT
dpc-1631	34	14	body	body	NOUN
dpc-1631	34	15	mass	mass	PROPN
dpc-1631	34	16	index	index	NOUN
dpc-1631	34	17	”	"	PUNCT
dpc-1631	34	18	or	or	CCONJ
dpc-1631	34	19	“	"	PUNCT
dpc-1631	34	20	obesity	obesity	NOUN
dpc-1631	34	21	”	"	PUNCT
dpc-1631	34	22	.	.	PUNCT
dpc-1631	35	1	we	we	PRON
dpc-1631	35	2	collected	collect	VERB
dpc-1631	35	3	full	full	ADJ
dpc-1631	35	4	article	article	NOUN
dpc-1631	35	5	copies	copy	NOUN
dpc-1631	35	6	that	that	PRON
dpc-1631	35	7	were	be	AUX
dpc-1631	35	8	considered	consider	VERB
dpc-1631	35	9	potentially	potentially	ADV
dpc-1631	35	10	eligible	eligible	ADJ
dpc-1631	35	11	,	,	PUNCT
dpc-1631	35	12	including	include	VERB
dpc-1631	35	13	review	review	NOUN
dpc-1631	35	14	articles	article	NOUN
dpc-1631	35	15	as	as	ADP
dpc-1631	35	16	appropriate	appropriate	ADJ
dpc-1631	35	17	.	.	PUNCT
dpc-1631	36	1	the	the	DET
dpc-1631	36	2	reference	reference	NOUN
dpc-1631	36	3	lists	list	NOUN
dpc-1631	36	4	of	of	ADP
dpc-1631	36	5	retrieved	retrieve	VERB
dpc-1631	36	6	manuscripts	manuscript	NOUN
dpc-1631	36	7	were	be	AUX
dpc-1631	36	8	also	also	ADV
dpc-1631	36	9	checked	check	VERB
dpc-1631	36	10	to	to	PART
dpc-1631	36	11	find	find	VERB
dpc-1631	36	12	other	other	ADJ
dpc-1631	36	13	eligible	eligible	ADJ
dpc-1631	36	14	papers	paper	NOUN
dpc-1631	36	15	.	.	PUNCT
dpc-1631	37	1	we	we	PRON
dpc-1631	37	2	selected	select	VERB
dpc-1631	37	3	articles	article	NOUN
dpc-1631	37	4	focused	focus	VERB
dpc-1631	37	5	on	on	ADP
dpc-1631	37	6	prognostic	prognostic	ADJ
dpc-1631	37	7	aspects	aspect	NOUN
dpc-1631	37	8	of	of	ADP
dpc-1631	37	9	melanoma	melanoma	NOUN
dpc-1631	37	10	(	(	PUNCT
dpc-1631	37	11	e.g.	e.g.	ADV
dpc-1631	37	12	,	,	PUNCT
dpc-1631	37	13	mortality	mortality	NOUN
dpc-1631	37	14	/	/	SYM
dpc-1631	37	15	survival	survival	NOUN
dpc-1631	37	16	,	,	PUNCT
dpc-1631	37	17	relapse	relapse	NOUN
dpc-1631	37	18	,	,	PUNCT
dpc-1631	37	19	metastases	metastasis	NOUN
dpc-1631	37	20	,	,	PUNCT
dpc-1631	37	21	progression	progression	NOUN
dpc-1631	37	22	,	,	PUNCT
dpc-1631	37	23	and	and	CCONJ
dpc-1631	37	24	histologic	histologic	ADJ
dpc-1631	37	25	prognostic	prognostic	ADJ
dpc-1631	37	26	factors	factor	NOUN
dpc-1631	37	27	)	)	PUNCT
dpc-1631	37	28	.	.	PUNCT
dpc-1631	38	1	articles	article	NOUN
dpc-1631	38	2	investigating	investigate	VERB
dpc-1631	38	3	the	the	DET
dpc-1631	38	4	risk	risk	NOUN
dpc-1631	38	5	and	and	CCONJ
dpc-1631	38	6	incidence	incidence	NOUN
dpc-1631	38	7	of	of	ADP
dpc-1631	38	8	melanoma	melanoma	NOUN
dpc-1631	38	9	were	be	AUX
dpc-1631	38	10	excluded	exclude	VERB
dpc-1631	38	11	,	,	PUNCT
dpc-1631	38	12	as	as	ADV
dpc-1631	38	13	well	well	ADV
dpc-1631	38	14	as	as	ADP
dpc-1631	38	15	those	those	PRON
dpc-1631	38	16	on	on	ADP
dpc-1631	38	17	morbidity	morbidity	NOUN
dpc-1631	38	18	and	and	CCONJ
dpc-1631	38	19	complications	complication	NOUN
dpc-1631	38	20	after	after	ADP
dpc-1631	38	21	surgical	surgical	ADJ
dpc-1631	38	22	procedures	procedure	NOUN
dpc-1631	38	23	.	.	PUNCT
dpc-1631	39	1	studies	study	NOUN
dpc-1631	39	2	regarding	regard	VERB
dpc-1631	39	3	patients	patient	NOUN
dpc-1631	39	4	with	with	ADP
dpc-1631	39	5	metastatic	metastatic	ADJ
dpc-1631	39	6	melanoma	melanoma	NOUN
dpc-1631	39	7	treated	treat	VERB
dpc-1631	39	8	with	with	ADP
dpc-1631	39	9	anti	anti	ADJ
dpc-1631	39	10	-	-	ADJ
dpc-1631	39	11	tumor	tumor	ADJ
dpc-1631	39	12	therapies	therapy	NOUN
dpc-1631	39	13	have	have	AUX
dpc-1631	39	14	also	also	ADV
dpc-1631	39	15	been	be	AUX
dpc-1631	39	16	excluded	exclude	VERB
dpc-1631	39	17	from	from	ADP
dpc-1631	39	18	our	our	PRON
dpc-1631	39	19	review	review	NOUN
dpc-1631	39	20	process	process	NOUN
dpc-1631	39	21	,	,	PUNCT
dpc-1631	39	22	as	as	SCONJ
dpc-1631	39	23	this	this	DET
dpc-1631	39	24	topic	topic	NOUN
dpc-1631	39	25	was	be	AUX
dpc-1631	39	26	beyond	beyond	ADP
dpc-1631	39	27	the	the	DET
dpc-1631	39	28	purposes	purpose	NOUN
dpc-1631	39	29	of	of	ADP
dpc-1631	39	30	this	this	DET
dpc-1631	39	31	manuscript	manuscript	NOUN
dpc-1631	39	32	and	and	CCONJ
dpc-1631	39	33	would	would	AUX
dpc-1631	39	34	deserve	deserve	VERB
dpc-1631	39	35	a	a	DET
dpc-1631	39	36	separate	separate	ADJ
dpc-1631	39	37	wide	wide	ADJ
dpc-1631	39	38	discussion	discussion	NOUN
dpc-1631	39	39	.	.	PUNCT
dpc-1631	40	1	results	result	VERB
dpc-1631	40	2	melanoma	melanoma	NOUN
dpc-1631	40	3	outcomes	outcome	NOUN
dpc-1631	40	4	only	only	ADV
dpc-1631	40	5	a	a	DET
dpc-1631	40	6	limited	limited	ADJ
dpc-1631	40	7	number	number	NOUN
dpc-1631	40	8	of	of	ADP
dpc-1631	40	9	studies	study	NOUN
dpc-1631	40	10	have	have	AUX
dpc-1631	40	11	evaluated	evaluate	VERB
dpc-1631	40	12	the	the	DET
dpc-1631	40	13	survival	survival	NOUN
dpc-1631	40	14	rate	rate	NOUN
dpc-1631	40	15	and/or	and/or	CCONJ
dpc-1631	40	16	the	the	DET
dpc-1631	40	17	risk	risk	NOUN
dpc-1631	40	18	of	of	ADP
dpc-1631	40	19	recurrence	recurrence	NOUN
dpc-1631	40	20	or	or	CCONJ
dpc-1631	40	21	progression	progression	NOUN
dpc-1631	40	22	in	in	ADP
dpc-1631	40	23	relation	relation	NOUN
dpc-1631	40	24	to	to	PART
dpc-1631	40	25	bmi	bmi	VERB
dpc-1631	40	26	among	among	ADP
dpc-1631	40	27	melanoma	melanoma	NOUN
dpc-1631	40	28	patients	patient	NOUN
dpc-1631	40	29	.	.	PUNCT
dpc-1631	41	1	as	as	SCONJ
dpc-1631	41	2	previously	previously	ADV
dpc-1631	41	3	specified	specify	VERB
dpc-1631	41	4	,	,	PUNCT
dpc-1631	41	5	our	our	PRON
dpc-1631	41	6	analysis	analysis	NOUN
dpc-1631	41	7	did	do	AUX
dpc-1631	41	8	not	not	PART
dpc-1631	41	9	include	include	VERB
dpc-1631	41	10	studies	study	NOUN
dpc-1631	41	11	assessing	assess	VERB
dpc-1631	41	12	outcomes	outcome	NOUN
dpc-1631	41	13	in	in	ADP
dpc-1631	41	14	patients	patient	NOUN
dpc-1631	41	15	with	with	ADP
dpc-1631	41	16	metastatic	metastatic	ADJ
dpc-1631	41	17	melanoma	melanoma	NOUN
dpc-1631	41	18	who	who	PRON
dpc-1631	41	19	received	receive	VERB
dpc-1631	41	20	targeted	target	VERB
dpc-1631	41	21	therapy	therapy	NOUN
dpc-1631	41	22	,	,	PUNCT
dpc-1631	41	23	immunotherapy	immunotherapy	NOUN
dpc-1631	41	24	,	,	PUNCT
dpc-1631	41	25	or	or	CCONJ
dpc-1631	41	26	chemotherapy	chemotherapy	NOUN
dpc-1631	41	27	.	.	PUNCT
dpc-1631	42	1	no	no	DET
dpc-1631	42	2	significant	significant	ADJ
dpc-1631	42	3	variations	variation	NOUN
dpc-1631	42	4	in	in	ADP
dpc-1631	42	5	the	the	DET
dpc-1631	42	6	overall	overall	ADJ
dpc-1631	42	7	risk	risk	NOUN
dpc-1631	42	8	of	of	ADP
dpc-1631	42	9	mortality	mortality	NOUN
dpc-1631	42	10	for	for	ADP
dpc-1631	42	11	melanoma	melanoma	NOUN
dpc-1631	42	12	according	accord	VERB
dpc-1631	42	13	to	to	ADP
dpc-1631	42	14	bmi	bmi	NOUN
dpc-1631	42	15	were	be	AUX
dpc-1631	42	16	detected	detect	VERB
dpc-1631	42	17	in	in	ADP
dpc-1631	42	18	a	a	DET
dpc-1631	42	19	prospective	prospective	ADJ
dpc-1631	42	20	cohort	cohort	NOUN
dpc-1631	42	21	study	study	NOUN
dpc-1631	42	22	involving	involve	VERB
dpc-1631	42	23	nearly	nearly	ADV
dpc-1631	42	24	1.2	1.2	NUM
dpc-1631	42	25	million	million	NUM
dpc-1631	42	26	uk	uk	PROPN
dpc-1631	42	27	women	woman	NOUN
dpc-1631	42	28	aged	age	VERB
dpc-1631	42	29	50	50	NUM
dpc-1631	42	30	-	-	SYM
dpc-1631	42	31	64	64	NUM
dpc-1631	42	32	years	year	NOUN
dpc-1631	42	33	who	who	PRON
dpc-1631	42	34	were	be	AUX
dpc-1631	42	35	recruited	recruit	VERB
dpc-1631	42	36	into	into	ADP
dpc-1631	42	37	the	the	DET
dpc-1631	42	38	million	million	NUM
dpc-1631	42	39	women	woman	NOUN
dpc-1631	42	40	study	study	VERB
dpc-1631	42	41	during	during	ADP
dpc-1631	42	42	the	the	DET
dpc-1631	42	43	period	period	NOUN
dpc-1631	42	44	1996	1996	NUM
dpc-1631	42	45	-	-	SYM
dpc-1631	42	46	2001	2001	NUM
dpc-1631	42	47	and	and	CCONJ
dpc-1631	42	48	followed	follow	VERB
dpc-1631	42	49	up	up	ADP
dpc-1631	42	50	,	,	PUNCT
dpc-1631	42	51	on	on	ADP
dpc-1631	42	52	average	average	ADJ
dpc-1631	42	53	,	,	PUNCT
dpc-1631	42	54	for	for	ADP
dpc-1631	42	55	5.4	5.4	NUM
dpc-1631	42	56	years	year	NOUN
dpc-1631	42	57	[	[	X
dpc-1631	42	58	10	10	NUM
dpc-1631	42	59	]	]	PUNCT
dpc-1631	42	60	.	.	PUNCT
dpc-1631	43	1	similarly	similarly	ADV
dpc-1631	43	2	,	,	PUNCT
dpc-1631	43	3	a	a	DET
dpc-1631	43	4	study	study	NOUN
dpc-1631	43	5	on	on	ADP
dpc-1631	43	6	more	more	ADJ
dpc-1631	43	7	than	than	ADP
dpc-1631	43	8	900,000	900,000	NUM
dpc-1631	43	9	adults	adult	NOUN
dpc-1631	43	10	in	in	ADP
dpc-1631	43	11	the	the	DET
dpc-1631	43	12	usa	usa	NOUN
dpc-1631	43	13	showed	show	VERB
dpc-1631	43	14	no	no	DET
dpc-1631	43	15	increased	increase	VERB
dpc-1631	43	16	mortality	mortality	NOUN
dpc-1631	43	17	rates	rate	NOUN
dpc-1631	43	18	from	from	ADP
dpc-1631	43	19	melanoma	melanoma	NOUN
dpc-1631	43	20	for	for	ADP
dpc-1631	43	21	higher	high	ADJ
dpc-1631	43	22	categories	category	NOUN
dpc-1631	43	23	of	of	ADP
dpc-1631	43	24	bmi	bmi	NOUN
dpc-1631	43	25	in	in	ADP
dpc-1631	43	26	males	male	NOUN
dpc-1631	43	27	or	or	CCONJ
dpc-1631	43	28	females	female	NOUN
dpc-1631	43	29	[	[	X
dpc-1631	43	30	11	11	NUM
dpc-1631	43	31	]	]	PUNCT
dpc-1631	43	32	.	.	PUNCT
dpc-1631	44	1	in	in	ADP
dpc-1631	44	2	a	a	DET
dpc-1631	44	3	total	total	NOUN
dpc-1631	44	4	of	of	ADP
dpc-1631	44	5	340	340	NUM
dpc-1631	44	6	italian	italian	ADJ
dpc-1631	44	7	melanoma	melanoma	NOUN
dpc-1631	44	8	patients	patient	NOUN
dpc-1631	44	9	(	(	PUNCT
dpc-1631	44	10	mean	mean	VERB
dpc-1631	44	11	breslow	breslow	NOUN
dpc-1631	44	12	thickness=0.4	thickness=0.4	NOUN
dpc-1631	44	13	mm	mm	PROPN
dpc-1631	44	14	)	)	PUNCT
dpc-1631	44	15	,	,	PUNCT
dpc-1631	44	16	prognosis	prognosis	NOUN
dpc-1631	44	17	was	be	AUX
dpc-1631	44	18	found	find	VERB
dpc-1631	44	19	to	to	PART
dpc-1631	44	20	be	be	AUX
dpc-1631	44	21	similar	similar	ADJ
dpc-1631	44	22	in	in	ADP
dpc-1631	44	23	normal	normal	ADJ
dpc-1631	44	24	weight	weight	NOUN
dpc-1631	44	25	patients	patient	NOUN
dpc-1631	44	26	and	and	CCONJ
dpc-1631	44	27	in	in	ADP
dpc-1631	44	28	overweight	overweight	ADJ
dpc-1631	44	29	/	/	SYM
dpc-1631	44	30	obese	obese	ADJ
dpc-1631	44	31	patients	patient	NOUN
dpc-1631	45	1	[	[	X
dpc-1631	45	2	12	12	NUM
dpc-1631	45	3	]	]	PUNCT
dpc-1631	45	4	.	.	PUNCT
dpc-1631	46	1	a	a	DET
dpc-1631	46	2	recent	recent	ADJ
dpc-1631	46	3	analysis	analysis	NOUN
dpc-1631	46	4	of	of	ADP
dpc-1631	46	5	the	the	DET
dpc-1631	46	6	leeds	leeds	PROPN
dpc-1631	46	7	melanoma	melanoma	PROPN
dpc-1631	46	8	cohort	cohort	NOUN
dpc-1631	46	9	,	,	PUNCT
dpc-1631	46	10	with	with	ADP
dpc-1631	46	11	a	a	DET
dpc-1631	46	12	median	median	ADJ
dpc-1631	46	13	follow	follow	NOUN
dpc-1631	46	14	-	-	PUNCT
dpc-1631	46	15	up	up	NOUN
dpc-1631	46	16	length	length	NOUN
dpc-1631	46	17	of	of	ADP
dpc-1631	46	18	6.7	6.7	NUM
dpc-1631	46	19	years	year	NOUN
dpc-1631	46	20	,	,	PUNCT
dpc-1631	46	21	showed	show	VERB
dpc-1631	46	22	that	that	SCONJ
dpc-1631	46	23	bmi	bmi	NOUN
dpc-1631	46	24	was	be	AUX
dpc-1631	46	25	not	not	PART
dpc-1631	46	26	associated	associate	VERB
dpc-1631	46	27	with	with	ADP
dpc-1631	46	28	overall	overall	ADJ
dpc-1631	46	29	and	and	CCONJ
dpc-1631	46	30	melanoma	melanoma	NOUN
dpc-1631	46	31	-	-	PUNCT
dpc-1631	46	32	specific	specific	ADJ
dpc-1631	46	33	survival	survival	NOUN
dpc-1631	46	34	[	[	X
dpc-1631	46	35	13	13	NUM
dpc-1631	46	36	]	]	PUNCT
dpc-1631	46	37	.	.	PUNCT
dpc-1631	47	1	the	the	DET
dpc-1631	47	2	comparison	comparison	NOUN
dpc-1631	47	3	of	of	ADP
dpc-1631	47	4	131	131	NUM
dpc-1631	47	5	relapsed	relapse	VERB
dpc-1631	47	6	melanoma	melanoma	NOUN
dpc-1631	47	7	patients	patient	NOUN
dpc-1631	47	8	with	with	ADP
dpc-1631	47	9	147	147	NUM
dpc-1631	47	10	non	non	NOUN
dpc-1631	47	11	-	-	NOUN
dpc-1631	47	12	relapsers	relapser	NOUN
dpc-1631	47	13	reported	report	VERB
dpc-1631	47	14	no	no	DET
dpc-1631	47	15	effect	effect	NOUN
dpc-1631	47	16	of	of	ADP
dpc-1631	47	17	bmi	bmi	NOUN
dpc-1631	47	18	on	on	ADP
dpc-1631	47	19	the	the	DET
dpc-1631	47	20	risk	risk	NOUN
dpc-1631	47	21	of	of	ADP
dpc-1631	47	22	relapse	relapse	NOUN
dpc-1631	47	23	[	[	X
dpc-1631	47	24	14	14	NUM
dpc-1631	47	25	]	]	PUNCT
dpc-1631	47	26	.	.	PUNCT
dpc-1631	48	1	in	in	ADP
dpc-1631	48	2	a	a	DET
dpc-1631	48	3	small	small	ADJ
dpc-1631	48	4	study	study	NOUN
dpc-1631	48	5	that	that	PRON
dpc-1631	48	6	found	find	VERB
dpc-1631	48	7	a	a	DET
dpc-1631	48	8	correlation	correlation	NOUN
dpc-1631	48	9	between	between	ADP
dpc-1631	48	10	serum	serum	NOUN
dpc-1631	48	11	levels	level	NOUN
dpc-1631	48	12	of	of	ADP
dpc-1631	48	13	leptin	leptin	NOUN
dpc-1631	48	14	and	and	CCONJ
dpc-1631	48	15	sentinel	sentinel	NOUN
dpc-1631	48	16	lymph	lymph	NOUN
dpc-1631	48	17	node	node	NOUN
dpc-1631	48	18	metastases	metastasis	NOUN
dpc-1631	48	19	in	in	ADP
dpc-1631	48	20	melanoma	melanoma	NOUN
dpc-1631	48	21	patients	patient	NOUN
dpc-1631	48	22	,	,	PUNCT
dpc-1631	48	23	the	the	DET
dpc-1631	48	24	mean	mean	ADJ
dpc-1631	48	25	bmi	bmi	NOUN
dpc-1631	48	26	was	be	AUX
dpc-1631	48	27	identical	identical	ADJ
dpc-1631	48	28	for	for	ADP
dpc-1631	48	29	the	the	DET
dpc-1631	48	30	sentinel	sentinel	ADJ
dpc-1631	48	31	node	node	NOUN
dpc-1631	48	32	-	-	PUNCT
dpc-1631	48	33	positive	positive	ADJ
dpc-1631	48	34	and	and	CCONJ
dpc-1631	48	35	sentinel	sentinel	ADJ
dpc-1631	48	36	node	node	NOUN
dpc-1631	48	37	-	-	PUNCT
dpc-1631	48	38	negative	negative	ADJ
dpc-1631	48	39	groups	group	NOUN
dpc-1631	48	40	,	,	PUNCT
dpc-1631	48	41	ruling	rule	VERB
dpc-1631	48	42	out	out	ADP
dpc-1631	48	43	obesity	obesity	NOUN
dpc-1631	48	44	as	as	ADP
dpc-1631	48	45	an	an	DET
dpc-1631	48	46	explanation	explanation	NOUN
dpc-1631	48	47	for	for	ADP
dpc-1631	48	48	higher	high	ADJ
dpc-1631	48	49	leptin	leptin	NOUN
dpc-1631	48	50	values	value	NOUN
dpc-1631	48	51	in	in	ADP
dpc-1631	48	52	patients	patient	NOUN
dpc-1631	48	53	with	with	ADP
dpc-1631	48	54	positive	positive	ADJ
dpc-1631	48	55	sentinel	sentinel	NOUN
dpc-1631	48	56	nodes	node	NOUN
dpc-1631	48	57	[	[	X
dpc-1631	48	58	15	15	NUM
dpc-1631	48	59	]	]	PUNCT
dpc-1631	48	60	.	.	PUNCT
dpc-1631	49	1	instead	instead	ADV
dpc-1631	49	2	,	,	PUNCT
dpc-1631	49	3	other	other	ADJ
dpc-1631	49	4	findings	finding	NOUN
dpc-1631	49	5	seemed	seem	VERB
dpc-1631	49	6	to	to	PART
dpc-1631	49	7	indicate	indicate	VERB
dpc-1631	49	8	a	a	DET
dpc-1631	49	9	variable	variable	ADJ
dpc-1631	49	10	influence	influence	NOUN
dpc-1631	49	11	of	of	ADP
dpc-1631	49	12	bmi	bmi	NOUN
dpc-1631	49	13	on	on	ADP
dpc-1631	49	14	melanoma	melanoma	NOUN
dpc-1631	49	15	outcomes	outcome	NOUN
dpc-1631	49	16	.	.	PUNCT
dpc-1631	50	1	a	a	DET
dpc-1631	50	2	study	study	NOUN
dpc-1631	50	3	of	of	ADP
dpc-1631	50	4	the	the	DET
dpc-1631	50	5	leeds	leeds	PROPN
dpc-1631	50	6	melanoma	melanoma	PROPN
dpc-1631	50	7	cohort	cohort	NOUN
dpc-1631	50	8	,	,	PUNCT
dpc-1631	50	9	comprising	comprise	VERB
dpc-1631	50	10	2,182	2,182	NUM
dpc-1631	50	11	melanoma	melanoma	NOUN
dpc-1631	50	12	patients	patient	NOUN
dpc-1631	50	13	enrolled	enrol	VERB
dpc-1631	50	14	in	in	ADP
dpc-1631	50	15	the	the	DET
dpc-1631	50	16	period	period	NOUN
dpc-1631	50	17	2001–2013	2001–2013	NUM
dpc-1631	50	18	,	,	PUNCT
dpc-1631	50	19	has	have	AUX
dpc-1631	50	20	revealed	reveal	VERB
dpc-1631	50	21	that	that	SCONJ
dpc-1631	50	22	bmi	bmi	NOUN
dpc-1631	50	23	was	be	AUX
dpc-1631	50	24	not	not	PART
dpc-1631	50	25	significantly	significantly	ADV
dpc-1631	50	26	associated	associate	VERB
dpc-1631	50	27	with	with	ADP
dpc-1631	50	28	survival	survival	NOUN
dpc-1631	50	29	when	when	SCONJ
dpc-1631	50	30	it	it	PRON
dpc-1631	50	31	was	be	AUX
dpc-1631	50	32	treated	treat	VERB
dpc-1631	50	33	as	as	ADP
dpc-1631	50	34	a	a	DET
dpc-1631	50	35	continuous	continuous	ADJ
dpc-1631	50	36	variable	variable	NOUN
dpc-1631	50	37	[	[	X
dpc-1631	50	38	hazard	hazard	NOUN
dpc-1631	50	39	ratio	ratio	NOUN
dpc-1631	50	40	(	(	PUNCT
dpc-1631	50	41	hr	hr	NOUN
dpc-1631	50	42	)	)	PUNCT
dpc-1631	50	43	1.04	1.04	NUM
dpc-1631	50	44	per	per	ADP
dpc-1631	50	45	5	5	NUM
dpc-1631	50	46	units	unit	NOUN
dpc-1631	50	47	,	,	PUNCT
dpc-1631	50	48	95	95	NUM
dpc-1631	50	49	%	%	NOUN
dpc-1631	50	50	confidence	confidence	NOUN
dpc-1631	50	51	interval	interval	NOUN
dpc-1631	50	52	(	(	PUNCT
dpc-1631	50	53	ci	ci	NOUN
dpc-1631	50	54	)	)	PUNCT
dpc-1631	50	55	0.91–1.18	0.91–1.18	NUM
dpc-1631	50	56	;	;	PUNCT
dpc-1631	50	57	p	p	X
dpc-1631	50	58	=	=	NOUN
dpc-1631	50	59	0.6	0.6	NUM
dpc-1631	50	60	)	)	PUNCT
dpc-1631	50	61	]	]	PUNCT
dpc-1631	51	1	[	[	X
dpc-1631	51	2	16	16	NUM
dpc-1631	51	3	]	]	PUNCT
dpc-1631	51	4	.	.	PUNCT
dpc-1631	52	1	instead	instead	ADV
dpc-1631	52	2	,	,	PUNCT
dpc-1631	52	3	overweight	overweight	ADJ
dpc-1631	52	4	individuals	individual	NOUN
dpc-1631	52	5	had	have	VERB
dpc-1631	52	6	better	well	ADJ
dpc-1631	52	7	survival	survival	NOUN
dpc-1631	52	8	than	than	ADP
dpc-1631	52	9	subjects	subject	NOUN
dpc-1631	52	10	with	with	ADP
dpc-1631	52	11	normal	normal	ADJ
dpc-1631	52	12	weight	weight	NOUN
dpc-1631	52	13	after	after	ADP
dpc-1631	52	14	adjustment	adjustment	NOUN
dpc-1631	52	15	for	for	ADP
dpc-1631	52	16	age	age	NOUN
dpc-1631	52	17	and	and	CCONJ
dpc-1631	52	18	sex	sex	NOUN
dpc-1631	52	19	,	,	PUNCT
dpc-1631	52	20	and	and	CCONJ
dpc-1631	52	21	after	after	ADP
dpc-1631	52	22	further	further	ADJ
dpc-1631	52	23	adjustment	adjustment	NOUN
dpc-1631	52	24	for	for	ADP
dpc-1631	52	25	site	site	NOUN
dpc-1631	52	26	and	and	CCONJ
dpc-1631	52	27	breslow	breslow	ADJ
dpc-1631	52	28	thickness	thickness	NOUN
dpc-1631	52	29	.	.	PUNCT
dpc-1631	53	1	the	the	DET
dpc-1631	53	2	protective	protective	ADJ
dpc-1631	53	3	effect	effect	NOUN
dpc-1631	53	4	was	be	AUX
dpc-1631	53	5	not	not	PART
dpc-1631	53	6	observed	observe	VERB
dpc-1631	53	7	in	in	ADP
dpc-1631	53	8	obese	obese	ADJ
dpc-1631	53	9	patients	patient	NOUN
dpc-1631	53	10	.	.	PUNCT
dpc-1631	54	1	an	an	DET
dpc-1631	54	2	analysis	analysis	NOUN
dpc-1631	54	3	of	of	ADP
dpc-1631	54	4	data	datum	NOUN
dpc-1631	54	5	from	from	ADP
dpc-1631	54	6	participants	participant	NOUN
dpc-1631	54	7	in	in	ADP
dpc-1631	54	8	the	the	DET
dpc-1631	54	9	same	same	ADJ
dpc-1631	54	10	cohort	cohort	NOUN
dpc-1631	54	11	previously	previously	ADV
dpc-1631	54	12	showed	show	VERB
dpc-1631	54	13	that	that	SCONJ
dpc-1631	54	14	bmi	bmi	NOUN
dpc-1631	54	15	was	be	AUX
dpc-1631	54	16	predictive	predictive	ADJ
dpc-1631	54	17	of	of	ADP
dpc-1631	54	18	relapse	relapse	NOUN
dpc-1631	54	19	even	even	ADV
dpc-1631	54	20	when	when	SCONJ
dpc-1631	54	21	corrected	correct	VERB
dpc-1631	54	22	for	for	ADP
dpc-1631	54	23	breslow	breslow	ADJ
dpc-1631	54	24	thickness	thickness	NOUN
dpc-1631	55	1	[	[	X
dpc-1631	55	2	17	17	NUM
dpc-1631	55	3	]	]	PUNCT
dpc-1631	55	4	.	.	PUNCT
dpc-1631	56	1	increased	increase	VERB
dpc-1631	56	2	bmi	bmi	NOUN
dpc-1631	56	3	has	have	AUX
dpc-1631	56	4	been	be	AUX
dpc-1631	56	5	associated	associate	VERB
dpc-1631	56	6	with	with	ADP
dpc-1631	56	7	worse	bad	ADJ
dpc-1631	56	8	survival	survival	NOUN
dpc-1631	56	9	in	in	ADP
dpc-1631	56	10	an	an	DET
dpc-1631	56	11	usa	usa	PROPN
dpc-1631	56	12	investigation	investigation	NOUN
dpc-1631	56	13	of	of	ADP
dpc-1631	56	14	1,186	1,186	NUM
dpc-1631	56	15	patients	patient	NOUN
dpc-1631	56	16	with	with	ADP
dpc-1631	56	17	surgically	surgically	ADV
dpc-1631	56	18	resected	resect	VERB
dpc-1631	56	19	melanoma	melanoma	NOUN
dpc-1631	56	20	,	,	PUNCT
dpc-1631	56	21	75	75	NUM
dpc-1631	56	22	%	%	NOUN
dpc-1631	56	23	of	of	ADP
dpc-1631	56	24	whom	whom	PRON
dpc-1631	56	25	had	have	AUX
dpc-1631	56	26	stage	stage	NOUN
dpc-1631	56	27	i	i	PRON
dpc-1631	56	28	or	or	CCONJ
dpc-1631	56	29	ii	ii	NUM
dpc-1631	56	30	disease	disease	NOUN
dpc-1631	56	31	[	[	X
dpc-1631	56	32	18	18	NUM
dpc-1631	56	33	]	]	PUNCT
dpc-1631	56	34	.	.	PUNCT
dpc-1631	57	1	overweight	overweight	ADJ
dpc-1631	57	2	patients	patient	NOUN
dpc-1631	57	3	showed	show	VERB
dpc-1631	57	4	a	a	DET
dpc-1631	57	5	trend	trend	NOUN
dpc-1631	57	6	towards	towards	ADP
dpc-1631	57	7	elevated	elevate	VERB
dpc-1631	57	8	review	review	NOUN
dpc-1631	57	9	|	|	ADV
dpc-1631	57	10	dermatol	dermatol	ADJ
dpc-1631	57	11	pract	pract	NOUN
dpc-1631	57	12	concept	concept	NOUN
dpc-1631	57	13	.	.	PUNCT
dpc-1631	58	1	2021;11(4	2021;11(4	NUM
dpc-1631	58	2	):	):	PUNCT
dpc-1631	58	3	e2021106	e2021106	NOUN
dpc-1631	58	4	3	3	NUM
dpc-1631	58	5	risks	risk	NOUN
dpc-1631	58	6	of	of	ADP
dpc-1631	58	7	disease	disease	NOUN
dpc-1631	58	8	recurrence	recurrence	NOUN
dpc-1631	58	9	and	and	CCONJ
dpc-1631	58	10	death	death	NOUN
dpc-1631	58	11	;	;	PUNCT
dpc-1631	58	12	such	such	ADJ
dpc-1631	58	13	risks	risk	NOUN
dpc-1631	58	14	were	be	AUX
dpc-1631	58	15	significantly	significantly	ADV
dpc-1631	58	16	increased	increase	VERB
dpc-1631	58	17	in	in	ADP
dpc-1631	58	18	obese	obese	ADJ
dpc-1631	58	19	patients	patient	NOUN
dpc-1631	58	20	(	(	PUNCT
dpc-1631	58	21	p	p	X
dpc-1631	58	22	<	<	X
dpc-1631	58	23	0.05	0.05	NUM
dpc-1631	58	24	)	)	PUNCT
dpc-1631	58	25	.	.	PUNCT
dpc-1631	59	1	however	however	ADV
dpc-1631	59	2	,	,	PUNCT
dpc-1631	59	3	outcome	outcome	NOUN
dpc-1631	59	4	associations	association	NOUN
dpc-1631	59	5	were	be	AUX
dpc-1631	59	6	weakened	weaken	VERB
dpc-1631	59	7	or	or	CCONJ
dpc-1631	59	8	lost	lose	VERB
dpc-1631	59	9	their	their	PRON
dpc-1631	59	10	significance	significance	NOUN
dpc-1631	59	11	following	follow	VERB
dpc-1631	59	12	adjustment	adjustment	NOUN
dpc-1631	59	13	for	for	ADP
dpc-1631	59	14	c	c	NOUN
dpc-1631	59	15	-	-	PUNCT
dpc-1631	59	16	reactive	reactive	ADJ
dpc-1631	59	17	protein	protein	NOUN
dpc-1631	59	18	(	(	PUNCT
dpc-1631	59	19	crp	crp	PROPN
dpc-1631	59	20	)	)	PUNCT
dpc-1631	59	21	.	.	PUNCT
dpc-1631	60	1	in	in	ADP
dpc-1631	60	2	a	a	DET
dpc-1631	60	3	retrospective	retrospective	ADJ
dpc-1631	60	4	analysis	analysis	NOUN
dpc-1631	60	5	of	of	ADP
dpc-1631	60	6	261	261	NUM
dpc-1631	60	7	korean	korean	ADJ
dpc-1631	60	8	patients	patient	NOUN
dpc-1631	60	9	with	with	ADP
dpc-1631	60	10	primary	primary	ADJ
dpc-1631	60	11	cutaneous	cutaneous	ADJ
dpc-1631	60	12	melanoma	melanoma	NOUN
dpc-1631	60	13	,	,	PUNCT
dpc-1631	60	14	overweight	overweight	NOUN
dpc-1631	60	15	and	and	CCONJ
dpc-1631	60	16	obesity	obesity	NOUN
dpc-1631	60	17	(	(	PUNCT
dpc-1631	60	18	bmi>23	bmi>23	PROPN
dpc-1631	60	19	kg	kg	PROPN
dpc-1631	60	20	/	/	SYM
dpc-1631	60	21	m2	m2	PROPN
dpc-1631	60	22	)	)	PUNCT
dpc-1631	60	23	were	be	AUX
dpc-1631	60	24	significantly	significantly	ADV
dpc-1631	60	25	associated	associate	VERB
dpc-1631	60	26	with	with	ADP
dpc-1631	60	27	the	the	DET
dpc-1631	60	28	development	development	NOUN
dpc-1631	60	29	of	of	ADP
dpc-1631	60	30	metastases	metastasis	NOUN
dpc-1631	60	31	[	[	X
dpc-1631	60	32	odds	odd	NOUN
dpc-1631	60	33	ratio	ratio	NOUN
dpc-1631	60	34	(	(	PUNCT
dpc-1631	60	35	or)=2.10	or)=2.10	PROPN
dpc-1631	60	36	,	,	PUNCT
dpc-1631	60	37	95	95	NUM
dpc-1631	60	38	%	%	NOUN
dpc-1631	60	39	ci	ci	NOUN
dpc-1631	60	40	1.2–3.6	1.2–3.6	NUM
dpc-1631	60	41	]	]	PUNCT
dpc-1631	60	42	and	and	CCONJ
dpc-1631	60	43	with	with	ADP
dpc-1631	60	44	shorter	short	ADJ
dpc-1631	60	45	overall	overall	ADJ
dpc-1631	60	46	survival	survival	NOUN
dpc-1631	60	47	(	(	PUNCT
dpc-1631	60	48	p	p	X
dpc-1631	60	49	=	=	NOUN
dpc-1631	60	50	0.033	0.033	NUM
dpc-1631	60	51	)	)	PUNCT
dpc-1631	61	1	[	[	X
dpc-1631	61	2	19	19	NUM
dpc-1631	61	3	]	]	PUNCT
dpc-1631	61	4	.	.	PUNCT
dpc-1631	62	1	it	it	PRON
dpc-1631	62	2	should	should	AUX
dpc-1631	62	3	be	be	AUX
dpc-1631	62	4	highlighted	highlight	VERB
dpc-1631	62	5	that	that	SCONJ
dpc-1631	62	6	the	the	DET
dpc-1631	62	7	cut	cut	VERB
dpc-1631	62	8	-	-	PUNCT
dpc-1631	62	9	off	off	ADP
dpc-1631	62	10	values	value	NOUN
dpc-1631	62	11	for	for	ADP
dpc-1631	62	12	the	the	DET
dpc-1631	62	13	definition	definition	NOUN
dpc-1631	62	14	of	of	ADP
dpc-1631	62	15	overweight	overweight	NOUN
dpc-1631	62	16	and	and	CCONJ
dpc-1631	62	17	obesity	obesity	NOUN
dpc-1631	62	18	are	be	AUX
dpc-1631	62	19	lower	low	ADJ
dpc-1631	62	20	for	for	ADP
dpc-1631	62	21	asian	asian	ADJ
dpc-1631	62	22	populations	population	NOUN
dpc-1631	62	23	as	as	SCONJ
dpc-1631	62	24	recommended	recommend	VERB
dpc-1631	62	25	by	by	ADP
dpc-1631	62	26	the	the	DET
dpc-1631	62	27	world	world	PROPN
dpc-1631	62	28	health	health	PROPN
dpc-1631	62	29	organization	organization	NOUN
dpc-1631	62	30	(	(	PUNCT
dpc-1631	62	31	who	who	PRON
dpc-1631	62	32	)	)	PUNCT
dpc-1631	62	33	,	,	PUNCT
dpc-1631	62	34	and	and	CCONJ
dpc-1631	62	35	in	in	ADP
dpc-1631	62	36	the	the	DET
dpc-1631	62	37	korean	korean	ADJ
dpc-1631	62	38	study	study	NOUN
dpc-1631	62	39	overweight	overweight	ADJ
dpc-1631	62	40	status	status	NOUN
dpc-1631	62	41	was	be	AUX
dpc-1631	62	42	defined	define	VERB
dpc-1631	62	43	as	as	ADP
dpc-1631	62	44	a	a	DET
dpc-1631	62	45	bmi	bmi	NOUN
dpc-1631	62	46	of	of	ADP
dpc-1631	62	47	23	23	NUM
dpc-1631	62	48	to	to	PART
dpc-1631	62	49	24.9	24.9	NUM
dpc-1631	62	50	kg/	kg/	NOUN
dpc-1631	62	51	m2	m2	PROPN
dpc-1631	62	52	,	,	PUNCT
dpc-1631	62	53	while	while	SCONJ
dpc-1631	62	54	a	a	DET
dpc-1631	62	55	bmi≥25	bmi≥25	PROPN
dpc-1631	62	56	kg	kg	PROPN
dpc-1631	62	57	/	/	SYM
dpc-1631	62	58	m2	m2	PROPN
dpc-1631	62	59	defined	define	VERB
dpc-1631	62	60	the	the	DET
dpc-1631	62	61	obesity	obesity	NOUN
dpc-1631	62	62	status	status	NOUN
dpc-1631	62	63	[	[	X
dpc-1631	62	64	19,20	19,20	NUM
dpc-1631	62	65	]	]	PUNCT
dpc-1631	62	66	.	.	PUNCT
dpc-1631	63	1	breslow	breslow	ADJ
dpc-1631	63	2	thickness	thickness	NOUN
dpc-1631	63	3	and	and	CCONJ
dpc-1631	63	4	other	other	ADJ
dpc-1631	63	5	histological	histological	ADJ
dpc-1631	63	6	prognostic	prognostic	ADJ
dpc-1631	63	7	factors	factor	NOUN
dpc-1631	63	8	some	some	DET
dpc-1631	63	9	studies	study	NOUN
dpc-1631	63	10	have	have	AUX
dpc-1631	63	11	investigated	investigate	VERB
dpc-1631	63	12	the	the	DET
dpc-1631	63	13	relationship	relationship	NOUN
dpc-1631	63	14	between	between	ADP
dpc-1631	63	15	bmi	bmi	NOUN
dpc-1631	63	16	and	and	CCONJ
dpc-1631	63	17	breslow	breslow	ADJ
dpc-1631	63	18	thickness	thickness	NOUN
dpc-1631	63	19	.	.	PUNCT
dpc-1631	64	1	the	the	DET
dpc-1631	64	2	characteristics	characteristic	NOUN
dpc-1631	64	3	of	of	ADP
dpc-1631	64	4	the	the	DET
dpc-1631	64	5	largest	large	ADJ
dpc-1631	64	6	and	and	CCONJ
dpc-1631	64	7	most	most	ADV
dpc-1631	64	8	important	important	ADJ
dpc-1631	64	9	studies	study	NOUN
dpc-1631	64	10	are	be	AUX
dpc-1631	64	11	summarized	summarize	VERB
dpc-1631	64	12	in	in	ADP
dpc-1631	64	13	table	table	NOUN
dpc-1631	64	14	1	1	NUM
dpc-1631	64	15	.	.	X
dpc-1631	64	16	de	de	PROPN
dpc-1631	64	17	giorgi	giorgi	PROPN
dpc-1631	64	18	et	et	PROPN
dpc-1631	64	19	al	al	PROPN
dpc-1631	64	20	reported	report	VERB
dpc-1631	64	21	no	no	DET
dpc-1631	64	22	association	association	NOUN
dpc-1631	64	23	between	between	ADP
dpc-1631	64	24	overweight	overweight	ADJ
dpc-1631	64	25	status	status	NOUN
dpc-1631	64	26	(	(	PUNCT
dpc-1631	64	27	bmi≥25	bmi≥25	PROPN
dpc-1631	64	28	kg	kg	PROPN
dpc-1631	64	29	/	/	SYM
dpc-1631	64	30	m2	m2	PROPN
dpc-1631	64	31	)	)	PUNCT
dpc-1631	64	32	and	and	CCONJ
dpc-1631	64	33	the	the	DET
dpc-1631	64	34	risk	risk	NOUN
dpc-1631	64	35	of	of	ADP
dpc-1631	64	36	thick	thick	ADJ
dpc-1631	64	37	melanoma	melanoma	NOUN
dpc-1631	64	38	(	(	PUNCT
dpc-1631	64	39	breslow	breslow	NOUN
dpc-1631	64	40	thickness	thickness	NOUN
dpc-1631	64	41	more	more	ADJ
dpc-1631	64	42	than	than	ADP
dpc-1631	64	43	1	1	NUM
dpc-1631	64	44	mm	mm	NOUN
dpc-1631	64	45	)	)	PUNCT
dpc-1631	64	46	in	in	ADP
dpc-1631	64	47	the	the	DET
dpc-1631	64	48	total	total	ADJ
dpc-1631	64	49	sample	sample	NOUN
dpc-1631	64	50	or	or	CCONJ
dpc-1631	64	51	men	man	NOUN
dpc-1631	64	52	,	,	PUNCT
dpc-1631	64	53	whereas	whereas	SCONJ
dpc-1631	64	54	a	a	DET
dpc-1631	64	55	trend	trend	NOUN
dpc-1631	64	56	towards	towards	ADP
dpc-1631	64	57	association	association	NOUN
dpc-1631	64	58	between	between	ADP
dpc-1631	64	59	bmi≥25	bmi≥25	PROPN
dpc-1631	64	60	kg	kg	PROPN
dpc-1631	64	61	/	/	SYM
dpc-1631	64	62	m2	m2	PROPN
dpc-1631	64	63	and	and	CCONJ
dpc-1631	64	64	the	the	DET
dpc-1631	64	65	risk	risk	NOUN
dpc-1631	64	66	of	of	ADP
dpc-1631	64	67	thick	thick	ADJ
dpc-1631	64	68	melanoma	melanoma	NOUN
dpc-1631	64	69	was	be	AUX
dpc-1631	64	70	shown	show	VERB
dpc-1631	64	71	among	among	ADP
dpc-1631	64	72	women	woman	NOUN
dpc-1631	64	73	(	(	PUNCT
dpc-1631	64	74	or=1.64	or=1.64	PROPN
dpc-1631	64	75	,	,	PUNCT
dpc-1631	64	76	95	95	NUM
dpc-1631	64	77	%	%	NOUN
dpc-1631	64	78	ci	ci	NOUN
dpc-1631	64	79	0.82–3.28	0.82–3.28	NOUN
dpc-1631	64	80	)	)	PUNCT
dpc-1631	64	81	,	,	PUNCT
dpc-1631	64	82	and	and	CCONJ
dpc-1631	64	83	especially	especially	ADV
dpc-1631	64	84	postmenopausal	postmenopausal	ADJ
dpc-1631	64	85	women	woman	NOUN
dpc-1631	64	86	(	(	PUNCT
dpc-1631	64	87	or=2.50	or=2.50	PROPN
dpc-1631	64	88	,	,	PUNCT
dpc-1631	64	89	95	95	NUM
dpc-1631	64	90	%	%	NOUN
dpc-1631	64	91	ci	ci	NOUN
dpc-1631	64	92	1.06–5.88	1.06–5.88	NUM
dpc-1631	64	93	)	)	PUNCT
dpc-1631	65	1	[	[	X
dpc-1631	65	2	21	21	NUM
dpc-1631	65	3	]	]	PUNCT
dpc-1631	65	4	.	.	PUNCT
dpc-1631	66	1	in	in	ADP
dpc-1631	66	2	the	the	DET
dpc-1631	66	3	report	report	NOUN
dpc-1631	66	4	by	by	ADP
dpc-1631	66	5	gandini	gandini	NOUN
dpc-1631	66	6	et	et	NOUN
dpc-1631	66	7	al	al	PROPN
dpc-1631	67	1	[	[	X
dpc-1631	67	2	22	22	NUM
dpc-1631	67	3	]	]	PUNCT
dpc-1631	67	4	,	,	PUNCT
dpc-1631	67	5	bmi	bmi	PROPN
dpc-1631	67	6	was	be	AUX
dpc-1631	67	7	independently	independently	ADV
dpc-1631	67	8	identified	identify	VERB
dpc-1631	67	9	as	as	ADP
dpc-1631	67	10	significantly	significantly	ADV
dpc-1631	67	11	associated	associate	VERB
dpc-1631	67	12	with	with	ADP
dpc-1631	67	13	breslow	breslow	ADJ
dpc-1631	67	14	thickness	thickness	NOUN
dpc-1631	67	15	.	.	PUNCT
dpc-1631	68	1	in	in	ADP
dpc-1631	68	2	the	the	DET
dpc-1631	68	3	multivariate	multivariate	NOUN
dpc-1631	68	4	random	random	ADJ
dpc-1631	68	5	effects	effect	NOUN
dpc-1631	68	6	model	model	NOUN
dpc-1631	68	7	,	,	PUNCT
dpc-1631	68	8	median	median	ADJ
dpc-1631	68	9	breslow	breslow	NOUN
dpc-1631	68	10	thickness	thickness	NOUN
dpc-1631	68	11	was	be	AUX
dpc-1631	68	12	1.2	1.2	NUM
dpc-1631	68	13	for	for	ADP
dpc-1631	68	14	bmi≥25	bmi≥25	PROPN
dpc-1631	68	15	kg	kg	PROPN
dpc-1631	68	16	/	/	SYM
dpc-1631	68	17	m2	m2	PROPN
dpc-1631	68	18	versus	versus	ADP
dpc-1631	68	19	0.8	0.8	NUM
dpc-1631	68	20	for	for	ADP
dpc-1631	68	21	bmi<25	bmi<25	PROPN
dpc-1631	68	22	kg	kg	PROPN
dpc-1631	68	23	/	/	SYM
dpc-1631	68	24	m2	m2	PROPN
dpc-1631	68	25	(	(	PUNCT
dpc-1631	68	26	p	p	NOUN
dpc-1631	68	27	=	=	NOUN
dpc-1631	68	28	0.0008	0.0008	NUM
dpc-1631	68	29	)	)	PUNCT
dpc-1631	68	30	,	,	PUNCT
dpc-1631	68	31	and	and	CCONJ
dpc-1631	68	32	the	the	DET
dpc-1631	68	33	multivariate	multivariate	NOUN
dpc-1631	68	34	logistic	logistic	ADJ
dpc-1631	68	35	model	model	NOUN
dpc-1631	68	36	disclosed	disclose	VERB
dpc-1631	68	37	a	a	DET
dpc-1631	68	38	significant	significant	ADJ
dpc-1631	68	39	association	association	NOUN
dpc-1631	68	40	of	of	ADP
dpc-1631	68	41	higher	high	ADJ
dpc-1631	68	42	bmi	bmi	NOUN
dpc-1631	68	43	with	with	ADP
dpc-1631	68	44	thick	thick	ADJ
dpc-1631	68	45	melanoma	melanoma	NOUN
dpc-1631	69	1	[	[	X
dpc-1631	69	2	the	the	DET
dpc-1631	69	3	comparison	comparison	NOUN
dpc-1631	69	4	of	of	ADP
dpc-1631	69	5	bmi≥25	bmi≥25	PROPN
dpc-1631	69	6	kg	kg	PROPN
dpc-1631	69	7	/	/	SYM
dpc-1631	69	8	m2	m2	PROPN
dpc-1631	69	9	vs.	vs.	ADP
dpc-1631	69	10	bmi<25	bmi<25	PROPN
dpc-1631	69	11	kg/	kg/	NOUN
dpc-1631	69	12	m2	m2	PROPN
dpc-1631	69	13	produced	produce	VERB
dpc-1631	69	14	an	an	PRON
dpc-1631	69	15	or	or	CCONJ
dpc-1631	69	16	of	of	ADP
dpc-1631	69	17	1.34	1.34	NUM
dpc-1631	69	18	(	(	PUNCT
dpc-1631	69	19	95	95	NUM
dpc-1631	69	20	%	%	NOUN
dpc-1631	69	21	ci	ci	NOUN
dpc-1631	69	22	1.12–1.59	1.12–1.59	NUM
dpc-1631	69	23	;	;	PUNCT
dpc-1631	69	24	p	p	X
dpc-1631	69	25	=	=	NOUN
dpc-1631	69	26	0.001	0.001	NUM
dpc-1631	69	27	)	)	PUNCT
dpc-1631	69	28	]	]	PUNCT
dpc-1631	69	29	.	.	PUNCT
dpc-1631	70	1	skowron	skowron	PROPN
dpc-1631	70	2	et	et	PROPN
dpc-1631	70	3	al	al	PROPN
dpc-1631	70	4	reported	report	VERB
dpc-1631	70	5	that	that	SCONJ
dpc-1631	70	6	bmi≥30	bmi≥30	PROPN
dpc-1631	70	7	kg	kg	PROPN
dpc-1631	70	8	/	/	SYM
dpc-1631	70	9	m2	m2	PROPN
dpc-1631	70	10	was	be	AUX
dpc-1631	70	11	associated	associate	VERB
dpc-1631	70	12	with	with	ADP
dpc-1631	70	13	the	the	DET
dpc-1631	70	14	risk	risk	NOUN
dpc-1631	70	15	of	of	ADP
dpc-1631	70	16	higher	high	ADJ
dpc-1631	70	17	breslow	breslow	ADJ
dpc-1631	70	18	thickness	thickness	NOUN
dpc-1631	70	19	(	(	PUNCT
dpc-1631	70	20	or=2.78	or=2.78	ADJ
dpc-1631	70	21	,	,	PUNCT
dpc-1631	70	22	95	95	NUM
dpc-1631	70	23	%	%	NOUN
dpc-1631	70	24	ci	ci	NOUN
dpc-1631	70	25	1.55–4.94	1.55–4.94	NUM
dpc-1631	70	26	;	;	PUNCT
dpc-1631	70	27	p	p	PROPN
dpc-1631	70	28	=	=	NOUN
dpc-1631	70	29	0.001	0.001	NUM
dpc-1631	70	30	)	)	PUNCT
dpc-1631	71	1	[	[	X
dpc-1631	71	2	23	23	NUM
dpc-1631	71	3	]	]	PUNCT
dpc-1631	71	4	.	.	PUNCT
dpc-1631	72	1	in	in	ADP
dpc-1631	72	2	the	the	DET
dpc-1631	72	3	multivariate	multivariate	NOUN
dpc-1631	72	4	analysis	analysis	NOUN
dpc-1631	72	5	of	of	ADP
dpc-1631	72	6	significant	significant	ADJ
dpc-1631	72	7	clinical	clinical	ADJ
dpc-1631	72	8	and	and	CCONJ
dpc-1631	72	9	histological	histological	ADJ
dpc-1631	72	10	criteria	criterion	NOUN
dpc-1631	72	11	,	,	PUNCT
dpc-1631	72	12	these	these	DET
dpc-1631	72	13	authors	author	NOUN
dpc-1631	72	14	found	find	VERB
dpc-1631	72	15	that	that	SCONJ
dpc-1631	72	16	obesity	obesity	NOUN
dpc-1631	72	17	had	have	VERB
dpc-1631	72	18	an	an	DET
dpc-1631	72	19	increased	increase	VERB
dpc-1631	72	20	risk	risk	NOUN
dpc-1631	72	21	of	of	ADP
dpc-1631	72	22	higher	high	ADJ
dpc-1631	72	23	tumor	tumor	NOUN
dpc-1631	72	24	thickness	thickness	NOUN
dpc-1631	72	25	(	(	PUNCT
dpc-1631	72	26	or=1.86	or=1.86	ADJ
dpc-1631	72	27	,	,	PUNCT
dpc-1631	72	28	95	95	NUM
dpc-1631	72	29	%	%	NOUN
dpc-1631	72	30	ci	ci	NOUN
dpc-1631	72	31	0.91–3.77	0.91–3.77	NUM
dpc-1631	72	32	)	)	PUNCT
dpc-1631	72	33	,	,	PUNCT
dpc-1631	72	34	but	but	CCONJ
dpc-1631	72	35	without	without	ADP
dpc-1631	72	36	any	any	DET
dpc-1631	72	37	statistical	statistical	ADJ
dpc-1631	72	38	significance	significance	NOUN
dpc-1631	72	39	(	(	PUNCT
dpc-1631	72	40	p	p	NOUN
dpc-1631	72	41	=	=	NOUN
dpc-1631	72	42	0.086	0.086	NUM
dpc-1631	72	43	)	)	PUNCT
dpc-1631	72	44	.	.	PUNCT
dpc-1631	73	1	when	when	SCONJ
dpc-1631	73	2	considering	consider	VERB
dpc-1631	73	3	only	only	ADJ
dpc-1631	73	4	clinical	clinical	ADJ
dpc-1631	73	5	features	feature	NOUN
dpc-1631	73	6	in	in	ADP
dpc-1631	73	7	the	the	DET
dpc-1631	73	8	model	model	NOUN
dpc-1631	73	9	,	,	PUNCT
dpc-1631	73	10	obesity	obesity	NOUN
dpc-1631	73	11	was	be	AUX
dpc-1631	73	12	significantly	significantly	ADV
dpc-1631	73	13	associated	associate	VERB
dpc-1631	73	14	with	with	ADP
dpc-1631	73	15	a	a	DET
dpc-1631	73	16	risk	risk	NOUN
dpc-1631	73	17	of	of	ADP
dpc-1631	73	18	higher	high	ADJ
dpc-1631	73	19	breslow	breslow	ADJ
dpc-1631	73	20	thickness	thickness	NOUN
dpc-1631	73	21	(	(	PUNCT
dpc-1631	73	22	or=2.33	or=2.33	NOUN
dpc-1631	73	23	,	,	PUNCT
dpc-1631	73	24	95	95	NUM
dpc-1631	73	25	%	%	NOUN
dpc-1631	73	26	ci	ci	NOUN
dpc-1631	73	27	1.21–4.49	1.21–4.49	NUM
dpc-1631	73	28	;	;	PUNCT
dpc-1631	73	29	p	p	X
dpc-1631	73	30	=	=	NOUN
dpc-1631	73	31	0.011	0.011	NUM
dpc-1631	73	32	)	)	PUNCT
dpc-1631	73	33	.	.	PUNCT
dpc-1631	74	1	the	the	DET
dpc-1631	74	2	clinical	clinical	ADJ
dpc-1631	74	3	characteristics	characteristic	NOUN
dpc-1631	74	4	of	of	ADP
dpc-1631	74	5	melanoma	melanoma	NOUN
dpc-1631	74	6	,	,	PUNCT
dpc-1631	74	7	its	its	PRON
dpc-1631	74	8	topography	topography	NOUN
dpc-1631	74	9	and	and	CCONJ
dpc-1631	74	10	visibility	visibility	NOUN
dpc-1631	74	11	were	be	AUX
dpc-1631	74	12	not	not	PART
dpc-1631	74	13	associated	associate	VERB
dpc-1631	74	14	table	table	NOUN
dpc-1631	74	15	1	1	NUM
dpc-1631	74	16	.	.	PUNCT
dpc-1631	75	1	principal	principal	ADJ
dpc-1631	75	2	studies	study	NOUN
dpc-1631	75	3	exploring	explore	VERB
dpc-1631	75	4	the	the	DET
dpc-1631	75	5	relationship	relationship	NOUN
dpc-1631	75	6	between	between	ADP
dpc-1631	75	7	bmi	bmi	NOUN
dpc-1631	75	8	and	and	CCONJ
dpc-1631	75	9	breslow	breslow	ADJ
dpc-1631	75	10	thickness	thickness	NOUN
dpc-1631	75	11	:	:	PUNCT
dpc-1631	75	12	general	general	ADJ
dpc-1631	75	13	aspects	aspect	NOUN
dpc-1631	75	14	and	and	CCONJ
dpc-1631	75	15	characteristics	characteristic	NOUN
dpc-1631	75	16	of	of	ADP
dpc-1631	75	17	melanoma	melanoma	NOUN
dpc-1631	75	18	cases	case	NOUN
dpc-1631	75	19	authors	author	NOUN
dpc-1631	75	20	de	de	ADP
dpc-1631	75	21	giorgi	giorgi	PROPN
dpc-1631	75	22	et	et	NOUN
dpc-1631	75	23	al	al	PROPN
dpc-1631	76	1	[	[	X
dpc-1631	76	2	21	21	NUM
dpc-1631	76	3	]	]	PUNCT
dpc-1631	76	4	gandini	gandini	NOUN
dpc-1631	76	5	et	et	NOUN
dpc-1631	76	6	al	al	PROPN
dpc-1631	77	1	[	[	X
dpc-1631	77	2	22	22	NUM
dpc-1631	77	3	]	]	PUNCT
dpc-1631	77	4	skowron	skowron	X
dpc-1631	77	5	et	et	PROPN
dpc-1631	77	6	al	al	PROPN
dpc-1631	78	1	[	[	X
dpc-1631	78	2	23	23	NUM
dpc-1631	78	3	]	]	PUNCT
dpc-1631	78	4	stenehjem	stenehjem	NOUN
dpc-1631	78	5	et	et	NOUN
dpc-1631	78	6	al	al	PROPN
dpc-1631	79	1	[	[	X
dpc-1631	79	2	24	24	NUM
dpc-1631	79	3	]	]	PUNCT
dpc-1631	79	4	study	study	NOUN
dpc-1631	79	5	type	type	NOUN
dpc-1631	79	6	retrospective	retrospective	ADJ
dpc-1631	79	7	caseseries	caseserie	NOUN
dpc-1631	79	8	study	study	NOUN
dpc-1631	79	9	(	(	PUNCT
dpc-1631	79	10	single	single	ADJ
dpc-1631	79	11	center	center	NOUN
dpc-1631	79	12	,	,	PUNCT
dpc-1631	79	13	florence	florence	NOUN
dpc-1631	79	14	,	,	PUNCT
dpc-1631	79	15	italy	italy	PROPN
dpc-1631	79	16	)	)	PUNCT
dpc-1631	79	17	hospital	hospital	NOUN
dpc-1631	79	18	-	-	PUNCT
dpc-1631	79	19	based	base	VERB
dpc-1631	79	20	multicenter	multicenter	NOUN
dpc-1631	79	21	study	study	NOUN
dpc-1631	79	22	(	(	PUNCT
dpc-1631	79	23	italy	italy	PROPN
dpc-1631	79	24	)	)	PUNCT
dpc-1631	79	25	cross	cross	ADJ
dpc-1631	79	26	-	-	ADJ
dpc-1631	79	27	sectional	sectional	ADJ
dpc-1631	79	28	study	study	NOUN
dpc-1631	79	29	in	in	ADP
dpc-1631	79	30	a	a	DET
dpc-1631	79	31	prospective	prospective	ADJ
dpc-1631	79	32	cohort	cohort	NOUN
dpc-1631	79	33	(	(	PUNCT
dpc-1631	79	34	single	single	ADJ
dpc-1631	79	35	center	center	NOUN
dpc-1631	79	36	,	,	PUNCT
dpc-1631	79	37	valence	valence	NOUN
dpc-1631	79	38	,	,	PUNCT
dpc-1631	79	39	france	france	PROPN
dpc-1631	79	40	)	)	PUNCT
dpc-1631	79	41	prospective	prospective	ADJ
dpc-1631	79	42	populationbased	populationbase	VERB
dpc-1631	79	43	cohort	cohort	NOUN
dpc-1631	79	44	study	study	NOUN
dpc-1631	79	45	;	;	PUNCT
dpc-1631	79	46	linkage	linkage	NOUN
dpc-1631	79	47	to	to	ADP
dpc-1631	79	48	national	national	ADJ
dpc-1631	79	49	cancer	cancer	NOUN
dpc-1631	79	50	registry	registry	NOUN
dpc-1631	79	51	(	(	PUNCT
dpc-1631	79	52	norway	norway	PROPN
dpc-1631	79	53	)	)	PUNCT
dpc-1631	79	54	study	study	NOUN
dpc-1631	79	55	period	period	NOUN
dpc-1631	79	56	jan	jan	PROPN
dpc-1631	79	57	1998	1998	NUM
dpc-1631	79	58	-	-	PUNCT
dpc-1631	79	59	jan	jan	PROPN
dpc-1631	79	60	2009	2009	NUM
dpc-1631	79	61	dec	dec	PROPN
dpc-1631	79	62	2010	2010	NUM
dpc-1631	79	63	-	-	PUNCT
dpc-1631	79	64	dec	dec	PROPN
dpc-1631	79	65	2013	2013	NUM
dpc-1631	79	66	may	may	NOUN
dpc-1631	79	67	2007	2007	NUM
dpc-1631	79	68	-	-	PUNCT
dpc-1631	79	69	may	may	AUX
dpc-1631	79	70	2010	2010	NUM
dpc-1631	79	71	1972	1972	NUM
dpc-1631	79	72	-	-	SYM
dpc-1631	79	73	2014	2014	NUM
dpc-1631	79	74	cases	case	NOUN
dpc-1631	79	75	of	of	ADP
dpc-1631	79	76	primary	primary	ADJ
dpc-1631	79	77	melanoma	melanoma	NOUN
dpc-1631	79	78	examined	examine	VERB
dpc-1631	79	79	605	605	NUM
dpc-1631	79	80	86.4	86.4	NUM
dpc-1631	79	81	%	%	NOUN
dpc-1631	79	82	thin	thin	ADJ
dpc-1631	79	83	melanomas	melanomas	NOUN
dpc-1631	79	84	(	(	PUNCT
dpc-1631	79	85	including	include	VERB
dpc-1631	79	86	in	in	ADP
dpc-1631	79	87	situ	situ	ADJ
dpc-1631	79	88	melanomas	melanomas	NOUN
dpc-1631	79	89	)	)	PUNCT
dpc-1631	79	90	2738	2738	NUM
dpc-1631	79	91	50	50	NUM
dpc-1631	79	92	%	%	NOUN
dpc-1631	79	93	thin	thin	ADJ
dpc-1631	79	94	melanomas	melanoma	NOUN
dpc-1631	79	95	;	;	PUNCT
dpc-1631	79	96	29	29	NUM
dpc-1631	79	97	%	%	NOUN
dpc-1631	79	98	very	very	ADV
dpc-1631	79	99	thick	thick	ADJ
dpc-1631	79	100	melanomas	melanoma	NOUN
dpc-1631	79	101	;	;	PUNCT
dpc-1631	79	102	25	25	NUM
dpc-1631	79	103	%	%	NOUN
dpc-1631	79	104	ulcerated	ulcerated	ADJ
dpc-1631	79	105	melanomas	melanoma	NOUN
dpc-1631	79	106	;	;	PUNCT
dpc-1631	79	107	1	1	NUM
dpc-1631	79	108	%	%	NOUN
dpc-1631	79	109	with	with	ADP
dpc-1631	79	110	distant	distant	ADJ
dpc-1631	79	111	metastases	metastasis	NOUN
dpc-1631	79	112	;	;	PUNCT
dpc-1631	79	113	13	13	NUM
dpc-1631	79	114	%	%	NOUN
dpc-1631	79	115	with	with	ADP
dpc-1631	79	116	lymph	lymph	NOUN
dpc-1631	79	117	node	node	NOUN
dpc-1631	79	118	involvement	involvement	NOUN
dpc-1631	79	119	427	427	NUM
dpc-1631	79	120	65	65	NUM
dpc-1631	79	121	%	%	NOUN
dpc-1631	79	122	thin	thin	ADJ
dpc-1631	79	123	melanomas	melanoma	NOUN
dpc-1631	79	124	;	;	PUNCT
dpc-1631	79	125	17.6	17.6	NUM
dpc-1631	79	126	%	%	NOUN
dpc-1631	79	127	very	very	ADV
dpc-1631	79	128	thick	thick	ADJ
dpc-1631	79	129	melanomas	melanomas	NOUN
dpc-1631	79	130	2570	2570	NUM
dpc-1631	79	131	53.4	53.4	NUM
dpc-1631	79	132	%	%	NOUN
dpc-1631	79	133	thin	thin	ADJ
dpc-1631	79	134	melanomas	melanoma	NOUN
dpc-1631	79	135	;	;	PUNCT
dpc-1631	79	136	23.7	23.7	NUM
dpc-1631	79	137	%	%	NOUN
dpc-1631	79	138	very	very	ADV
dpc-1631	79	139	thick	thick	ADJ
dpc-1631	79	140	melanomas	melanoma	NOUN
dpc-1631	79	141	;	;	PUNCT
dpc-1631	79	142	4	4	NUM
dpc-1631	79	143	%	%	NOUN
dpc-1631	79	144	with	with	ADP
dpc-1631	79	145	regional	regional	ADJ
dpc-1631	79	146	metastases	metastasis	NOUN
dpc-1631	79	147	,	,	PUNCT
dpc-1631	79	148	1	1	NUM
dpc-1631	79	149	%	%	NOUN
dpc-1631	79	150	with	with	ADP
dpc-1631	79	151	distant	distant	ADJ
dpc-1631	79	152	metastases	metastasis	NOUN
dpc-1631	79	153	;	;	PUNCT
dpc-1631	79	154	16	16	NUM
dpc-1631	79	155	%	%	NOUN
dpc-1631	79	156	unspecified	unspecified	ADJ
dpc-1631	79	157	excluded	exclude	VERB
dpc-1631	79	158	cases	case	NOUN
dpc-1631	79	159	patients	patient	NOUN
dpc-1631	79	160	<	<	X
dpc-1631	79	161	40	40	NUM
dpc-1631	79	162	yrs	yr	NOUN
dpc-1631	79	163	of	of	ADP
dpc-1631	79	164	age	age	NOUN
dpc-1631	79	165	(	(	PUNCT
dpc-1631	79	166	when	when	SCONJ
dpc-1631	79	167	stratifying	stratify	VERB
dpc-1631	79	168	by	by	ADP
dpc-1631	79	169	age	age	NOUN
dpc-1631	79	170	,	,	PUNCT
dpc-1631	79	171	because	because	SCONJ
dpc-1631	79	172	of	of	ADP
dpc-1631	79	173	their	their	PRON
dpc-1631	79	174	low	low	ADJ
dpc-1631	79	175	number	number	NOUN
dpc-1631	79	176	)	)	PUNCT
dpc-1631	79	177	alm	alm	NOUN
dpc-1631	79	178	,	,	PUNCT
dpc-1631	79	179	mucosal	mucosal	NOUN
dpc-1631	79	180	,	,	PUNCT
dpc-1631	79	181	in	in	ADP
dpc-1631	79	182	situ	situ	NOUN
dpc-1631	79	183	and	and	CCONJ
dpc-1631	79	184	retrospective	retrospective	ADJ
dpc-1631	79	185	melanomas	melanomas	NOUN
dpc-1631	79	186	in	in	ADP
dpc-1631	79	187	situ	situ	NOUN
dpc-1631	79	188	,	,	PUNCT
dpc-1631	79	189	recurrent	recurrent	NOUN
dpc-1631	79	190	,	,	PUNCT
dpc-1631	79	191	ocular	ocular	ADJ
dpc-1631	79	192	,	,	PUNCT
dpc-1631	79	193	mucosal	mucosal	NOUN
dpc-1631	79	194	and	and	CCONJ
dpc-1631	79	195	metastatic	metastatic	ADJ
dpc-1631	79	196	melanomas	melanoma	NOUN
dpc-1631	79	197	not	not	PART
dpc-1631	79	198	histologically	histologically	ADV
dpc-1631	79	199	verified	verify	VERB
dpc-1631	79	200	or	or	CCONJ
dpc-1631	79	201	retrospective	retrospective	ADJ
dpc-1631	79	202	melanomas	melanomas	NOUN
dpc-1631	79	203	gender	gender	NOUN
dpc-1631	79	204	55	55	NUM
dpc-1631	79	205	%	%	NOUN
dpc-1631	79	206	women	woman	NOUN
dpc-1631	79	207	;	;	PUNCT
dpc-1631	79	208	45	45	NUM
dpc-1631	79	209	%	%	NOUN
dpc-1631	79	210	men	man	NOUN
dpc-1631	79	211	49	49	NUM
dpc-1631	79	212	%	%	NOUN
dpc-1631	79	213	women	woman	NOUN
dpc-1631	79	214	;	;	PUNCT
dpc-1631	79	215	51	51	NUM
dpc-1631	79	216	%	%	NOUN
dpc-1631	79	217	men	man	NOUN
dpc-1631	79	218	50	50	NUM
dpc-1631	79	219	%	%	NOUN
dpc-1631	79	220	women	woman	NOUN
dpc-1631	79	221	;	;	PUNCT
dpc-1631	79	222	50	50	NUM
dpc-1631	79	223	%	%	NOUN
dpc-1631	79	224	men	man	NOUN
dpc-1631	79	225	44.6	44.6	NUM
dpc-1631	79	226	%	%	NOUN
dpc-1631	79	227	women	woman	NOUN
dpc-1631	79	228	;	;	PUNCT
dpc-1631	79	229	55.4	55.4	NUM
dpc-1631	79	230	%	%	NOUN
dpc-1631	79	231	men	man	NOUN
dpc-1631	79	232	age	age	NOUN
dpc-1631	79	233	,	,	PUNCT
dpc-1631	79	234	yrs	yr	NOUN
dpc-1631	79	235	mean	mean	VERB
dpc-1631	79	236	53.06	53.06	NUM
dpc-1631	79	237	(	(	PUNCT
dpc-1631	79	238	sd	sd	ADP
dpc-1631	79	239	16.02	16.02	NUM
dpc-1631	79	240	)	)	PUNCT
dpc-1631	79	241	median	median	NOUN
dpc-1631	79	242	55	55	NUM
dpc-1631	79	243	mean	mean	NOUN
dpc-1631	79	244	57.74	57.74	NUM
dpc-1631	79	245	(	(	PUNCT
dpc-1631	79	246	sd	sd	NOUN
dpc-1631	79	247	16.1	16.1	NUM
dpc-1631	79	248	)	)	PUNCT
dpc-1631	79	249	mean	mean	VERB
dpc-1631	79	250	age	age	NOUN
dpc-1631	79	251	at	at	ADP
dpc-1631	79	252	diagnosis	diagnosis	NOUN
dpc-1631	79	253	60	60	NUM
dpc-1631	79	254	height	height	NOUN
dpc-1631	79	255	and	and	CCONJ
dpc-1631	79	256	weight	weight	NOUN
dpc-1631	79	257	at	at	ADP
dpc-1631	79	258	the	the	DET
dpc-1631	79	259	first	first	ADJ
dpc-1631	79	260	visit	visit	NOUN
dpc-1631	79	261	,	,	PUNCT
dpc-1631	79	262	measured	measure	VERB
dpc-1631	79	263	by	by	ADP
dpc-1631	79	264	a	a	DET
dpc-1631	79	265	physician	physician	NOUN
dpc-1631	79	266	collected	collect	VERB
dpc-1631	79	267	through	through	ADP
dpc-1631	79	268	a	a	DET
dpc-1631	79	269	self	self	NOUN
dpc-1631	79	270	-	-	PUNCT
dpc-1631	79	271	administered	administer	VERB
dpc-1631	79	272	questionnaire	questionnaire	NOUN
dpc-1631	79	273	measured	measure	VERB
dpc-1631	79	274	(	(	PUNCT
dpc-1631	79	275	information	information	NOUN
dpc-1631	79	276	not	not	PART
dpc-1631	79	277	further	far	ADV
dpc-1631	79	278	specified	specify	VERB
dpc-1631	79	279	)	)	PUNCT
dpc-1631	79	280	measured	measure	VERB
dpc-1631	79	281	by	by	ADP
dpc-1631	79	282	trained	train	VERB
dpc-1631	79	283	staff	staff	NOUN
dpc-1631	79	284	mean	mean	VERB
dpc-1631	79	285	bmi	bmi	NOUN
dpc-1631	79	286	(	(	PUNCT
dpc-1631	79	287	sd	sd	NOUN
dpc-1631	79	288	)	)	PUNCT
dpc-1631	79	289	,	,	PUNCT
dpc-1631	79	290	kg	kg	PROPN
dpc-1631	79	291	/	/	SYM
dpc-1631	79	292	m2	m2	PROPN
dpc-1631	79	293	24.78	24.78	NUM
dpc-1631	79	294	(	(	PUNCT
dpc-1631	79	295	4.09	4.09	NUM
dpc-1631	79	296	)	)	PUNCT
dpc-1631	79	297	not	not	PART
dpc-1631	79	298	reported	report	VERB
dpc-1631	79	299	25.38	25.38	NUM
dpc-1631	79	300	(	(	PUNCT
dpc-1631	79	301	4.61	4.61	NUM
dpc-1631	79	302	)	)	PUNCT
dpc-1631	79	303	24.7	24.7	NUM
dpc-1631	79	304	(	(	PUNCT
dpc-1631	79	305	3.3	3.3	NUM
dpc-1631	79	306	)	)	PUNCT
dpc-1631	79	307	table	table	NOUN
dpc-1631	79	308	1	1	NUM
dpc-1631	79	309	continues	continue	VERB
dpc-1631	79	310	4	4	NUM
dpc-1631	79	311	review	review	NOUN
dpc-1631	79	312	|	|	ADV
dpc-1631	79	313	dermatol	dermatol	ADJ
dpc-1631	79	314	pract	pract	NOUN
dpc-1631	79	315	concept	concept	NOUN
dpc-1631	79	316	.	.	PUNCT
dpc-1631	80	1	2021;11(4	2021;11(4	NUM
dpc-1631	80	2	):	):	PUNCT
dpc-1631	80	3	e2021106	e2021106	NOUN
dpc-1631	80	4	with	with	ADP
dpc-1631	80	5	the	the	DET
dpc-1631	80	6	distribution	distribution	NOUN
dpc-1631	80	7	of	of	ADP
dpc-1631	80	8	bmi	bmi	NOUN
dpc-1631	80	9	categories	category	NOUN
dpc-1631	80	10	.	.	PUNCT
dpc-1631	81	1	instead	instead	ADV
dpc-1631	81	2	,	,	PUNCT
dpc-1631	81	3	melanoma	melanoma	NOUN
dpc-1631	81	4	subtypes	subtype	NOUN
dpc-1631	81	5	were	be	AUX
dpc-1631	81	6	differently	differently	ADV
dpc-1631	81	7	distributed	distribute	VERB
dpc-1631	81	8	according	accord	VERB
dpc-1631	81	9	to	to	ADP
dpc-1631	81	10	bmi	bmi	PROPN
dpc-1631	81	11	categories	category	NOUN
dpc-1631	81	12	(	(	PUNCT
dpc-1631	81	13	p	p	X
dpc-1631	81	14	=	=	NOUN
dpc-1631	81	15	0.007	0.007	NUM
dpc-1631	81	16	)	)	PUNCT
dpc-1631	81	17	,	,	PUNCT
dpc-1631	81	18	with	with	ADP
dpc-1631	81	19	superficial	superficial	ADJ
dpc-1631	81	20	spreading	spread	VERB
dpc-1631	81	21	,	,	PUNCT
dpc-1631	81	22	lentigo	lentigo	ADJ
dpc-1631	81	23	maligna	maligna	PROPN
dpc-1631	81	24	,	,	PUNCT
dpc-1631	81	25	and	and	CCONJ
dpc-1631	81	26	unclassified	unclassified	ADJ
dpc-1631	81	27	melanomas	melanoma	NOUN
dpc-1631	81	28	mostly	mostly	ADV
dpc-1631	81	29	found	find	VERB
dpc-1631	81	30	in	in	ADP
dpc-1631	81	31	patients	patient	NOUN
dpc-1631	81	32	with	with	ADP
dpc-1631	81	33	normal	normal	ADJ
dpc-1631	81	34	bmi	bmi	NOUN
dpc-1631	81	35	,	,	PUNCT
dpc-1631	81	36	acral	acral	ADJ
dpc-1631	81	37	lentiginous	lentiginous	ADJ
dpc-1631	81	38	melanoma	melanoma	NOUN
dpc-1631	81	39	in	in	ADP
dpc-1631	81	40	preobese	preobese	ADJ
dpc-1631	81	41	patients	patient	NOUN
dpc-1631	81	42	and	and	CCONJ
dpc-1631	81	43	nodular	nodular	ADJ
dpc-1631	81	44	melanoma	melanoma	NOUN
dpc-1631	81	45	in	in	ADP
dpc-1631	81	46	the	the	DET
dpc-1631	81	47	obese	obese	ADJ
dpc-1631	81	48	patients	patient	NOUN
dpc-1631	81	49	[	[	X
dpc-1631	81	50	23	23	NUM
dpc-1631	81	51	]	]	PUNCT
dpc-1631	81	52	.	.	PUNCT
dpc-1631	82	1	following	follow	VERB
dpc-1631	82	2	these	these	DET
dpc-1631	82	3	publications	publication	NOUN
dpc-1631	82	4	,	,	PUNCT
dpc-1631	82	5	the	the	DET
dpc-1631	82	6	study	study	NOUN
dpc-1631	82	7	of	of	ADP
dpc-1631	82	8	stenehjem	stenehjem	NOUN
dpc-1631	82	9	et	et	PROPN
dpc-1631	82	10	al	al	PROPN
dpc-1631	82	11	was	be	AUX
dpc-1631	82	12	the	the	DET
dpc-1631	82	13	first	first	ADJ
dpc-1631	82	14	to	to	PART
dpc-1631	82	15	model	model	VERB
dpc-1631	82	16	breslow	breslow	ADJ
dpc-1631	82	17	thickness	thickness	NOUN
dpc-1631	82	18	as	as	ADP
dpc-1631	82	19	a	a	DET
dpc-1631	82	20	continuous	continuous	ADJ
dpc-1631	82	21	outcome	outcome	NOUN
dpc-1631	82	22	in	in	ADP
dpc-1631	82	23	relation	relation	NOUN
dpc-1631	82	24	to	to	ADP
dpc-1631	82	25	anthropometric	anthropometric	ADJ
dpc-1631	82	26	measures	measure	NOUN
dpc-1631	82	27	which	which	PRON
dpc-1631	82	28	were	be	AUX
dpc-1631	82	29	obtained	obtain	VERB
dpc-1631	82	30	prediagnostically	prediagnostically	ADV
dpc-1631	82	31	[	[	X
dpc-1631	82	32	24	24	NUM
dpc-1631	82	33	]	]	PUNCT
dpc-1631	82	34	.	.	PUNCT
dpc-1631	83	1	breslow	breslow	ADJ
dpc-1631	83	2	thickness	thickness	NOUN
dpc-1631	83	3	was	be	AUX
dpc-1631	83	4	found	find	VERB
dpc-1631	83	5	to	to	PART
dpc-1631	83	6	be	be	AUX
dpc-1631	83	7	significantly	significantly	ADV
dpc-1631	83	8	increased	increase	VERB
dpc-1631	83	9	with	with	ADP
dpc-1631	83	10	increasing	increase	VERB
dpc-1631	83	11	values	value	NOUN
dpc-1631	83	12	of	of	ADP
dpc-1631	83	13	bmi	bmi	NOUN
dpc-1631	83	14	(	(	PUNCT
dpc-1631	83	15	ptrend	ptrend	NOUN
dpc-1631	83	16	=	=	PUNCT
dpc-1631	83	17	0.009	0.009	NUM
dpc-1631	83	18	)	)	PUNCT
dpc-1631	83	19	.	.	PUNCT
dpc-1631	84	1	a	a	DET
dpc-1631	84	2	bmi>30	bmi>30	ADJ
dpc-1631	84	3	kg	kg	PROPN
dpc-1631	84	4	/	/	SYM
dpc-1631	84	5	m2	m2	PROPN
dpc-1631	84	6	was	be	AUX
dpc-1631	84	7	associated	associate	VERB
dpc-1631	84	8	with	with	ADP
dpc-1631	84	9	significantly	significantly	ADV
dpc-1631	84	10	higher	high	ADJ
dpc-1631	84	11	tumor	tumor	NOUN
dpc-1631	84	12	thickness	thickness	NOUN
dpc-1631	84	13	as	as	SCONJ
dpc-1631	84	14	compared	compare	VERB
dpc-1631	84	15	to	to	ADP
dpc-1631	84	16	normal	normal	ADJ
dpc-1631	84	17	weight	weight	NOUN
dpc-1631	84	18	patients	patient	NOUN
dpc-1631	84	19	(	(	PUNCT
dpc-1631	84	20	geometric	geometric	ADJ
dpc-1631	84	21	mean	mean	NOUN
dpc-1631	84	22	ratio	ratio	NOUN
dpc-1631	84	23	1.16	1.16	NUM
dpc-1631	84	24	,	,	PUNCT
dpc-1631	84	25	95	95	NUM
dpc-1631	84	26	%	%	NOUN
dpc-1631	84	27	ci	ci	NOUN
dpc-1631	84	28	1.04–1.30	1.04–1.30	NUM
dpc-1631	84	29	)	)	PUNCT
dpc-1631	84	30	.	.	PUNCT
dpc-1631	85	1	when	when	SCONJ
dpc-1631	85	2	melanomas	melanomas	PROPN
dpc-1631	85	3	were	be	AUX
dpc-1631	85	4	stratified	stratify	VERB
dpc-1631	85	5	by	by	ADP
dpc-1631	85	6	anatomical	anatomical	ADJ
dpc-1631	85	7	site	site	NOUN
dpc-1631	85	8	and	and	CCONJ
dpc-1631	85	9	histological	histological	ADJ
dpc-1631	85	10	variants	variant	NOUN
dpc-1631	85	11	,	,	PUNCT
dpc-1631	85	12	significant	significant	ADJ
dpc-1631	85	13	positive	positive	ADJ
dpc-1631	85	14	trends	trend	NOUN
dpc-1631	85	15	were	be	AUX
dpc-1631	85	16	seen	see	VERB
dpc-1631	85	17	for	for	ADP
dpc-1631	85	18	continuous	continuous	ADJ
dpc-1631	85	19	variables	variable	NOUN
dpc-1631	85	20	of	of	ADP
dpc-1631	85	21	bmi	bmi	NOUN
dpc-1631	85	22	in	in	ADP
dpc-1631	85	23	trunk	trunk	NOUN
dpc-1631	85	24	and	and	CCONJ
dpc-1631	85	25	lower	low	ADJ
dpc-1631	85	26	limb	limb	NOUN
dpc-1631	85	27	melanomas	melanoma	NOUN
dpc-1631	85	28	and	and	CCONJ
dpc-1631	85	29	in	in	ADP
dpc-1631	85	30	superficial	superficial	ADJ
dpc-1631	85	31	spreading	spread	VERB
dpc-1631	85	32	melanomas	melanoma	NOUN
dpc-1631	85	33	,	,	PUNCT
dpc-1631	85	34	respectively	respectively	ADV
dpc-1631	85	35	,	,	PUNCT
dpc-1631	85	36	but	but	CCONJ
dpc-1631	85	37	not	not	PART
dpc-1631	85	38	in	in	ADP
dpc-1631	85	39	melanomas	melanomas	NOUN
dpc-1631	85	40	localized	localize	VERB
dpc-1631	85	41	in	in	ADP
dpc-1631	85	42	other	other	ADJ
dpc-1631	85	43	sites	site	NOUN
dpc-1631	85	44	or	or	CCONJ
dpc-1631	85	45	in	in	ADP
dpc-1631	85	46	other	other	ADJ
dpc-1631	85	47	histological	histological	ADJ
dpc-1631	85	48	subtypes	subtype	NOUN
dpc-1631	85	49	.	.	PUNCT
dpc-1631	86	1	the	the	DET
dpc-1631	86	2	shape	shape	NOUN
dpc-1631	86	3	of	of	ADP
dpc-1631	86	4	the	the	DET
dpc-1631	86	5	expoauthors	expoauthors	PROPN
dpc-1631	86	6	de	de	ADP
dpc-1631	86	7	giorgi	giorgi	PROPN
dpc-1631	86	8	et	et	NOUN
dpc-1631	86	9	al	al	PROPN
dpc-1631	87	1	[	[	X
dpc-1631	87	2	21	21	NUM
dpc-1631	87	3	]	]	PUNCT
dpc-1631	87	4	gandini	gandini	NOUN
dpc-1631	87	5	et	et	NOUN
dpc-1631	87	6	al	al	PROPN
dpc-1631	88	1	[	[	X
dpc-1631	88	2	22	22	NUM
dpc-1631	88	3	]	]	PUNCT
dpc-1631	88	4	skowron	skowron	X
dpc-1631	88	5	et	et	PROPN
dpc-1631	88	6	al	al	PROPN
dpc-1631	89	1	[	[	X
dpc-1631	89	2	23	23	NUM
dpc-1631	89	3	]	]	PUNCT
dpc-1631	89	4	stenehjem	stenehjem	NOUN
dpc-1631	89	5	et	et	NOUN
dpc-1631	89	6	al	al	PROPN
dpc-1631	90	1	[	[	X
dpc-1631	90	2	24	24	NUM
dpc-1631	90	3	]	]	PUNCT
dpc-1631	90	4	bmi	bmi	NOUN
dpc-1631	90	5	categories	category	NOUN
dpc-1631	90	6	,	,	PUNCT
dpc-1631	90	7	kg/	kg/	NOUN
dpc-1631	90	8	m2	m2	PROPN
dpc-1631	90	9	(	(	PUNCT
dpc-1631	90	10	%	%	INTJ
dpc-1631	90	11	)	)	PUNCT
dpc-1631	91	1	<	<	X
dpc-1631	91	2	25	25	NUM
dpc-1631	91	3	(	(	PUNCT
dpc-1631	91	4	58	58	NUM
dpc-1631	91	5	%	%	NOUN
dpc-1631	91	6	)	)	PUNCT
dpc-1631	91	7	;	;	PUNCT
dpc-1631	91	8	≥25	≥25	X
dpc-1631	91	9	(	(	PUNCT
dpc-1631	91	10	42	42	NUM
dpc-1631	91	11	%	%	NOUN
dpc-1631	91	12	)	)	PUNCT
dpc-1631	92	1	<	<	X
dpc-1631	92	2	25	25	NUM
dpc-1631	92	3	(	(	PUNCT
dpc-1631	92	4	47	47	NUM
dpc-1631	92	5	%	%	NOUN
dpc-1631	92	6	)	)	PUNCT
dpc-1631	92	7	;	;	PUNCT
dpc-1631	92	8	≥25	≥25	X
dpc-1631	92	9	(	(	PUNCT
dpc-1631	92	10	53	53	NUM
dpc-1631	92	11	%	%	NOUN
dpc-1631	92	12	)	)	PUNCT
dpc-1631	93	1	<	<	X
dpc-1631	93	2	25	25	NUM
dpc-1631	93	3	(	(	PUNCT
dpc-1631	93	4	49	49	NUM
dpc-1631	93	5	%	%	NOUN
dpc-1631	93	6	)	)	PUNCT
dpc-1631	93	7	;	;	PUNCT
dpc-1631	93	8	25	25	NUM
dpc-1631	93	9	-	-	SYM
dpc-1631	93	10	29.9	29.9	NUM
dpc-1631	93	11	(	(	PUNCT
dpc-1631	93	12	38	38	NUM
dpc-1631	93	13	%	%	NOUN
dpc-1631	93	14	)	)	PUNCT
dpc-1631	94	1	;	;	PUNCT
dpc-1631	94	2	≥30	≥30	PROPN
dpc-1631	94	3	(	(	PUNCT
dpc-1631	94	4	13	13	NUM
dpc-1631	94	5	%	%	NOUN
dpc-1631	94	6	)	)	PUNCT
dpc-1631	94	7	<	<	X
dpc-1631	94	8	18.5	18.5	NUM
dpc-1631	94	9	;	;	PUNCT
dpc-1631	94	10	18.5	18.5	NUM
dpc-1631	94	11	-	-	SYM
dpc-1631	94	12	22.9	22.9	NUM
dpc-1631	94	13	;	;	PUNCT
dpc-1631	94	14	23	23	NUM
dpc-1631	94	15	-	-	SYM
dpc-1631	94	16	24.9	24.9	NUM
dpc-1631	94	17	;	;	PUNCT
dpc-1631	94	18	25	25	NUM
dpc-1631	94	19	-	-	SYM
dpc-1631	94	20	27.4	27.4	NUM
dpc-1631	94	21	;	;	PUNCT
dpc-1631	94	22	27.5	27.5	NUM
dpc-1631	94	23	-	-	SYM
dpc-1631	94	24	29.9	29.9	NUM
dpc-1631	94	25	;	;	PUNCT
dpc-1631	94	26	≥30	≥30	PROPN
dpc-1631	94	27	(	(	PUNCT
dpc-1631	94	28	%	%	INTJ
dpc-1631	94	29	not	not	PART
dpc-1631	94	30	reported	report	VERB
dpc-1631	94	31	)	)	PUNCT
dpc-1631	94	32	main	main	ADJ
dpc-1631	94	33	statistical	statistical	ADJ
dpc-1631	94	34	and	and	CCONJ
dpc-1631	94	35	methodological	methodological	ADJ
dpc-1631	94	36	information	information	NOUN
dpc-1631	94	37	effect	effect	NOUN
dpc-1631	94	38	of	of	ADP
dpc-1631	94	39	bmi	bmi	NOUN
dpc-1631	94	40	on	on	ADP
dpc-1631	94	41	the	the	DET
dpc-1631	94	42	risk	risk	NOUN
dpc-1631	94	43	of	of	ADP
dpc-1631	94	44	thick	thick	ADJ
dpc-1631	94	45	melanoma	melanoma	NOUN
dpc-1631	94	46	estimated	estimate	VERB
dpc-1631	94	47	in	in	ADP
dpc-1631	94	48	terms	term	NOUN
dpc-1631	94	49	of	of	ADP
dpc-1631	94	50	or	or	CCONJ
dpc-1631	94	51	using	use	VERB
dpc-1631	94	52	a	a	DET
dpc-1631	94	53	logistic	logistic	ADJ
dpc-1631	94	54	regression	regression	NOUN
dpc-1631	94	55	analysis	analysis	NOUN
dpc-1631	94	56	.	.	PUNCT
dpc-1631	95	1	stratification	stratification	NOUN
dpc-1631	95	2	for	for	ADP
dpc-1631	95	3	sex	sex	NOUN
dpc-1631	95	4	and	and	CCONJ
dpc-1631	95	5	age	age	NOUN
dpc-1631	95	6	classes	class	NOUN
dpc-1631	95	7	,	,	PUNCT
dpc-1631	95	8	with	with	ADP
dpc-1631	95	9	adjustment	adjustment	NOUN
dpc-1631	95	10	for	for	ADP
dpc-1631	95	11	age	age	NOUN
dpc-1631	95	12	(	(	PUNCT
dpc-1631	95	13	linear	linear	NOUN
dpc-1631	95	14	)	)	PUNCT
dpc-1631	95	15	within	within	ADP
dpc-1631	95	16	each	each	DET
dpc-1631	95	17	age	age	NOUN
dpc-1631	95	18	class	class	NOUN
dpc-1631	95	19	and	and	CCONJ
dpc-1631	95	20	histological	histological	ADJ
dpc-1631	95	21	subtype	subtype	NOUN
dpc-1631	95	22	.	.	PUNCT
dpc-1631	96	1	breslow	breslow	ADJ
dpc-1631	96	2	thickness	thickness	NOUN
dpc-1631	96	3	stratified	stratify	VERB
dpc-1631	96	4	into	into	ADP
dpc-1631	96	5	two	two	NUM
dpc-1631	96	6	groups	group	NOUN
dpc-1631	96	7	:	:	PUNCT
dpc-1631	96	8	thick	thick	ADJ
dpc-1631	96	9	and	and	CCONJ
dpc-1631	96	10	thin	thin	ADJ
dpc-1631	96	11	multivariate	multivariate	NOUN
dpc-1631	96	12	analyses	analysis	NOUN
dpc-1631	96	13	with	with	ADP
dpc-1631	96	14	breslow	breslow	ADJ
dpc-1631	96	15	thickness	thickness	NOUN
dpc-1631	96	16	as	as	ADP
dpc-1631	96	17	the	the	DET
dpc-1631	96	18	response	response	NOUN
dpc-1631	96	19	variable	variable	NOUN
dpc-1631	96	20	.	.	PUNCT
dpc-1631	97	1	multivariate	multivariate	VERB
dpc-1631	97	2	random	random	ADJ
dpc-1631	97	3	effects	effect	NOUN
dpc-1631	97	4	models	model	NOUN
dpc-1631	97	5	,	,	PUNCT
dpc-1631	97	6	with	with	ADP
dpc-1631	97	7	center	center	NOUN
dpc-1631	97	8	as	as	ADP
dpc-1631	97	9	a	a	DET
dpc-1631	97	10	random	random	ADJ
dpc-1631	97	11	factor	factor	NOUN
dpc-1631	97	12	;	;	PUNCT
dpc-1631	97	13	multivariate	multivariate	NOUN
dpc-1631	97	14	logistic	logistic	ADJ
dpc-1631	97	15	models	model	NOUN
dpc-1631	97	16	,	,	PUNCT
dpc-1631	97	17	taking	take	VERB
dpc-1631	97	18	into	into	ADP
dpc-1631	97	19	account	account	NOUN
dpc-1631	97	20	possible	possible	ADJ
dpc-1631	97	21	confounding	confound	VERB
dpc-1631	97	22	factors	factor	NOUN
dpc-1631	97	23	(	(	PUNCT
dpc-1631	97	24	including	include	VERB
dpc-1631	97	25	age	age	NOUN
dpc-1631	97	26	,	,	PUNCT
dpc-1631	97	27	gender	gender	NOUN
dpc-1631	97	28	,	,	PUNCT
dpc-1631	97	29	educational	educational	ADJ
dpc-1631	97	30	and	and	CCONJ
dpc-1631	97	31	professional	professional	ADJ
dpc-1631	97	32	level	level	NOUN
dpc-1631	97	33	,	,	PUNCT
dpc-1631	97	34	phenotype	phenotype	NOUN
dpc-1631	97	35	,	,	PUNCT
dpc-1631	97	36	residence	residence	NOUN
dpc-1631	97	37	,	,	PUNCT
dpc-1631	97	38	season	season	NOUN
dpc-1631	97	39	of	of	ADP
dpc-1631	97	40	diagnosis	diagnosis	NOUN
dpc-1631	97	41	,	,	PUNCT
dpc-1631	97	42	speciality	speciality	NOUN
dpc-1631	97	43	of	of	ADP
dpc-1631	97	44	diagnosing	diagnose	VERB
dpc-1631	97	45	doctor	doctor	NOUN
dpc-1631	97	46	)	)	PUNCT
dpc-1631	97	47	.	.	PUNCT
dpc-1631	98	1	breslow	breslow	ADJ
dpc-1631	98	2	thickness	thickness	NOUN
dpc-1631	98	3	stratified	stratify	VERB
dpc-1631	98	4	into	into	ADP
dpc-1631	98	5	two	two	NUM
dpc-1631	98	6	groups	group	NOUN
dpc-1631	98	7	:	:	PUNCT
dpc-1631	98	8	thin	thin	ADJ
dpc-1631	98	9	and	and	CCONJ
dpc-1631	98	10	thick	thick	ADJ
dpc-1631	98	11	,	,	PUNCT
dpc-1631	98	12	considering	consider	VERB
dpc-1631	98	13	also	also	ADV
dpc-1631	98	14	very	very	ADV
dpc-1631	98	15	thick	thick	ADJ
dpc-1631	98	16	melanoma	melanoma	NOUN
dpc-1631	98	17	and	and	CCONJ
dpc-1631	98	18	additionally	additionally	ADV
dpc-1631	98	19	evaluating	evaluate	VERB
dpc-1631	98	20	breslow	breslow	ADJ
dpc-1631	98	21	thickness	thickness	NOUN
dpc-1631	98	22	as	as	ADP
dpc-1631	98	23	a	a	DET
dpc-1631	98	24	continuous	continuous	ADJ
dpc-1631	98	25	measure	measure	NOUN
dpc-1631	98	26	univariate	univariate	ADJ
dpc-1631	98	27	and	and	CCONJ
dpc-1631	98	28	multivariate	multivariate	NOUN
dpc-1631	98	29	analyses	analysis	NOUN
dpc-1631	98	30	,	,	PUNCT
dpc-1631	98	31	accounting	account	VERB
dpc-1631	98	32	for	for	ADP
dpc-1631	98	33	significant	significant	ADJ
dpc-1631	98	34	clinical	clinical	ADJ
dpc-1631	98	35	and	and	CCONJ
dpc-1631	98	36	histopathological	histopathological	ADJ
dpc-1631	98	37	features	feature	NOUN
dpc-1631	98	38	.	.	PUNCT
dpc-1631	99	1	breslow	breslow	ADJ
dpc-1631	99	2	thickness	thickness	NOUN
dpc-1631	99	3	stratified	stratify	VERB
dpc-1631	99	4	in	in	ADP
dpc-1631	99	5	four	four	NUM
dpc-1631	99	6	groups	group	NOUN
dpc-1631	99	7	following	follow	VERB
dpc-1631	99	8	the	the	DET
dpc-1631	99	9	ajccms	ajccms	NOUN
dpc-1631	99	10	,	,	PUNCT
dpc-1631	99	11	7th	7th	ADJ
dpc-1631	99	12	ed	ed	NOUN
dpc-1631	99	13	.	.	PUNCT
dpc-1631	100	1	linear	linear	ADJ
dpc-1631	100	2	regression	regression	NOUN
dpc-1631	100	3	with	with	ADP
dpc-1631	100	4	loge	loge	PROPN
dpc-1631	100	5	-	-	PUNCT
dpc-1631	100	6	transformed	transform	VERB
dpc-1631	100	7	breslow	breslow	ADJ
dpc-1631	100	8	thickness	thickness	NOUN
dpc-1631	100	9	(	(	PUNCT
dpc-1631	100	10	relationship	relationship	NOUN
dpc-1631	100	11	with	with	ADP
dpc-1631	100	12	breslow	breslow	ADJ
dpc-1631	100	13	thickness	thickness	NOUN
dpc-1631	100	14	as	as	ADP
dpc-1631	100	15	a	a	DET
dpc-1631	100	16	continuous	continuous	ADJ
dpc-1631	100	17	outcome	outcome	NOUN
dpc-1631	100	18	)	)	PUNCT
dpc-1631	100	19	.	.	PUNCT
dpc-1631	101	1	adjustment	adjustment	NOUN
dpc-1631	101	2	for	for	ADP
dpc-1631	101	3	age	age	NOUN
dpc-1631	101	4	at	at	ADP
dpc-1631	101	5	diagnosis	diagnosis	NOUN
dpc-1631	101	6	,	,	PUNCT
dpc-1631	101	7	sex	sex	NOUN
dpc-1631	101	8	,	,	PUNCT
dpc-1631	101	9	ambient	ambient	ADJ
dpc-1631	101	10	uv	uv	NOUN
dpc-1631	101	11	radiation	radiation	NOUN
dpc-1631	101	12	of	of	ADP
dpc-1631	101	13	residence	residence	NOUN
dpc-1631	101	14	,	,	PUNCT
dpc-1631	101	15	average	average	ADJ
dpc-1631	101	16	intensity	intensity	NOUN
dpc-1631	101	17	of	of	ADP
dpc-1631	101	18	sunburns	sunburn	NOUN
dpc-1631	101	19	,	,	PUNCT
dpc-1631	101	20	occupational	occupational	ADJ
dpc-1631	101	21	uv	uv	NOUN
dpc-1631	101	22	exposure	exposure	NOUN
dpc-1631	101	23	,	,	PUNCT
dpc-1631	101	24	physical	physical	ADJ
dpc-1631	101	25	activity	activity	NOUN
dpc-1631	101	26	,	,	PUNCT
dpc-1631	101	27	education	education	NOUN
dpc-1631	101	28	,	,	PUNCT
dpc-1631	101	29	smoking	smoking	NOUN
dpc-1631	101	30	status	status	NOUN
dpc-1631	101	31	,	,	PUNCT
dpc-1631	101	32	height	height	NOUN
dpc-1631	101	33	.	.	PUNCT
dpc-1631	102	1	use	use	NOUN
dpc-1631	102	2	of	of	ADP
dpc-1631	102	3	adjusted	adjusted	ADJ
dpc-1631	102	4	mean	mean	ADJ
dpc-1631	102	5	values	value	NOUN
dpc-1631	102	6	of	of	ADP
dpc-1631	102	7	breslow	breslow	ADJ
dpc-1631	102	8	thickness	thickness	NOUN
dpc-1631	102	9	(	(	PUNCT
dpc-1631	102	10	in	in	ADP
dpc-1631	102	11	mm	mm	INTJ
dpc-1631	102	12	)	)	PUNCT
dpc-1631	102	13	by	by	ADP
dpc-1631	102	14	restricted	restrict	VERB
dpc-1631	102	15	cubic	cubic	ADJ
dpc-1631	102	16	splines	spline	NOUN
dpc-1631	102	17	in	in	ADP
dpc-1631	102	18	generalized	generalized	ADJ
dpc-1631	102	19	linear	linear	ADJ
dpc-1631	102	20	regression	regression	NOUN
dpc-1631	102	21	models	model	NOUN
dpc-1631	102	22	(	(	PUNCT
dpc-1631	102	23	shape	shape	NOUN
dpc-1631	102	24	of	of	ADP
dpc-1631	102	25	the	the	DET
dpc-1631	102	26	associations	association	NOUN
dpc-1631	102	27	with	with	ADP
dpc-1631	102	28	breslow	breslow	ADJ
dpc-1631	102	29	thickness	thickness	NOUN
dpc-1631	102	30	)	)	PUNCT
dpc-1631	102	31	.	.	PUNCT
dpc-1631	103	1	site	site	NOUN
dpc-1631	103	2	of	of	ADP
dpc-1631	103	3	melanoma	melanoma	NOUN
dpc-1631	103	4	,	,	PUNCT
dpc-1631	103	5	%	%	INTJ
dpc-1631	103	6	not	not	PART
dpc-1631	103	7	reported	report	VERB
dpc-1631	103	8	not	not	PART
dpc-1631	103	9	reported	report	VERB
dpc-1631	103	10	trunk	trunk	NOUN
dpc-1631	103	11	48	48	NUM
dpc-1631	103	12	%	%	NOUN
dpc-1631	103	13	;	;	PUNCT
dpc-1631	103	14	head	head	NOUN
dpc-1631	103	15	and	and	CCONJ
dpc-1631	103	16	neck	neck	NOUN
dpc-1631	103	17	15	15	NUM
dpc-1631	103	18	%	%	NOUN
dpc-1631	103	19	;	;	PUNCT
dpc-1631	103	20	upper	upper	ADJ
dpc-1631	103	21	limbs	limb	NOUN
dpc-1631	103	22	13	13	NUM
dpc-1631	103	23	%	%	NOUN
dpc-1631	103	24	;	;	PUNCT
dpc-1631	103	25	lower	low	ADJ
dpc-1631	103	26	limbs	limb	NOUN
dpc-1631	103	27	24	24	NUM
dpc-1631	103	28	%	%	NOUN
dpc-1631	103	29	trunk	trunk	NOUN
dpc-1631	103	30	51	51	NUM
dpc-1631	103	31	%	%	NOUN
dpc-1631	103	32	;	;	PUNCT
dpc-1631	103	33	head	head	NOUN
dpc-1631	103	34	and	and	CCONJ
dpc-1631	103	35	neck	neck	NOUN
dpc-1631	103	36	11	11	NUM
dpc-1631	103	37	%	%	NOUN
dpc-1631	103	38	;	;	PUNCT
dpc-1631	103	39	upper	upper	ADJ
dpc-1631	103	40	limbs	limb	NOUN
dpc-1631	103	41	12.5	12.5	NUM
dpc-1631	103	42	%	%	NOUN
dpc-1631	103	43	;	;	PUNCT
dpc-1631	103	44	lower	low	ADJ
dpc-1631	103	45	limbs	limb	NOUN
dpc-1631	103	46	24	24	NUM
dpc-1631	103	47	%	%	NOUN
dpc-1631	103	48	;	;	PUNCT
dpc-1631	103	49	not	not	PART
dpc-1631	103	50	specified	specify	VERB
dpc-1631	103	51	1.5	1.5	NUM
dpc-1631	103	52	%	%	NOUN
dpc-1631	103	53	histopathological	histopathological	ADJ
dpc-1631	103	54	subtype	subtype	NOUN
dpc-1631	103	55	of	of	ADP
dpc-1631	103	56	melanoma	melanoma	PROPN
dpc-1631	103	57	ssm	ssm	PROPN
dpc-1631	103	58	89.8	89.8	NUM
dpc-1631	103	59	%	%	NOUN
dpc-1631	103	60	;	;	PUNCT
dpc-1631	103	61	um	um	INTJ
dpc-1631	103	62	1.15	1.15	NUM
dpc-1631	103	63	%	%	NOUN
dpc-1631	103	64	;	;	PUNCT
dpc-1631	103	65	lmm	lmm	PROPN
dpc-1631	103	66	3.3	3.3	NUM
dpc-1631	103	67	%	%	NOUN
dpc-1631	103	68	;	;	PUNCT
dpc-1631	103	69	nm	nm	PRON
dpc-1631	103	70	2.65	2.65	NUM
dpc-1631	103	71	%	%	NOUN
dpc-1631	103	72	;	;	PUNCT
dpc-1631	103	73	alm	alm	NOUN
dpc-1631	103	74	1.8	1.8	NUM
dpc-1631	103	75	%	%	NOUN
dpc-1631	103	76	;	;	PUNCT
dpc-1631	103	77	rm	rm	NOUN
dpc-1631	103	78	1.3	1.3	NUM
dpc-1631	103	79	%	%	NOUN
dpc-1631	103	80	not	not	PART
dpc-1631	103	81	reported	report	VERB
dpc-1631	103	82	ssm	ssm	PROPN
dpc-1631	103	83	62	62	NUM
dpc-1631	103	84	%	%	NOUN
dpc-1631	103	85	;	;	PUNCT
dpc-1631	103	86	um	um	INTJ
dpc-1631	103	87	17	17	NUM
dpc-1631	103	88	%	%	NOUN
dpc-1631	103	89	;	;	PUNCT
dpc-1631	103	90	lmm	lmm	PROPN
dpc-1631	103	91	13.5	13.5	NUM
dpc-1631	103	92	%	%	NOUN
dpc-1631	103	93	;	;	PUNCT
dpc-1631	103	94	nm	nm	NOUN
dpc-1631	103	95	4	4	NUM
dpc-1631	103	96	%	%	NOUN
dpc-1631	103	97	;	;	PUNCT
dpc-1631	103	98	alm	alm	NOUN
dpc-1631	103	99	3.5	3.5	NUM
dpc-1631	103	100	%	%	NOUN
dpc-1631	103	101	ssm	ssm	NOUN
dpc-1631	103	102	63	63	NUM
dpc-1631	103	103	%	%	NOUN
dpc-1631	103	104	;	;	PUNCT
dpc-1631	103	105	nm	nm	NOUN
dpc-1631	103	106	19	19	NUM
dpc-1631	103	107	%	%	NOUN
dpc-1631	103	108	;	;	PUNCT
dpc-1631	103	109	other	other	ADJ
dpc-1631	103	110	4	4	NUM
dpc-1631	103	111	%	%	NOUN
dpc-1631	103	112	;	;	PUNCT
dpc-1631	103	113	not	not	PART
dpc-1631	103	114	specified	specify	VERB
dpc-1631	103	115	14	14	NUM
dpc-1631	103	116	%	%	NOUN
dpc-1631	103	117	breslow	breslow	NOUN
dpc-1631	103	118	thickness	thickness	NOUN
dpc-1631	103	119	(	(	PUNCT
dpc-1631	103	120	mm	mm	NOUN
dpc-1631	103	121	)	)	PUNCT
dpc-1631	103	122	mean	mean	NOUN
dpc-1631	103	123	0.87	0.87	NUM
dpc-1631	103	124	(	(	PUNCT
dpc-1631	103	125	sd	sd	NOUN
dpc-1631	103	126	1.07	1.07	NUM
dpc-1631	103	127	)	)	PUNCT
dpc-1631	103	128	not	not	PART
dpc-1631	103	129	reported	report	VERB
dpc-1631	103	130	mean	mean	PROPN
dpc-1631	103	131	1.36	1.36	NUM
dpc-1631	103	132	mm	mm	NOUN
dpc-1631	103	133	(	(	PUNCT
dpc-1631	103	134	sd	sd	ADP
dpc-1631	103	135	2.47	2.47	NUM
dpc-1631	103	136	)	)	PUNCT
dpc-1631	103	137	median	median	NOUN
dpc-1631	103	138	1.0	1.0	NUM
dpc-1631	103	139	(	(	PUNCT
dpc-1631	103	140	iqr	iqr	X
dpc-1631	103	141	0.6	0.6	NUM
dpc-1631	103	142	-	-	SYM
dpc-1631	103	143	2	2	NUM
dpc-1631	103	144	)	)	PUNCT
dpc-1631	103	145	thin	thin	ADJ
dpc-1631	103	146	melanoma	melanoma	NOUN
dpc-1631	103	147	=	=	SYM
dpc-1631	103	148	breslow	breslow	NOUN
dpc-1631	103	149	thickness	thickness	NOUN
dpc-1631	103	150	≤1	≤1	PROPN
dpc-1631	103	151	mm	mm	PROPN
dpc-1631	103	152	;	;	PUNCT
dpc-1631	103	153	thick	thick	ADJ
dpc-1631	103	154	melanoma	melanoma	NOUN
dpc-1631	103	155	=	=	SYM
dpc-1631	103	156	breslow	breslow	NOUN
dpc-1631	103	157	thickness	thickness	NOUN
dpc-1631	103	158	>	>	X
dpc-1631	103	159	1	1	NUM
dpc-1631	103	160	mm	mm	NOUN
dpc-1631	103	161	;	;	PUNCT
dpc-1631	103	162	very	very	ADV
dpc-1631	103	163	thick	thick	ADJ
dpc-1631	103	164	melanoma	melanoma	NOUN
dpc-1631	103	165	=	=	SYM
dpc-1631	103	166	breslow	breslow	NOUN
dpc-1631	103	167	thickness	thickness	NOUN
dpc-1631	103	168	>	>	X
dpc-1631	103	169	2	2	NUM
dpc-1631	103	170	mm	mm	PROPN
dpc-1631	103	171	ajccms=	ajccms=	NUM
dpc-1631	103	172	american	american	ADJ
dpc-1631	103	173	joint	joint	PROPN
dpc-1631	103	174	committee	committee	PROPN
dpc-1631	103	175	on	on	ADP
dpc-1631	103	176	cancer	cancer	NOUN
dpc-1631	103	177	melanoma	melanoma	PROPN
dpc-1631	103	178	staging	staging	NOUN
dpc-1631	103	179	;	;	PUNCT
dpc-1631	103	180	alm=	alm=	NUM
dpc-1631	103	181	acral	acral	ADJ
dpc-1631	103	182	lentiginous	lentiginous	ADJ
dpc-1631	103	183	melanoma	melanoma	NOUN
dpc-1631	103	184	;	;	PUNCT
dpc-1631	103	185	bmi=	bmi=	PROPN
dpc-1631	103	186	body	body	NOUN
dpc-1631	103	187	mass	mass	PROPN
dpc-1631	103	188	index	index	NOUN
dpc-1631	103	189	;	;	PUNCT
dpc-1631	103	190	iqr=	iqr=	CCONJ
dpc-1631	103	191	interquartile	interquartile	NOUN
dpc-1631	103	192	range	range	NOUN
dpc-1631	103	193	;	;	PUNCT
dpc-1631	103	194	lmm=	lmm=	PROPN
dpc-1631	103	195	lentigo	lentigo	ADJ
dpc-1631	103	196	maligna	maligna	NOUN
dpc-1631	103	197	melanoma	melanoma	PROPN
dpc-1631	103	198	;	;	PUNCT
dpc-1631	103	199	nm=	nm=	NOUN
dpc-1631	103	200	nodular	nodular	ADJ
dpc-1631	103	201	melanoma	melanoma	NOUN
dpc-1631	103	202	;	;	PUNCT
dpc-1631	103	203	or=	or=	PROPN
dpc-1631	103	204	odds	odd	NOUN
dpc-1631	103	205	ratio	ratio	NOUN
dpc-1631	103	206	;	;	PUNCT
dpc-1631	103	207	rm=	rm=	ADJ
dpc-1631	103	208	rare	rare	ADJ
dpc-1631	103	209	melanoma	melanoma	NOUN
dpc-1631	103	210	;	;	PUNCT
dpc-1631	103	211	sd=	sd=	PROPN
dpc-1631	103	212	standard	standard	ADJ
dpc-1631	103	213	deviation	deviation	NOUN
dpc-1631	103	214	;	;	PUNCT
dpc-1631	103	215	ssm=	ssm=	ADV
dpc-1631	103	216	superficial	superficial	ADJ
dpc-1631	103	217	spreading	spread	VERB
dpc-1631	103	218	melanoma	melanoma	NOUN
dpc-1631	103	219	;	;	PUNCT
dpc-1631	103	220	um=	um=	ADJ
dpc-1631	103	221	unclassifiable	unclassifiable	ADJ
dpc-1631	103	222	/	/	SYM
dpc-1631	103	223	unclassified	unclassified	ADJ
dpc-1631	103	224	melanoma	melanoma	NOUN
dpc-1631	103	225	;	;	PUNCT
dpc-1631	103	226	uv=	uv=	PROPN
dpc-1631	103	227	ultraviolet	ultraviolet	NOUN
dpc-1631	103	228	table	table	NOUN
dpc-1631	103	229	1	1	NUM
dpc-1631	103	230	.	.	PUNCT
dpc-1631	104	1	principal	principal	ADJ
dpc-1631	104	2	studies	study	NOUN
dpc-1631	104	3	exploring	explore	VERB
dpc-1631	104	4	the	the	DET
dpc-1631	104	5	relationship	relationship	NOUN
dpc-1631	104	6	between	between	ADP
dpc-1631	104	7	bmi	bmi	NOUN
dpc-1631	104	8	and	and	CCONJ
dpc-1631	104	9	breslow	breslow	ADJ
dpc-1631	104	10	thickness	thickness	NOUN
dpc-1631	104	11	:	:	PUNCT
dpc-1631	104	12	general	general	ADJ
dpc-1631	104	13	aspects	aspect	NOUN
dpc-1631	104	14	and	and	CCONJ
dpc-1631	104	15	characteristics	characteristic	NOUN
dpc-1631	104	16	of	of	ADP
dpc-1631	104	17	melanoma	melanoma	NOUN
dpc-1631	104	18	cases	case	NOUN
dpc-1631	104	19	(	(	PUNCT
dpc-1631	104	20	continued	continued	ADJ
dpc-1631	104	21	)	)	PUNCT
dpc-1631	104	22	review	review	NOUN
dpc-1631	104	23	|	|	ADV
dpc-1631	104	24	dermatol	dermatol	ADJ
dpc-1631	104	25	pract	pract	NOUN
dpc-1631	104	26	concept	concept	NOUN
dpc-1631	104	27	.	.	PUNCT
dpc-1631	105	1	2021;11(4	2021;11(4	NUM
dpc-1631	105	2	):	):	PUNCT
dpc-1631	105	3	e2021106	e2021106	NOUN
dpc-1631	105	4	5	5	NUM
dpc-1631	105	5	sure	sure	ADJ
dpc-1631	105	6	–	–	PUNCT
dpc-1631	105	7	response	response	NOUN
dpc-1631	105	8	curves	curve	NOUN
dpc-1631	105	9	indicated	indicate	VERB
dpc-1631	105	10	that	that	SCONJ
dpc-1631	105	11	mean	mean	VERB
dpc-1631	105	12	breslow	breslow	ADJ
dpc-1631	105	13	thickness	thickness	NOUN
dpc-1631	105	14	increased	increase	VERB
dpc-1631	105	15	until	until	ADP
dpc-1631	105	16	a	a	DET
dpc-1631	105	17	bmi	bmi	NOUN
dpc-1631	105	18	of	of	ADP
dpc-1631	105	19	29	29	NUM
dpc-1631	105	20	kg	kg	NOUN
dpc-1631	105	21	/	/	SYM
dpc-1631	105	22	m2	m2	PROPN
dpc-1631	105	23	,	,	PUNCT
dpc-1631	105	24	then	then	ADV
dpc-1631	105	25	plateaued	plateaue	VERB
dpc-1631	105	26	at	at	ADP
dpc-1631	105	27	a	a	DET
dpc-1631	105	28	mean	mean	NOUN
dpc-1631	105	29	of	of	ADP
dpc-1631	105	30	approximately	approximately	ADV
dpc-1631	105	31	2.5	2.5	NUM
dpc-1631	105	32	mm	mm	NOUN
dpc-1631	105	33	before	before	ADP
dpc-1631	105	34	declining	decline	VERB
dpc-1631	105	35	for	for	ADP
dpc-1631	105	36	the	the	DET
dpc-1631	105	37	highest	high	ADJ
dpc-1631	105	38	values	value	NOUN
dpc-1631	105	39	.	.	PUNCT
dpc-1631	106	1	in	in	ADP
dpc-1631	106	2	addition	addition	NOUN
dpc-1631	106	3	,	,	PUNCT
dpc-1631	106	4	when	when	SCONJ
dpc-1631	106	5	breslow	breslow	ADJ
dpc-1631	106	6	thickness	thickness	NOUN
dpc-1631	106	7	was	be	AUX
dpc-1631	106	8	examined	examine	VERB
dpc-1631	106	9	as	as	ADP
dpc-1631	106	10	a	a	DET
dpc-1631	106	11	dichotomous	dichotomous	ADJ
dpc-1631	106	12	outcome	outcome	NOUN
dpc-1631	106	13	according	accord	VERB
dpc-1631	106	14	to	to	ADP
dpc-1631	106	15	bmi	bmi	NOUN
dpc-1631	106	16	in	in	ADP
dpc-1631	106	17	overweight	overweight	ADJ
dpc-1631	106	18	and	and	CCONJ
dpc-1631	106	19	postmenopausal	postmenopausal	ADJ
dpc-1631	106	20	women	woman	NOUN
dpc-1631	106	21	,	,	PUNCT
dpc-1631	106	22	as	as	SCONJ
dpc-1631	106	23	previously	previously	ADV
dpc-1631	106	24	done	do	VERB
dpc-1631	106	25	by	by	ADP
dpc-1631	106	26	de	de	PROPN
dpc-1631	106	27	giorgi	giorgi	PROPN
dpc-1631	106	28	et	et	NOUN
dpc-1631	106	29	al	al	PROPN
dpc-1631	107	1	[	[	X
dpc-1631	107	2	21	21	NUM
dpc-1631	107	3	]	]	PUNCT
dpc-1631	107	4	,	,	PUNCT
dpc-1631	107	5	stenehjem	stenehjem	NOUN
dpc-1631	107	6	et	et	NOUN
dpc-1631	107	7	al	al	PROPN
dpc-1631	107	8	did	do	AUX
dpc-1631	107	9	not	not	PART
dpc-1631	107	10	confirm	confirm	VERB
dpc-1631	107	11	a	a	DET
dpc-1631	107	12	significant	significant	ADJ
dpc-1631	107	13	association	association	NOUN
dpc-1631	107	14	;	;	PUNCT
dpc-1631	107	15	however	however	ADV
dpc-1631	107	16	they	they	PRON
dpc-1631	107	17	did	do	AUX
dpc-1631	107	18	not	not	PART
dpc-1631	107	19	stratify	stratify	VERB
dpc-1631	107	20	by	by	ADP
dpc-1631	107	21	menopausal	menopausal	ADJ
dpc-1631	107	22	status	status	NOUN
dpc-1631	107	23	owing	owe	VERB
dpc-1631	107	24	to	to	ADP
dpc-1631	107	25	the	the	DET
dpc-1631	107	26	low	low	ADJ
dpc-1631	107	27	number	number	NOUN
dpc-1631	107	28	of	of	ADP
dpc-1631	107	29	postmenopausal	postmenopausal	ADJ
dpc-1631	107	30	participants	participant	NOUN
dpc-1631	107	31	at	at	ADP
dpc-1631	107	32	baseline	baseline	NOUN
dpc-1631	107	33	[	[	X
dpc-1631	107	34	24	24	NUM
dpc-1631	107	35	]	]	PUNCT
dpc-1631	107	36	.	.	PUNCT
dpc-1631	108	1	the	the	DET
dpc-1631	108	2	relationship	relationship	NOUN
dpc-1631	108	3	between	between	ADP
dpc-1631	108	4	bmi	bmi	NOUN
dpc-1631	108	5	and	and	CCONJ
dpc-1631	108	6	breslow	breslow	NOUN
dpc-1631	108	7	thickness	thickness	NOUN
dpc-1631	108	8	has	have	AUX
dpc-1631	108	9	been	be	AUX
dpc-1631	108	10	examined	examine	VERB
dpc-1631	108	11	in	in	ADP
dpc-1631	108	12	other	other	ADJ
dpc-1631	108	13	investigations	investigation	NOUN
dpc-1631	108	14	.	.	PUNCT
dpc-1631	109	1	fang	fang	PROPN
dpc-1631	109	2	et	et	PROPN
dpc-1631	109	3	al	al	PROPN
dpc-1631	109	4	enrolled	enrol	VERB
dpc-1631	109	5	1,804	1,804	NUM
dpc-1631	109	6	patients	patient	NOUN
dpc-1631	109	7	with	with	ADP
dpc-1631	109	8	melanoma	melanoma	NOUN
dpc-1631	109	9	from	from	ADP
dpc-1631	109	10	1998	1998	NUM
dpc-1631	109	11	to	to	ADP
dpc-1631	109	12	2008	2008	NUM
dpc-1631	109	13	,	,	PUNCT
dpc-1631	109	14	and	and	CCONJ
dpc-1631	109	15	bmi	bmi	PROPN
dpc-1631	109	16	information	information	NOUN
dpc-1631	109	17	was	be	AUX
dpc-1631	109	18	available	available	ADJ
dpc-1631	109	19	for	for	ADP
dpc-1631	109	20	1,186	1,186	NUM
dpc-1631	109	21	patients	patient	NOUN
dpc-1631	109	22	.	.	PUNCT
dpc-1631	110	1	they	they	PRON
dpc-1631	110	2	found	find	VERB
dpc-1631	110	3	that	that	SCONJ
dpc-1631	110	4	increased	increase	VERB
dpc-1631	110	5	bmi	bmi	NOUN
dpc-1631	110	6	was	be	AUX
dpc-1631	110	7	weakly	weakly	ADV
dpc-1631	110	8	associated	associate	VERB
dpc-1631	110	9	with	with	ADP
dpc-1631	110	10	increased	increase	VERB
dpc-1631	110	11	tumor	tumor	NOUN
dpc-1631	110	12	thickness	thickness	NOUN
dpc-1631	110	13	,	,	PUNCT
dpc-1631	110	14	and	and	CCONJ
dpc-1631	110	15	also	also	ADV
dpc-1631	110	16	with	with	ADP
dpc-1631	110	17	older	old	ADJ
dpc-1631	110	18	age	age	NOUN
dpc-1631	110	19	and	and	CCONJ
dpc-1631	110	20	increased	increase	VERB
dpc-1631	110	21	log	log	NOUN
dpc-1631	111	1	[	[	X
dpc-1631	111	2	crp	crp	X
dpc-1631	111	3	]	]	X
dpc-1631	112	1	[	[	X
dpc-1631	112	2	18	18	NUM
dpc-1631	112	3	]	]	PUNCT
dpc-1631	112	4	.	.	PUNCT
dpc-1631	113	1	in	in	ADP
dpc-1631	113	2	a	a	DET
dpc-1631	113	3	retrospective	retrospective	ADJ
dpc-1631	113	4	study	study	NOUN
dpc-1631	113	5	of	of	ADP
dpc-1631	113	6	261	261	NUM
dpc-1631	113	7	patients	patient	NOUN
dpc-1631	113	8	diagnosed	diagnose	VERB
dpc-1631	113	9	with	with	ADP
dpc-1631	113	10	primary	primary	ADJ
dpc-1631	113	11	cutaneous	cutaneous	ADJ
dpc-1631	113	12	melanoma	melanoma	NOUN
dpc-1631	113	13	in	in	ADP
dpc-1631	113	14	7	7	NUM
dpc-1631	113	15	korean	korean	ADJ
dpc-1631	113	16	centers	center	NOUN
dpc-1631	113	17	between	between	ADP
dpc-1631	113	18	1997	1997	NUM
dpc-1631	113	19	and	and	CCONJ
dpc-1631	113	20	2017	2017	NUM
dpc-1631	113	21	,	,	PUNCT
dpc-1631	113	22	overweight	overweight	NOUN
dpc-1631	113	23	and	and	CCONJ
dpc-1631	113	24	obesity	obesity	NOUN
dpc-1631	113	25	statuses	status	NOUN
dpc-1631	113	26	(	(	PUNCT
dpc-1631	113	27	bmi>23	bmi>23	PROPN
dpc-1631	113	28	kg	kg	PROPN
dpc-1631	113	29	/	/	SYM
dpc-1631	113	30	m2	m2	PROPN
dpc-1631	113	31	)	)	PUNCT
dpc-1631	113	32	were	be	AUX
dpc-1631	113	33	significantly	significantly	ADV
dpc-1631	113	34	associated	associate	VERB
dpc-1631	113	35	with	with	ADP
dpc-1631	113	36	increased	increase	VERB
dpc-1631	113	37	breslow	breslow	ADJ
dpc-1631	113	38	thickness	thickness	NOUN
dpc-1631	113	39	[	[	X
dpc-1631	113	40	19	19	NUM
dpc-1631	113	41	]	]	PUNCT
dpc-1631	113	42	.	.	PUNCT
dpc-1631	114	1	a	a	DET
dpc-1631	114	2	multivariate	multivariate	NOUN
dpc-1631	114	3	cox	cox	PROPN
dpc-1631	114	4	’s	’s	PART
dpc-1631	114	5	proportional	proportional	ADJ
dpc-1631	114	6	hazards	hazard	NOUN
dpc-1631	114	7	analysis	analysis	NOUN
dpc-1631	114	8	gave	give	VERB
dpc-1631	114	9	a	a	DET
dpc-1631	114	10	hr	hr	NOUN
dpc-1631	114	11	value	value	NOUN
dpc-1631	114	12	of	of	ADP
dpc-1631	114	13	25.62	25.62	NUM
dpc-1631	114	14	(	(	PUNCT
dpc-1631	114	15	95	95	NUM
dpc-1631	114	16	%	%	NOUN
dpc-1631	114	17	ci	ci	NOUN
dpc-1631	114	18	5.44–120.65	5.44–120.65	NUM
dpc-1631	114	19	;	;	PUNCT
dpc-1631	114	20	p	p	X
dpc-1631	114	21	<	<	X
dpc-1631	114	22	0.001	0.001	NUM
dpc-1631	114	23	)	)	PUNCT
dpc-1631	114	24	for	for	ADP
dpc-1631	114	25	the	the	DET
dpc-1631	114	26	association	association	NOUN
dpc-1631	114	27	between	between	ADP
dpc-1631	114	28	breslow	breslow	ADJ
dpc-1631	114	29	thickness	thickness	NOUN
dpc-1631	114	30	and	and	CCONJ
dpc-1631	114	31	bmi	bmi	VERB
dpc-1631	114	32	categories	category	NOUN
dpc-1631	114	33	more	more	ADJ
dpc-1631	114	34	than	than	ADP
dpc-1631	114	35	25	25	NUM
dpc-1631	114	36	kg	kg	NOUN
dpc-1631	114	37	/	/	SYM
dpc-1631	114	38	m2	m2	PROPN
dpc-1631	114	39	.	.	PUNCT
dpc-1631	115	1	in	in	ADP
dpc-1631	115	2	100	100	NUM
dpc-1631	115	3	melanoma	melanoma	NOUN
dpc-1631	115	4	patients	patient	NOUN
dpc-1631	115	5	enrolled	enrol	VERB
dpc-1631	115	6	within	within	ADP
dpc-1631	115	7	days	day	NOUN
dpc-1631	115	8	of	of	ADP
dpc-1631	115	9	their	their	PRON
dpc-1631	115	10	melanoma	melanoma	ADJ
dpc-1631	115	11	diagnosis	diagnosis	NOUN
dpc-1631	115	12	in	in	ADP
dpc-1631	115	13	brisbane	brisbane	NOUN
dpc-1631	115	14	,	,	PUNCT
dpc-1631	115	15	australia	australia	PROPN
dpc-1631	115	16	,	,	PUNCT
dpc-1631	115	17	there	there	PRON
dpc-1631	115	18	was	be	VERB
dpc-1631	115	19	a	a	DET
dpc-1631	115	20	positive	positive	ADJ
dpc-1631	115	21	association	association	NOUN
dpc-1631	115	22	between	between	ADP
dpc-1631	115	23	bmi	bmi	NOUN
dpc-1631	115	24	and	and	CCONJ
dpc-1631	115	25	breslow	breslow	ADJ
dpc-1631	115	26	thickness	thickness	NOUN
dpc-1631	115	27	(	(	PUNCT
dpc-1631	115	28	or	or	CCONJ
dpc-1631	115	29	1.12	1.12	NUM
dpc-1631	115	30	,	,	PUNCT
dpc-1631	115	31	95	95	NUM
dpc-1631	115	32	%	%	NOUN
dpc-1631	115	33	ci	ci	NOUN
dpc-1631	115	34	1.01	1.01	NUM
dpc-1631	115	35	-	-	SYM
dpc-1631	115	36	1.26	1.26	NUM
dpc-1631	115	37	;	;	PUNCT
dpc-1631	115	38	p	p	X
dpc-1631	115	39	=	=	NOUN
dpc-1631	115	40	0.04	0.04	NUM
dpc-1631	115	41	per	per	ADP
dpc-1631	115	42	unit	unit	NOUN
dpc-1631	115	43	increase	increase	NOUN
dpc-1631	115	44	in	in	ADP
dpc-1631	115	45	bmi	bmi	NOUN
dpc-1631	115	46	)	)	PUNCT
dpc-1631	116	1	[	[	X
dpc-1631	116	2	25	25	NUM
dpc-1631	116	3	]	]	PUNCT
dpc-1631	116	4	.	.	PUNCT
dpc-1631	117	1	in	in	ADP
dpc-1631	117	2	a	a	DET
dpc-1631	117	3	total	total	NOUN
dpc-1631	117	4	of	of	ADP
dpc-1631	117	5	340	340	NUM
dpc-1631	117	6	italian	italian	ADJ
dpc-1631	117	7	patients	patient	NOUN
dpc-1631	117	8	with	with	ADP
dpc-1631	117	9	melanoma	melanoma	NOUN
dpc-1631	117	10	(	(	PUNCT
dpc-1631	117	11	mean	mean	VERB
dpc-1631	117	12	breslow	breslow	ADJ
dpc-1631	117	13	thickness	thickness	NOUN
dpc-1631	117	14	of	of	ADP
dpc-1631	117	15	0.4	0.4	NUM
dpc-1631	117	16	mm	mm	NOUN
dpc-1631	117	17	)	)	PUNCT
dpc-1631	117	18	,	,	PUNCT
dpc-1631	117	19	a	a	DET
dpc-1631	117	20	significant	significant	ADJ
dpc-1631	117	21	correlation	correlation	NOUN
dpc-1631	117	22	between	between	ADP
dpc-1631	117	23	bmi	bmi	NOUN
dpc-1631	117	24	and	and	CCONJ
dpc-1631	117	25	breslow	breslow	ADJ
dpc-1631	117	26	thickness	thickness	NOUN
dpc-1631	117	27	(	(	PUNCT
dpc-1631	117	28	p	p	X
dpc-1631	117	29	<	<	X
dpc-1631	117	30	0.01	0.01	NUM
dpc-1631	117	31	)	)	PUNCT
dpc-1631	117	32	was	be	AUX
dpc-1631	117	33	noted	note	VERB
dpc-1631	117	34	[	[	X
dpc-1631	117	35	12	12	NUM
dpc-1631	117	36	]	]	PUNCT
dpc-1631	117	37	.	.	PUNCT
dpc-1631	118	1	a	a	DET
dpc-1631	118	2	recent	recent	ADJ
dpc-1631	118	3	analysis	analysis	NOUN
dpc-1631	118	4	of	of	ADP
dpc-1631	118	5	the	the	DET
dpc-1631	118	6	leeds	leed	NOUN
dpc-1631	118	7	melanoma	melanoma	PROPN
dpc-1631	118	8	cohort	cohort	NOUN
dpc-1631	118	9	has	have	AUX
dpc-1631	118	10	evidenced	evidence	VERB
dpc-1631	118	11	that	that	SCONJ
dpc-1631	118	12	bmi	bmi	NOUN
dpc-1631	118	13	was	be	AUX
dpc-1631	118	14	independently	independently	ADV
dpc-1631	118	15	associated	associate	VERB
dpc-1631	118	16	with	with	ADP
dpc-1631	118	17	thicker	thick	ADJ
dpc-1631	118	18	melanomas	melanomas	NOUN
dpc-1631	119	1	[	[	X
dpc-1631	119	2	13	13	NUM
dpc-1631	119	3	]	]	PUNCT
dpc-1631	119	4	.	.	PUNCT
dpc-1631	120	1	there	there	PRON
dpc-1631	120	2	are	be	VERB
dpc-1631	120	3	few	few	ADJ
dpc-1631	120	4	data	datum	NOUN
dpc-1631	120	5	regarding	regard	VERB
dpc-1631	120	6	the	the	DET
dpc-1631	120	7	association	association	NOUN
dpc-1631	120	8	of	of	ADP
dpc-1631	120	9	bmi	bmi	PROPN
dpc-1631	120	10	with	with	ADP
dpc-1631	120	11	other	other	ADJ
dpc-1631	120	12	histological	histological	ADJ
dpc-1631	120	13	features	feature	NOUN
dpc-1631	120	14	that	that	PRON
dpc-1631	120	15	have	have	VERB
dpc-1631	120	16	a	a	DET
dpc-1631	120	17	prognostic	prognostic	ADJ
dpc-1631	120	18	value	value	NOUN
dpc-1631	120	19	.	.	PUNCT
dpc-1631	121	1	skowron	skowron	PROPN
dpc-1631	121	2	et	et	PROPN
dpc-1631	121	3	al	al	PROPN
dpc-1631	121	4	,	,	PUNCT
dpc-1631	121	5	in	in	ADP
dpc-1631	121	6	their	their	PRON
dpc-1631	121	7	study	study	NOUN
dpc-1631	121	8	focusing	focus	VERB
dpc-1631	121	9	on	on	ADP
dpc-1631	121	10	breslow	breslow	ADJ
dpc-1631	121	11	thickness	thickness	NOUN
dpc-1631	121	12	,	,	PUNCT
dpc-1631	121	13	observed	observe	VERB
dpc-1631	121	14	that	that	SCONJ
dpc-1631	121	15	ulceration	ulceration	NOUN
dpc-1631	121	16	was	be	AUX
dpc-1631	121	17	more	more	ADV
dpc-1631	121	18	frequent	frequent	ADJ
dpc-1631	121	19	in	in	ADP
dpc-1631	121	20	obese	obese	ADJ
dpc-1631	121	21	patients	patient	NOUN
dpc-1631	121	22	,	,	PUNCT
dpc-1631	121	23	although	although	SCONJ
dpc-1631	121	24	the	the	DET
dpc-1631	121	25	trend	trend	NOUN
dpc-1631	121	26	was	be	AUX
dpc-1631	121	27	not	not	PART
dpc-1631	121	28	significant	significant	ADJ
dpc-1631	121	29	[	[	X
dpc-1631	121	30	23	23	NUM
dpc-1631	121	31	]	]	PUNCT
dpc-1631	121	32	.	.	PUNCT
dpc-1631	122	1	similarly	similarly	ADV
dpc-1631	122	2	,	,	PUNCT
dpc-1631	122	3	von	von	PROPN
dpc-1631	122	4	schuckmann	schuckmann	PROPN
dpc-1631	122	5	et	et	PROPN
dpc-1631	122	6	al	al	PROPN
dpc-1631	122	7	noted	note	VERB
dpc-1631	122	8	that	that	SCONJ
dpc-1631	122	9	overweight	overweight	ADJ
dpc-1631	122	10	/	/	SYM
dpc-1631	122	11	obese	obese	ADJ
dpc-1631	122	12	status	status	NOUN
dpc-1631	122	13	was	be	AUX
dpc-1631	122	14	positively	positively	ADV
dpc-1631	122	15	associated	associate	VERB
dpc-1631	122	16	with	with	ADP
dpc-1631	122	17	ulcerated	ulcerated	ADJ
dpc-1631	122	18	melanoma	melanoma	NOUN
dpc-1631	122	19	,	,	PUNCT
dpc-1631	122	20	but	but	CCONJ
dpc-1631	122	21	,	,	PUNCT
dpc-1631	122	22	again	again	ADV
dpc-1631	122	23	,	,	PUNCT
dpc-1631	122	24	not	not	PART
dpc-1631	122	25	significantly	significantly	ADV
dpc-1631	122	26	[	[	X
dpc-1631	122	27	26	26	NUM
dpc-1631	122	28	]	]	PUNCT
dpc-1631	122	29	.	.	PUNCT
dpc-1631	123	1	the	the	DET
dpc-1631	123	2	evaluation	evaluation	NOUN
dpc-1631	123	3	of	of	ADP
dpc-1631	123	4	the	the	DET
dpc-1631	123	5	leeds	leed	NOUN
dpc-1631	123	6	melanoma	melanoma	PROPN
dpc-1631	123	7	cohort	cohort	NOUN
dpc-1631	123	8	showed	show	VERB
dpc-1631	123	9	that	that	SCONJ
dpc-1631	123	10	higher	high	ADJ
dpc-1631	123	11	bmi	bmi	NOUN
dpc-1631	123	12	was	be	AUX
dpc-1631	123	13	associated	associate	VERB
dpc-1631	123	14	with	with	ADP
dpc-1631	123	15	ulceration	ulceration	NOUN
dpc-1631	123	16	,	,	PUNCT
dpc-1631	123	17	in	in	ADP
dpc-1631	123	18	the	the	DET
dpc-1631	123	19	univariable	univariable	ADJ
dpc-1631	123	20	analysis	analysis	NOUN
dpc-1631	123	21	,	,	PUNCT
dpc-1631	123	22	but	but	CCONJ
dpc-1631	123	23	this	this	DET
dpc-1631	123	24	association	association	NOUN
dpc-1631	123	25	did	do	AUX
dpc-1631	123	26	not	not	PART
dpc-1631	123	27	persist	persist	VERB
dpc-1631	123	28	in	in	ADP
dpc-1631	123	29	the	the	DET
dpc-1631	123	30	multivariable	multivariable	ADJ
dpc-1631	123	31	analysis	analysis	NOUN
dpc-1631	123	32	.	.	PUNCT
dpc-1631	124	1	ulceration	ulceration	NOUN
dpc-1631	124	2	was	be	AUX
dpc-1631	124	3	also	also	ADV
dpc-1631	124	4	associated	associate	VERB
dpc-1631	124	5	with	with	ADP
dpc-1631	124	6	lower	low	ADJ
dpc-1631	124	7	vitamin	vitamin	NOUN
dpc-1631	124	8	d	d	NOUN
dpc-1631	124	9	levels	level	NOUN
dpc-1631	124	10	[	[	X
dpc-1631	124	11	16	16	NUM
dpc-1631	124	12	]	]	PUNCT
dpc-1631	124	13	.	.	PUNCT
dpc-1631	125	1	in	in	ADP
dpc-1631	125	2	an	an	DET
dpc-1631	125	3	italian	italian	ADJ
dpc-1631	125	4	cohort	cohort	NOUN
dpc-1631	125	5	,	,	PUNCT
dpc-1631	125	6	a	a	DET
dpc-1631	125	7	significant	significant	ADJ
dpc-1631	125	8	correlation	correlation	NOUN
dpc-1631	125	9	between	between	ADP
dpc-1631	125	10	bmi	bmi	NOUN
dpc-1631	125	11	and	and	CCONJ
dpc-1631	125	12	mitotic	mitotic	ADJ
dpc-1631	125	13	rate	rate	NOUN
dpc-1631	125	14	(	(	PUNCT
dpc-1631	125	15	p	p	NOUN
dpc-1631	125	16	=	=	NOUN
dpc-1631	125	17	0.02	0.02	NUM
dpc-1631	125	18	)	)	PUNCT
dpc-1631	125	19	was	be	AUX
dpc-1631	125	20	seen	see	VERB
dpc-1631	125	21	[	[	X
dpc-1631	125	22	12	12	NUM
dpc-1631	125	23	]	]	PUNCT
dpc-1631	125	24	.	.	PUNCT
dpc-1631	126	1	in	in	ADP
dpc-1631	126	2	another	another	DET
dpc-1631	126	3	italian	italian	ADJ
dpc-1631	126	4	study	study	NOUN
dpc-1631	126	5	,	,	PUNCT
dpc-1631	126	6	absence	absence	NOUN
dpc-1631	126	7	of	of	ADP
dpc-1631	126	8	tumor	tumor	NOUN
dpc-1631	126	9	infiltrating	infiltrate	VERB
dpc-1631	126	10	lymphocytes	lymphocyte	NOUN
dpc-1631	126	11	,	,	PUNCT
dpc-1631	126	12	a	a	DET
dpc-1631	126	13	finding	finding	NOUN
dpc-1631	126	14	that	that	PRON
dpc-1631	126	15	appears	appear	VERB
dpc-1631	126	16	to	to	PART
dpc-1631	126	17	predispose	predispose	VERB
dpc-1631	126	18	to	to	PART
dpc-1631	126	19	metastatic	metastatic	VERB
dpc-1631	126	20	melanoma	melanoma	NOUN
dpc-1631	126	21	,	,	PUNCT
dpc-1631	126	22	was	be	AUX
dpc-1631	126	23	detected	detect	VERB
dpc-1631	126	24	more	more	ADV
dpc-1631	126	25	frequently	frequently	ADV
dpc-1631	126	26	in	in	ADP
dpc-1631	126	27	obese	obese	NOUN
dpc-1631	126	28	than	than	ADP
dpc-1631	126	29	in	in	ADP
dpc-1631	126	30	non	non	ADJ
dpc-1631	126	31	-	-	ADJ
dpc-1631	126	32	obese	obese	ADJ
dpc-1631	126	33	melanoma	melanoma	NOUN
dpc-1631	126	34	patients	patient	NOUN
dpc-1631	126	35	(	(	PUNCT
dpc-1631	126	36	or=3.92	or=3.92	NOUN
dpc-1631	126	37	,	,	PUNCT
dpc-1631	126	38	95	95	NUM
dpc-1631	126	39	%	%	NOUN
dpc-1631	126	40	ci	ci	NOUN
dpc-1631	126	41	1.31–11.7	1.31–11.7	PROPN
dpc-1631	126	42	;	;	PUNCT
dpc-1631	126	43	p	p	X
dpc-1631	126	44	=	=	NOUN
dpc-1631	126	45	0.010	0.010	NUM
dpc-1631	126	46	)	)	PUNCT
dpc-1631	127	1	[	[	X
dpc-1631	127	2	27	27	NUM
dpc-1631	127	3	]	]	PUNCT
dpc-1631	127	4	.	.	PUNCT
dpc-1631	128	1	discussion	discussion	NOUN
dpc-1631	128	2	the	the	DET
dpc-1631	128	3	relationship	relationship	NOUN
dpc-1631	128	4	between	between	ADP
dpc-1631	128	5	obesity	obesity	NOUN
dpc-1631	128	6	and	and	CCONJ
dpc-1631	128	7	melanoma	melanoma	NOUN
dpc-1631	128	8	appears	appear	VERB
dpc-1631	128	9	to	to	PART
dpc-1631	128	10	be	be	AUX
dpc-1631	128	11	complex	complex	ADJ
dpc-1631	128	12	.	.	PUNCT
dpc-1631	129	1	there	there	PRON
dpc-1631	129	2	are	be	VERB
dpc-1631	129	3	conflicting	conflicting	ADJ
dpc-1631	129	4	findings	finding	NOUN
dpc-1631	129	5	regarding	regard	VERB
dpc-1631	129	6	the	the	DET
dpc-1631	129	7	association	association	NOUN
dpc-1631	129	8	between	between	ADP
dpc-1631	129	9	obesity	obesity	NOUN
dpc-1631	129	10	and	and	CCONJ
dpc-1631	129	11	risk	risk	NOUN
dpc-1631	129	12	of	of	ADP
dpc-1631	129	13	cutaneous	cutaneous	ADJ
dpc-1631	129	14	melanoma	melanoma	NOUN
dpc-1631	129	15	[	[	X
dpc-1631	129	16	4,5	4,5	NUM
dpc-1631	129	17	]	]	PUNCT
dpc-1631	129	18	.	.	PUNCT
dpc-1631	130	1	some	some	DET
dpc-1631	130	2	cohort	cohort	NOUN
dpc-1631	130	3	and	and	CCONJ
dpc-1631	130	4	case	case	NOUN
dpc-1631	130	5	-	-	PUNCT
dpc-1631	130	6	control	control	NOUN
dpc-1631	130	7	studies	study	NOUN
dpc-1631	130	8	showed	show	VERB
dpc-1631	130	9	a	a	DET
dpc-1631	130	10	variable	variable	ADJ
dpc-1631	130	11	positive	positive	ADJ
dpc-1631	130	12	correlation	correlation	NOUN
dpc-1631	130	13	between	between	ADP
dpc-1631	130	14	obesity	obesity	NOUN
dpc-1631	130	15	and	and	CCONJ
dpc-1631	130	16	melanoma	melanoma	NOUN
dpc-1631	130	17	risk	risk	NOUN
dpc-1631	130	18	,	,	PUNCT
dpc-1631	130	19	at	at	ADP
dpc-1631	130	20	least	least	ADJ
dpc-1631	130	21	in	in	ADP
dpc-1631	130	22	men	man	NOUN
dpc-1631	130	23	,	,	PUNCT
dpc-1631	130	24	while	while	SCONJ
dpc-1631	130	25	other	other	ADJ
dpc-1631	130	26	studies	study	NOUN
dpc-1631	130	27	found	find	VERB
dpc-1631	130	28	no	no	DET
dpc-1631	130	29	convincing	convincing	ADJ
dpc-1631	130	30	proofs	proof	NOUN
dpc-1631	130	31	of	of	ADP
dpc-1631	130	32	any	any	DET
dpc-1631	130	33	association	association	NOUN
dpc-1631	130	34	[	[	X
dpc-1631	130	35	5,10,28	5,10,28	NUM
dpc-1631	130	36	-	-	SYM
dpc-1631	130	37	32	32	NUM
dpc-1631	130	38	]	]	PUNCT
dpc-1631	130	39	.	.	PUNCT
dpc-1631	131	1	caution	caution	NOUN
dpc-1631	131	2	should	should	AUX
dpc-1631	131	3	be	be	AUX
dpc-1631	131	4	used	use	VERB
dpc-1631	131	5	for	for	ADP
dpc-1631	131	6	the	the	DET
dpc-1631	131	7	interpretation	interpretation	NOUN
dpc-1631	131	8	of	of	ADP
dpc-1631	131	9	such	such	ADJ
dpc-1631	131	10	data	datum	NOUN
dpc-1631	131	11	.	.	PUNCT
dpc-1631	132	1	first	first	ADV
dpc-1631	132	2	,	,	PUNCT
dpc-1631	132	3	evidence	evidence	NOUN
dpc-1631	132	4	for	for	ADP
dpc-1631	132	5	an	an	DET
dpc-1631	132	6	association	association	NOUN
dpc-1631	132	7	does	do	AUX
dpc-1631	132	8	not	not	PART
dpc-1631	132	9	necessarily	necessarily	ADV
dpc-1631	132	10	support	support	VERB
dpc-1631	132	11	a	a	DET
dpc-1631	132	12	causal	causal	ADJ
dpc-1631	132	13	relationship	relationship	NOUN
dpc-1631	132	14	.	.	PUNCT
dpc-1631	133	1	moreover	moreover	ADV
dpc-1631	133	2	,	,	PUNCT
dpc-1631	133	3	methodological	methodological	ADJ
dpc-1631	133	4	aspects	aspect	NOUN
dpc-1631	133	5	differ	differ	VERB
dpc-1631	133	6	between	between	ADP
dpc-1631	133	7	studies	study	NOUN
dpc-1631	133	8	and	and	CCONJ
dpc-1631	133	9	could	could	AUX
dpc-1631	133	10	explain	explain	VERB
dpc-1631	133	11	such	such	ADJ
dpc-1631	133	12	divergences	divergence	NOUN
dpc-1631	133	13	.	.	PUNCT
dpc-1631	134	1	it	it	PRON
dpc-1631	134	2	has	have	AUX
dpc-1631	134	3	been	be	AUX
dpc-1631	134	4	suggested	suggest	VERB
dpc-1631	134	5	to	to	PART
dpc-1631	134	6	consider	consider	VERB
dpc-1631	134	7	the	the	DET
dpc-1631	134	8	possible	possible	ADJ
dpc-1631	134	9	effect	effect	NOUN
dpc-1631	134	10	of	of	ADP
dpc-1631	134	11	residual	residual	ADJ
dpc-1631	134	12	confounding	confounding	NOUN
dpc-1631	134	13	by	by	ADP
dpc-1631	134	14	environmental	environmental	ADJ
dpc-1631	134	15	and	and	CCONJ
dpc-1631	134	16	lifestyle	lifestyle	NOUN
dpc-1631	134	17	risk	risk	NOUN
dpc-1631	134	18	factors	factor	NOUN
dpc-1631	134	19	,	,	PUNCT
dpc-1631	134	20	such	such	ADJ
dpc-1631	134	21	as	as	ADP
dpc-1631	134	22	sunlight	sunlight	NOUN
dpc-1631	134	23	exposure	exposure	NOUN
dpc-1631	134	24	,	,	PUNCT
dpc-1631	134	25	among	among	ADP
dpc-1631	134	26	obese	obese	ADJ
dpc-1631	134	27	and	and	CCONJ
dpc-1631	134	28	overweight	overweight	ADJ
dpc-1631	134	29	subjects	subject	NOUN
dpc-1631	134	30	,	,	PUNCT
dpc-1631	134	31	as	as	ADV
dpc-1631	134	32	well	well	ADV
dpc-1631	134	33	as	as	ADP
dpc-1631	134	34	the	the	DET
dpc-1631	134	35	variation	variation	NOUN
dpc-1631	134	36	of	of	ADP
dpc-1631	134	37	both	both	DET
dpc-1631	134	38	bmi	bmi	NOUN
dpc-1631	134	39	and	and	CCONJ
dpc-1631	134	40	other	other	ADJ
dpc-1631	134	41	factors	factor	NOUN
dpc-1631	134	42	over	over	ADP
dpc-1631	134	43	time	time	NOUN
dpc-1631	134	44	[	[	X
dpc-1631	134	45	29	29	NUM
dpc-1631	134	46	]	]	PUNCT
dpc-1631	134	47	.	.	PUNCT
dpc-1631	135	1	the	the	DET
dpc-1631	135	2	assessment	assessment	NOUN
dpc-1631	135	3	of	of	ADP
dpc-1631	135	4	the	the	DET
dpc-1631	135	5	association	association	NOUN
dpc-1631	135	6	between	between	ADP
dpc-1631	135	7	bmi	bmi	NOUN
dpc-1631	135	8	and	and	CCONJ
dpc-1631	135	9	different	different	ADJ
dpc-1631	135	10	clinical	clinical	ADJ
dpc-1631	135	11	outcomes	outcome	NOUN
dpc-1631	135	12	in	in	ADP
dpc-1631	135	13	melanoma	melanoma	NOUN
dpc-1631	135	14	patients	patient	NOUN
dpc-1631	135	15	(	(	PUNCT
dpc-1631	135	16	mortality	mortality	NOUN
dpc-1631	135	17	/	/	SYM
dpc-1631	135	18	survival	survival	NOUN
dpc-1631	135	19	,	,	PUNCT
dpc-1631	135	20	risk	risk	NOUN
dpc-1631	135	21	for	for	ADP
dpc-1631	135	22	recurrence	recurrence	NOUN
dpc-1631	135	23	,	,	PUNCT
dpc-1631	135	24	sentinel	sentinel	ADJ
dpc-1631	135	25	node	node	NOUN
dpc-1631	135	26	positivity	positivity	NOUN
dpc-1631	135	27	,	,	PUNCT
dpc-1631	135	28	and	and	CCONJ
dpc-1631	135	29	metastases	metastasis	NOUN
dpc-1631	135	30	)	)	PUNCT
dpc-1631	135	31	yielded	yield	VERB
dpc-1631	135	32	mixed	mixed	ADJ
dpc-1631	135	33	results	result	NOUN
dpc-1631	135	34	,	,	PUNCT
dpc-1631	135	35	with	with	ADP
dpc-1631	135	36	absence	absence	NOUN
dpc-1631	135	37	of	of	ADP
dpc-1631	135	38	any	any	DET
dpc-1631	135	39	apparent	apparent	ADJ
dpc-1631	135	40	influence	influence	NOUN
dpc-1631	135	41	according	accord	VERB
dpc-1631	135	42	to	to	ADP
dpc-1631	135	43	some	some	DET
dpc-1631	135	44	studies	study	NOUN
dpc-1631	135	45	[	[	X
dpc-1631	135	46	10	10	NUM
dpc-1631	135	47	-	-	SYM
dpc-1631	135	48	16	16	NUM
dpc-1631	135	49	]	]	PUNCT
dpc-1631	135	50	,	,	PUNCT
dpc-1631	135	51	better	well	ADJ
dpc-1631	135	52	prognosis	prognosis	NOUN
dpc-1631	135	53	for	for	ADP
dpc-1631	135	54	overweight	overweight	ADJ
dpc-1631	135	55	subjects	subject	NOUN
dpc-1631	135	56	but	but	CCONJ
dpc-1631	135	57	not	not	PART
dpc-1631	135	58	for	for	ADP
dpc-1631	135	59	obese	obese	ADJ
dpc-1631	135	60	patients	patient	NOUN
dpc-1631	135	61	shown	show	VERB
dpc-1631	135	62	in	in	ADP
dpc-1631	135	63	one	one	NUM
dpc-1631	135	64	study	study	NOUN
dpc-1631	135	65	[	[	X
dpc-1631	135	66	16	16	NUM
dpc-1631	135	67	]	]	PUNCT
dpc-1631	135	68	,	,	PUNCT
dpc-1631	135	69	and	and	CCONJ
dpc-1631	135	70	worse	bad	ADJ
dpc-1631	135	71	outcomes	outcome	NOUN
dpc-1631	135	72	for	for	ADP
dpc-1631	135	73	increased	increase	VERB
dpc-1631	135	74	bmi	bmi	NOUN
dpc-1631	135	75	values	value	NOUN
dpc-1631	135	76	found	find	VERB
dpc-1631	135	77	by	by	ADP
dpc-1631	135	78	other	other	ADJ
dpc-1631	135	79	authors	author	NOUN
dpc-1631	135	80	[	[	X
dpc-1631	135	81	17	17	NUM
dpc-1631	135	82	-	-	SYM
dpc-1631	135	83	19	19	NUM
dpc-1631	135	84	]	]	PUNCT
dpc-1631	135	85	.	.	PUNCT
dpc-1631	136	1	the	the	DET
dpc-1631	136	2	unfavourable	unfavourable	ADJ
dpc-1631	136	3	outcome	outcome	NOUN
dpc-1631	136	4	associations	association	NOUN
dpc-1631	136	5	observed	observe	VERB
dpc-1631	136	6	by	by	ADP
dpc-1631	136	7	fang	fang	PROPN
dpc-1631	136	8	et	et	PROPN
dpc-1631	136	9	al	al	PROPN
dpc-1631	136	10	were	be	AUX
dpc-1631	136	11	weakened	weaken	VERB
dpc-1631	136	12	or	or	CCONJ
dpc-1631	136	13	lost	lose	VERB
dpc-1631	136	14	their	their	PRON
dpc-1631	136	15	significance	significance	NOUN
dpc-1631	136	16	after	after	ADP
dpc-1631	136	17	adjustment	adjustment	NOUN
dpc-1631	136	18	for	for	ADP
dpc-1631	136	19	crp	crp	PROPN
dpc-1631	136	20	,	,	PUNCT
dpc-1631	136	21	suggesting	suggest	VERB
dpc-1631	136	22	that	that	SCONJ
dpc-1631	136	23	elevated	elevated	ADJ
dpc-1631	136	24	bmi	bmi	NOUN
dpc-1631	136	25	can	can	AUX
dpc-1631	136	26	affect	affect	VERB
dpc-1631	136	27	melanoma	melanoma	NOUN
dpc-1631	136	28	progression	progression	NOUN
dpc-1631	136	29	through	through	ADP
dpc-1631	136	30	mechanisms	mechanism	NOUN
dpc-1631	136	31	related	relate	VERB
dpc-1631	136	32	to	to	ADP
dpc-1631	136	33	metabolic	metabolic	NOUN
dpc-1631	136	34	syndrome	syndrome	NOUN
dpc-1631	136	35	and/or	and/or	CCONJ
dpc-1631	136	36	chronic	chronic	ADJ
dpc-1631	136	37	systemic	systemic	ADJ
dpc-1631	136	38	inflammation	inflammation	NOUN
dpc-1631	136	39	,	,	PUNCT
dpc-1631	136	40	as	as	SCONJ
dpc-1631	136	41	indicated	indicate	VERB
dpc-1631	136	42	by	by	ADP
dpc-1631	136	43	crp	crp	PROPN
dpc-1631	136	44	concentration	concentration	NOUN
dpc-1631	137	1	[	[	X
dpc-1631	137	2	18	18	NUM
dpc-1631	137	3	]	]	PUNCT
dpc-1631	137	4	.	.	PUNCT
dpc-1631	138	1	various	various	ADJ
dpc-1631	138	2	reports	report	NOUN
dpc-1631	138	3	have	have	AUX
dpc-1631	138	4	highlighted	highlight	VERB
dpc-1631	138	5	the	the	DET
dpc-1631	138	6	link	link	NOUN
dpc-1631	138	7	between	between	ADP
dpc-1631	138	8	bmi	bmi	NOUN
dpc-1631	138	9	and	and	CCONJ
dpc-1631	138	10	breslow	breslow	ADJ
dpc-1631	138	11	thickness	thickness	NOUN
dpc-1631	139	1	[	[	X
dpc-1631	139	2	12,13,18,19,21	12,13,18,19,21	NUM
dpc-1631	139	3	-	-	SYM
dpc-1631	139	4	25	25	NUM
dpc-1631	139	5	]	]	PUNCT
dpc-1631	139	6	,	,	PUNCT
dpc-1631	139	7	a	a	DET
dpc-1631	139	8	well	well	ADV
dpc-1631	139	9	-	-	PUNCT
dpc-1631	139	10	established	establish	VERB
dpc-1631	139	11	prognostic	prognostic	ADJ
dpc-1631	139	12	factor	factor	NOUN
dpc-1631	139	13	of	of	ADP
dpc-1631	139	14	cutaneous	cutaneous	ADJ
dpc-1631	139	15	melanoma	melanoma	NOUN
dpc-1631	139	16	[	[	X
dpc-1631	139	17	33	33	NUM
dpc-1631	139	18	]	]	PUNCT
dpc-1631	139	19	.	.	PUNCT
dpc-1631	140	1	a	a	DET
dpc-1631	140	2	great	great	ADJ
dpc-1631	140	3	part	part	NOUN
dpc-1631	140	4	of	of	ADP
dpc-1631	140	5	the	the	DET
dpc-1631	140	6	literature	literature	NOUN
dpc-1631	140	7	exploring	explore	VERB
dpc-1631	140	8	the	the	DET
dpc-1631	140	9	obesity	obesity	NOUN
dpc-1631	140	10	-	-	PUNCT
dpc-1631	140	11	melanoma	melanoma	NOUN
dpc-1631	140	12	connection	connection	NOUN
dpc-1631	140	13	is	be	AUX
dpc-1631	140	14	based	base	VERB
dpc-1631	140	15	on	on	ADP
dpc-1631	140	16	studies	study	NOUN
dpc-1631	140	17	that	that	PRON
dpc-1631	140	18	adopted	adopt	VERB
dpc-1631	140	19	bmi	bmi	NOUN
dpc-1631	140	20	levels	level	NOUN
dpc-1631	140	21	to	to	PART
dpc-1631	140	22	define	define	VERB
dpc-1631	140	23	obesity	obesity	NOUN
dpc-1631	140	24	.	.	PUNCT
dpc-1631	141	1	nevertheless	nevertheless	ADV
dpc-1631	141	2	,	,	PUNCT
dpc-1631	141	3	bmi	bmi	PROPN
dpc-1631	141	4	is	be	AUX
dpc-1631	141	5	thought	think	VERB
dpc-1631	141	6	to	to	PART
dpc-1631	141	7	be	be	AUX
dpc-1631	141	8	an	an	DET
dpc-1631	141	9	imperfect	imperfect	ADJ
dpc-1631	141	10	measure	measure	NOUN
dpc-1631	141	11	of	of	ADP
dpc-1631	141	12	body	body	NOUN
dpc-1631	141	13	composition	composition	NOUN
dpc-1631	141	14	that	that	PRON
dpc-1631	141	15	is	be	AUX
dpc-1631	141	16	not	not	PART
dpc-1631	141	17	able	able	ADJ
dpc-1631	141	18	to	to	PART
dpc-1631	141	19	differentiate	differentiate	VERB
dpc-1631	141	20	between	between	ADP
dpc-1631	141	21	muscle	muscle	NOUN
dpc-1631	141	22	and	and	CCONJ
dpc-1631	141	23	adipose	adipose	NOUN
dpc-1631	141	24	tissues	tissue	NOUN
dpc-1631	141	25	or	or	CCONJ
dpc-1631	141	26	to	to	PART
dpc-1631	141	27	provide	provide	VERB
dpc-1631	141	28	information	information	NOUN
dpc-1631	141	29	on	on	ADP
dpc-1631	141	30	the	the	DET
dpc-1631	141	31	distribution	distribution	NOUN
dpc-1631	141	32	of	of	ADP
dpc-1631	141	33	adipose	adipose	ADJ
dpc-1631	141	34	tissues	tissue	NOUN
dpc-1631	141	35	,	,	PUNCT
dpc-1631	141	36	whether	whether	SCONJ
dpc-1631	141	37	central	central	ADJ
dpc-1631	141	38	,	,	PUNCT
dpc-1631	141	39	peripheral	peripheral	ADJ
dpc-1631	141	40	or	or	CCONJ
dpc-1631	141	41	in	in	ADP
dpc-1631	141	42	the	the	DET
dpc-1631	141	43	context	context	NOUN
dpc-1631	141	44	or	or	CCONJ
dpc-1631	141	45	proximity	proximity	NOUN
dpc-1631	141	46	of	of	ADP
dpc-1631	141	47	target	target	NOUN
dpc-1631	141	48	organs	organ	NOUN
dpc-1631	141	49	[	[	X
dpc-1631	141	50	2,34	2,34	X
dpc-1631	141	51	]	]	X
dpc-1631	141	52	.	.	PUNCT
dpc-1631	142	1	it	it	PRON
dpc-1631	142	2	is	be	AUX
dpc-1631	142	3	increasingly	increasingly	ADV
dpc-1631	142	4	accepted	accept	VERB
dpc-1631	142	5	that	that	SCONJ
dpc-1631	142	6	other	other	ADJ
dpc-1631	142	7	parameters	parameter	NOUN
dpc-1631	142	8	(	(	PUNCT
dpc-1631	142	9	eg	eg	NOUN
dpc-1631	142	10	,	,	PUNCT
dpc-1631	142	11	hip	hip	NOUN
dpc-1631	142	12	circumference	circumference	NOUN
dpc-1631	142	13	,	,	PUNCT
dpc-1631	142	14	waist	waist	NOUN
dpc-1631	142	15	circumference	circumference	NOUN
dpc-1631	142	16	,	,	PUNCT
dpc-1631	142	17	waist	waist	NOUN
dpc-1631	142	18	-	-	PUNCT
dpc-1631	142	19	to	to	ADP
dpc-1631	142	20	-	-	PUNCT
dpc-1631	142	21	height	height	NOUN
dpc-1631	142	22	ratio	ratio	NOUN
dpc-1631	142	23	and	and	CCONJ
dpc-1631	142	24	waist	waist	NOUN
dpc-1631	142	25	-	-	PUNCT
dpc-1631	142	26	to	to	ADP
dpc-1631	142	27	-	-	PUNCT
dpc-1631	142	28	hip	hip	NOUN
dpc-1631	142	29	ratio	ratio	NOUN
dpc-1631	142	30	)	)	PUNCT
dpc-1631	142	31	may	may	AUX
dpc-1631	142	32	more	more	ADV
dpc-1631	142	33	accurately	accurately	ADV
dpc-1631	142	34	reflect	reflect	VERB
dpc-1631	142	35	body	body	NOUN
dpc-1631	142	36	fat	fat	ADJ
dpc-1631	142	37	distribution	distribution	NOUN
dpc-1631	142	38	.	.	PUNCT
dpc-1631	143	1	furthermore	furthermore	ADV
dpc-1631	143	2	,	,	PUNCT
dpc-1631	143	3	bmi	bmi	PROPN
dpc-1631	143	4	can	can	AUX
dpc-1631	143	5	be	be	AUX
dpc-1631	143	6	a	a	DET
dpc-1631	143	7	less	less	ADV
dpc-1631	143	8	accurate	accurate	ADJ
dpc-1631	143	9	marker	marker	NOUN
dpc-1631	143	10	of	of	ADP
dpc-1631	143	11	adiposity	adiposity	NOUN
dpc-1631	143	12	among	among	ADP
dpc-1631	143	13	older	old	ADJ
dpc-1631	143	14	people	people	NOUN
dpc-1631	143	15	,	,	PUNCT
dpc-1631	143	16	due	due	ADP
dpc-1631	143	17	to	to	ADP
dpc-1631	143	18	the	the	DET
dpc-1631	143	19	natural	natural	ADJ
dpc-1631	143	20	trends	trend	NOUN
dpc-1631	143	21	toward	toward	ADP
dpc-1631	143	22	reduction	reduction	NOUN
dpc-1631	143	23	in	in	ADP
dpc-1631	143	24	height	height	NOUN
dpc-1631	143	25	,	,	PUNCT
dpc-1631	143	26	loss	loss	NOUN
dpc-1631	143	27	of	of	ADP
dpc-1631	143	28	muscle	muscle	NOUN
dpc-1631	143	29	and	and	CCONJ
dpc-1631	143	30	increase	increase	NOUN
dpc-1631	143	31	of	of	ADP
dpc-1631	143	32	adipose	adipose	ADJ
dpc-1631	143	33	tissue	tissue	NOUN
dpc-1631	143	34	in	in	ADP
dpc-1631	143	35	ageing	age	VERB
dpc-1631	143	36	,	,	PUNCT
dpc-1631	143	37	especially	especially	ADV
dpc-1631	143	38	in	in	ADP
dpc-1631	143	39	6	6	NUM
dpc-1631	143	40	review	review	NOUN
dpc-1631	143	41	|	|	ADV
dpc-1631	143	42	dermatol	dermatol	ADJ
dpc-1631	143	43	pract	pract	NOUN
dpc-1631	143	44	concept	concept	NOUN
dpc-1631	143	45	.	.	PUNCT
dpc-1631	144	1	2021;11(4	2021;11(4	NUM
dpc-1631	144	2	):	):	PUNCT
dpc-1631	144	3	e2021106	e2021106	NOUN
dpc-1631	144	4	post	post	ADJ
dpc-1631	144	5	-	-	ADJ
dpc-1631	144	6	menopausal	menopausal	ADJ
dpc-1631	144	7	women	woman	NOUN
dpc-1631	144	8	[	[	X
dpc-1631	144	9	2	2	NUM
dpc-1631	144	10	]	]	PUNCT
dpc-1631	144	11	.	.	PUNCT
dpc-1631	145	1	regardless	regardless	ADV
dpc-1631	145	2	of	of	ADP
dpc-1631	145	3	the	the	DET
dpc-1631	145	4	above	above	ADV
dpc-1631	145	5	-	-	PUNCT
dpc-1631	145	6	mentioned	mention	VERB
dpc-1631	145	7	limitations	limitation	NOUN
dpc-1631	145	8	and	and	CCONJ
dpc-1631	145	9	the	the	DET
dpc-1631	145	10	need	need	NOUN
dpc-1631	145	11	of	of	ADP
dpc-1631	145	12	further	further	ADJ
dpc-1631	145	13	studies	study	NOUN
dpc-1631	145	14	specifically	specifically	ADV
dpc-1631	145	15	designed	design	VERB
dpc-1631	145	16	to	to	PART
dpc-1631	145	17	overcome	overcome	VERB
dpc-1631	145	18	such	such	ADJ
dpc-1631	145	19	limitations	limitation	NOUN
dpc-1631	145	20	,	,	PUNCT
dpc-1631	145	21	bmi	bmi	PROPN
dpc-1631	145	22	may	may	AUX
dpc-1631	145	23	be	be	AUX
dpc-1631	145	24	interpreted	interpret	VERB
dpc-1631	145	25	as	as	ADP
dpc-1631	145	26	a	a	DET
dpc-1631	145	27	marker	marker	NOUN
dpc-1631	145	28	reflecting	reflect	VERB
dpc-1631	145	29	,	,	PUNCT
dpc-1631	145	30	at	at	ADP
dpc-1631	145	31	least	least	ADJ
dpc-1631	145	32	partially	partially	ADV
dpc-1631	145	33	,	,	PUNCT
dpc-1631	145	34	the	the	DET
dpc-1631	145	35	effect	effect	NOUN
dpc-1631	145	36	of	of	ADP
dpc-1631	145	37	genetic	genetic	ADJ
dpc-1631	145	38	and	and	CCONJ
dpc-1631	145	39	biological	biological	ADJ
dpc-1631	145	40	mechanisms	mechanism	NOUN
dpc-1631	145	41	,	,	PUNCT
dpc-1631	145	42	as	as	ADV
dpc-1631	145	43	well	well	ADV
dpc-1631	145	44	as	as	ADP
dpc-1631	145	45	lifestyle	lifestyle	NOUN
dpc-1631	145	46	and	and	CCONJ
dpc-1631	145	47	environmental	environmental	ADJ
dpc-1631	145	48	factors	factor	NOUN
dpc-1631	145	49	.	.	PUNCT
dpc-1631	146	1	the	the	DET
dpc-1631	146	2	biological	biological	ADJ
dpc-1631	146	3	mechanisms	mechanism	NOUN
dpc-1631	146	4	underlying	underlie	VERB
dpc-1631	146	5	the	the	DET
dpc-1631	146	6	obesity	obesity	NOUN
dpc-1631	146	7	-	-	PUNCT
dpc-1631	146	8	cancer	cancer	NOUN
dpc-1631	146	9	link	link	NOUN
dpc-1631	146	10	seem	seem	VERB
dpc-1631	146	11	to	to	PART
dpc-1631	146	12	be	be	AUX
dpc-1631	146	13	intricate	intricate	ADJ
dpc-1631	146	14	and	and	CCONJ
dpc-1631	146	15	are	be	AUX
dpc-1631	146	16	still	still	ADV
dpc-1631	146	17	unclear	unclear	ADJ
dpc-1631	146	18	.	.	PUNCT
dpc-1631	147	1	ever	ever	ADV
dpc-1631	147	2	-	-	PUNCT
dpc-1631	147	3	growing	grow	VERB
dpc-1631	147	4	evidence	evidence	NOUN
dpc-1631	147	5	supports	support	VERB
dpc-1631	147	6	the	the	DET
dpc-1631	147	7	involvement	involvement	NOUN
dpc-1631	147	8	of	of	ADP
dpc-1631	147	9	adipose	adipose	ADJ
dpc-1631	147	10	tissue	tissue	NOUN
dpc-1631	147	11	in	in	ADP
dpc-1631	147	12	tumor	tumor	NOUN
dpc-1631	147	13	development	development	NOUN
dpc-1631	147	14	and	and	CCONJ
dpc-1631	147	15	progression	progression	NOUN
dpc-1631	147	16	via	via	ADP
dpc-1631	147	17	endocrine	endocrine	NOUN
dpc-1631	147	18	and/or	and/or	CCONJ
dpc-1631	147	19	paracrine	paracrine	ADJ
dpc-1631	147	20	pathways	pathway	NOUN
dpc-1631	147	21	,	,	PUNCT
dpc-1631	147	22	secreting	secrete	VERB
dpc-1631	147	23	a	a	DET
dpc-1631	147	24	variety	variety	NOUN
dpc-1631	147	25	of	of	ADP
dpc-1631	147	26	molecules	molecule	NOUN
dpc-1631	147	27	that	that	PRON
dpc-1631	147	28	alter	alter	VERB
dpc-1631	147	29	systemic	systemic	ADJ
dpc-1631	147	30	and	and	CCONJ
dpc-1631	147	31	local	local	ADJ
dpc-1631	147	32	microenvironments	microenvironment	NOUN
dpc-1631	147	33	[	[	X
dpc-1631	147	34	1	1	NUM
dpc-1631	147	35	]	]	PUNCT
dpc-1631	147	36	.	.	PUNCT
dpc-1631	148	1	the	the	DET
dpc-1631	148	2	obesity	obesity	NOUN
dpc-1631	148	3	-	-	PUNCT
dpc-1631	148	4	related	relate	VERB
dpc-1631	148	5	dysfunctional	dysfunctional	ADJ
dpc-1631	148	6	adipose	adipose	NOUN
dpc-1631	148	7	tissue	tissue	NOUN
dpc-1631	148	8	and	and	CCONJ
dpc-1631	148	9	the	the	DET
dpc-1631	148	10	active	active	ADJ
dpc-1631	148	11	cross	cross	NOUN
dpc-1631	148	12	talk	talk	NOUN
dpc-1631	148	13	between	between	ADP
dpc-1631	148	14	adipocytes	adipocyte	NOUN
dpc-1631	148	15	and	and	CCONJ
dpc-1631	148	16	melanoma	melanoma	NOUN
dpc-1631	148	17	cells	cell	NOUN
dpc-1631	148	18	can	can	AUX
dpc-1631	148	19	contribute	contribute	VERB
dpc-1631	148	20	to	to	ADP
dpc-1631	148	21	melanoma	melanoma	NOUN
dpc-1631	148	22	aggressiveness	aggressiveness	NOUN
dpc-1631	148	23	and	and	CCONJ
dpc-1631	148	24	progression	progression	NOUN
dpc-1631	148	25	through	through	ADP
dpc-1631	148	26	the	the	DET
dpc-1631	148	27	release	release	NOUN
dpc-1631	148	28	of	of	ADP
dpc-1631	148	29	pro	pro	ADJ
dpc-1631	148	30	-	-	ADJ
dpc-1631	148	31	inflammatory	inflammatory	ADJ
dpc-1631	148	32	,	,	PUNCT
dpc-1631	148	33	pro	pro	ADJ
dpc-1631	148	34	-	-	ADJ
dpc-1631	148	35	angiogenic	angiogenic	ADJ
dpc-1631	148	36	and	and	CCONJ
dpc-1631	148	37	lymphangiogenic	lymphangiogenic	ADJ
dpc-1631	148	38	factors	factor	NOUN
dpc-1631	148	39	,	,	PUNCT
dpc-1631	148	40	as	as	ADV
dpc-1631	148	41	well	well	ADV
dpc-1631	148	42	as	as	ADP
dpc-1631	148	43	extracellular	extracellular	ADJ
dpc-1631	148	44	matrix	matrix	NOUN
dpc-1631	148	45	remodelling	remodelling	NOUN
dpc-1631	148	46	molecules	molecule	NOUN
dpc-1631	148	47	,	,	PUNCT
dpc-1631	148	48	fatty	fatty	NOUN
dpc-1631	148	49	acids	acid	NOUN
dpc-1631	148	50	,	,	PUNCT
dpc-1631	148	51	and	and	CCONJ
dpc-1631	148	52	probably	probably	ADV
dpc-1631	148	53	other	other	ADJ
dpc-1631	148	54	substances	substance	NOUN
dpc-1631	148	55	contained	contain	VERB
dpc-1631	148	56	into	into	ADP
dpc-1631	148	57	the	the	DET
dpc-1631	148	58	adipocyte	adipocyte	NOUN
dpc-1631	148	59	exosomes	exosome	NOUN
dpc-1631	149	1	[	[	X
dpc-1631	149	2	4,35	4,35	NUM
dpc-1631	149	3	-	-	SYM
dpc-1631	149	4	40	40	NUM
dpc-1631	149	5	]	]	PUNCT
dpc-1631	149	6	.	.	PUNCT
dpc-1631	150	1	the	the	DET
dpc-1631	150	2	obesity	obesity	NOUN
dpc-1631	150	3	-	-	PUNCT
dpc-1631	150	4	related	relate	VERB
dpc-1631	150	5	changes	change	NOUN
dpc-1631	150	6	include	include	VERB
dpc-1631	150	7	a	a	DET
dpc-1631	150	8	chronic	chronic	ADJ
dpc-1631	150	9	state	state	NOUN
dpc-1631	150	10	of	of	ADP
dpc-1631	150	11	low	low	ADJ
dpc-1631	150	12	-	-	PUNCT
dpc-1631	150	13	grade	grade	NOUN
dpc-1631	150	14	inflammation	inflammation	NOUN
dpc-1631	150	15	,	,	PUNCT
dpc-1631	150	16	adipokine	adipokine	ADJ
dpc-1631	150	17	imbalances	imbalance	NOUN
dpc-1631	150	18	,	,	PUNCT
dpc-1631	150	19	elevated	elevated	ADJ
dpc-1631	150	20	levels	level	NOUN
dpc-1631	150	21	of	of	ADP
dpc-1631	150	22	growth	growth	NOUN
dpc-1631	150	23	factors	factor	NOUN
dpc-1631	150	24	,	,	PUNCT
dpc-1631	150	25	and	and	CCONJ
dpc-1631	150	26	hormones	hormone	NOUN
dpc-1631	150	27	,	,	PUNCT
dpc-1631	150	28	such	such	ADJ
dpc-1631	150	29	as	as	ADP
dpc-1631	150	30	insulin	insulin	NOUN
dpc-1631	150	31	,	,	PUNCT
dpc-1631	150	32	insulin	insulin	NOUN
dpc-1631	150	33	-	-	PUNCT
dpc-1631	150	34	like	like	ADJ
dpc-1631	150	35	growth	growth	NOUN
dpc-1631	150	36	factor	factor	NOUN
dpc-1631	150	37	(	(	PUNCT
dpc-1631	150	38	igf)-1	igf)-1	ADJ
dpc-1631	150	39	,	,	PUNCT
dpc-1631	150	40	and	and	CCONJ
dpc-1631	150	41	estrogens	estrogen	NOUN
dpc-1631	150	42	[	[	X
dpc-1631	150	43	1,3	1,3	NUM
dpc-1631	150	44	]	]	PUNCT
dpc-1631	150	45	.	.	PUNCT
dpc-1631	151	1	the	the	DET
dpc-1631	151	2	cytokine	cytokine	ADJ
dpc-1631	151	3	profile	profile	NOUN
dpc-1631	151	4	of	of	ADP
dpc-1631	151	5	adipose	adipose	ADJ
dpc-1631	151	6	tissue	tissue	NOUN
dpc-1631	151	7	includes	include	VERB
dpc-1631	151	8	specific	specific	ADJ
dpc-1631	151	9	adipokines	adipokine	NOUN
dpc-1631	151	10	that	that	PRON
dpc-1631	151	11	may	may	AUX
dpc-1631	151	12	interfere	interfere	VERB
dpc-1631	151	13	with	with	ADP
dpc-1631	151	14	cellular	cellular	ADJ
dpc-1631	151	15	processes	process	NOUN
dpc-1631	151	16	by	by	ADP
dpc-1631	151	17	acting	act	VERB
dpc-1631	151	18	on	on	ADP
dpc-1631	151	19	signaling	signal	VERB
dpc-1631	151	20	pathways	pathway	NOUN
dpc-1631	151	21	,	,	PUNCT
dpc-1631	151	22	such	such	ADJ
dpc-1631	151	23	as	as	ADP
dpc-1631	151	24	pi3k	pi3k	PROPN
dpc-1631	151	25	/	/	SYM
dpc-1631	151	26	akt	akt	PROPN
dpc-1631	151	27	,	,	PUNCT
dpc-1631	151	28	mapk	mapk	NOUN
dpc-1631	151	29	,	,	PUNCT
dpc-1631	151	30	and	and	CCONJ
dpc-1631	151	31	jak	jak	PROPN
dpc-1631	151	32	/	/	SYM
dpc-1631	151	33	stat	stat	PROPN
dpc-1631	152	1	[	[	X
dpc-1631	152	2	41	41	NUM
dpc-1631	152	3	]	]	PUNCT
dpc-1631	152	4	.	.	PUNCT
dpc-1631	153	1	in	in	ADP
dpc-1631	153	2	obesity	obesity	NOUN
dpc-1631	153	3	,	,	PUNCT
dpc-1631	153	4	adipocytes	adipocyte	NOUN
dpc-1631	153	5	produce	produce	VERB
dpc-1631	153	6	less	less	ADJ
dpc-1631	153	7	adiponectin	adiponectin	NOUN
dpc-1631	153	8	,	,	PUNCT
dpc-1631	153	9	that	that	PRON
dpc-1631	153	10	has	have	VERB
dpc-1631	153	11	anti	anti	ADJ
dpc-1631	153	12	-	-	ADJ
dpc-1631	153	13	inflammatory	inflammatory	ADJ
dpc-1631	153	14	and	and	CCONJ
dpc-1631	153	15	anti	anti	ADJ
dpc-1631	153	16	-	-	ADJ
dpc-1631	153	17	neoplastic	neoplastic	ADJ
dpc-1631	153	18	effects	effect	NOUN
dpc-1631	153	19	,	,	PUNCT
dpc-1631	153	20	but	but	CCONJ
dpc-1631	153	21	more	more	ADJ
dpc-1631	153	22	leptin	leptin	NOUN
dpc-1631	153	23	,	,	PUNCT
dpc-1631	153	24	that	that	PRON
dpc-1631	153	25	can	can	AUX
dpc-1631	153	26	contribute	contribute	VERB
dpc-1631	153	27	to	to	ADP
dpc-1631	153	28	melanoma	melanoma	NOUN
dpc-1631	153	29	growth	growth	NOUN
dpc-1631	153	30	and	and	CCONJ
dpc-1631	153	31	metastases	metastasis	NOUN
dpc-1631	153	32	[	[	X
dpc-1631	153	33	4,5,15	4,5,15	NUM
dpc-1631	153	34	]	]	PUNCT
dpc-1631	153	35	.	.	PUNCT
dpc-1631	154	1	experimental	experimental	ADJ
dpc-1631	154	2	findings	finding	NOUN
dpc-1631	154	3	suggest	suggest	VERB
dpc-1631	154	4	the	the	DET
dpc-1631	154	5	association	association	NOUN
dpc-1631	154	6	between	between	ADP
dpc-1631	154	7	obesity	obesity	NOUN
dpc-1631	154	8	and	and	CCONJ
dpc-1631	154	9	aggressive	aggressive	ADJ
dpc-1631	154	10	tumor	tumor	NOUN
dpc-1631	154	11	biology	biology	NOUN
dpc-1631	154	12	with	with	ADP
dpc-1631	154	13	a	a	DET
dpc-1631	154	14	“	"	PUNCT
dpc-1631	154	15	meta	meta	ADJ
dpc-1631	154	16	-	-	PUNCT
dpc-1631	154	17	inflammatory	inflammatory	ADJ
dpc-1631	154	18	”	"	PUNCT
dpc-1631	154	19	state	state	NOUN
dpc-1631	154	20	,	,	PUNCT
dpc-1631	154	21	increased	increase	VERB
dpc-1631	154	22	immune	immune	ADJ
dpc-1631	154	23	aging	aging	NOUN
dpc-1631	154	24	and	and	CCONJ
dpc-1631	154	25	t	t	NOUN
dpc-1631	154	26	cell	cell	NOUN
dpc-1631	154	27	dysfunction	dysfunction	NOUN
dpc-1631	154	28	[	[	X
dpc-1631	154	29	7	7	NUM
dpc-1631	154	30	]	]	PUNCT
dpc-1631	154	31	.	.	PUNCT
dpc-1631	155	1	a	a	DET
dpc-1631	155	2	direct	direct	ADJ
dpc-1631	155	3	role	role	NOUN
dpc-1631	155	4	of	of	ADP
dpc-1631	155	5	obesity	obesity	NOUN
dpc-1631	155	6	on	on	ADP
dpc-1631	155	7	melanoma	melanoma	NOUN
dpc-1631	155	8	growth	growth	NOUN
dpc-1631	155	9	and	and	CCONJ
dpc-1631	155	10	progression	progression	NOUN
dpc-1631	155	11	has	have	AUX
dpc-1631	155	12	been	be	AUX
dpc-1631	155	13	documented	document	VERB
dpc-1631	155	14	by	by	ADP
dpc-1631	155	15	investigations	investigation	NOUN
dpc-1631	155	16	in	in	ADP
dpc-1631	155	17	animal	animal	NOUN
dpc-1631	155	18	models	model	NOUN
dpc-1631	155	19	.	.	PUNCT
dpc-1631	156	1	diet	diet	NOUN
dpc-1631	156	2	-	-	PUNCT
dpc-1631	156	3	induced	induce	VERB
dpc-1631	156	4	obesity	obesity	NOUN
dpc-1631	156	5	has	have	AUX
dpc-1631	156	6	been	be	AUX
dpc-1631	156	7	demonstrated	demonstrate	VERB
dpc-1631	156	8	to	to	PART
dpc-1631	156	9	increase	increase	VERB
dpc-1631	156	10	melanoma	melanoma	ADJ
dpc-1631	156	11	progression	progression	NOUN
dpc-1631	156	12	in	in	ADP
dpc-1631	156	13	mice	mouse	NOUN
dpc-1631	156	14	[	[	X
dpc-1631	156	15	42	42	NUM
dpc-1631	156	16	]	]	PUNCT
dpc-1631	156	17	,	,	PUNCT
dpc-1631	156	18	while	while	SCONJ
dpc-1631	156	19	controlling	control	VERB
dpc-1631	156	20	obesity	obesity	NOUN
dpc-1631	156	21	has	have	AUX
dpc-1631	156	22	proved	prove	VERB
dpc-1631	156	23	to	to	PART
dpc-1631	156	24	reverse	reverse	VERB
dpc-1631	156	25	the	the	DET
dpc-1631	156	26	effect	effect	NOUN
dpc-1631	156	27	on	on	ADP
dpc-1631	156	28	melanoma	melanoma	ADJ
dpc-1631	156	29	progression	progression	NOUN
dpc-1631	157	1	[	[	X
dpc-1631	157	2	43	43	NUM
dpc-1631	157	3	]	]	PUNCT
dpc-1631	157	4	.	.	PUNCT
dpc-1631	158	1	the	the	DET
dpc-1631	158	2	association	association	NOUN
dpc-1631	158	3	between	between	ADP
dpc-1631	158	4	obesity	obesity	NOUN
dpc-1631	158	5	and	and	CCONJ
dpc-1631	158	6	melanoma	melanoma	NOUN
dpc-1631	158	7	might	might	AUX
dpc-1631	158	8	be	be	AUX
dpc-1631	158	9	conditioned	condition	VERB
dpc-1631	158	10	by	by	ADP
dpc-1631	158	11	many	many	ADJ
dpc-1631	158	12	other	other	ADJ
dpc-1631	158	13	factors	factor	NOUN
dpc-1631	158	14	,	,	PUNCT
dpc-1631	158	15	such	such	ADJ
dpc-1631	158	16	as	as	ADP
dpc-1631	158	17	genetic	genetic	ADJ
dpc-1631	158	18	mechanisms	mechanism	NOUN
dpc-1631	158	19	and	and	CCONJ
dpc-1631	158	20	insulin	insulin	NOUN
dpc-1631	158	21	resistance	resistance	NOUN
dpc-1631	158	22	,	,	PUNCT
dpc-1631	158	23	as	as	ADV
dpc-1631	158	24	well	well	ADV
dpc-1631	158	25	as	as	ADP
dpc-1631	158	26	the	the	DET
dpc-1631	158	27	increased	increase	VERB
dpc-1631	158	28	body	body	NOUN
dpc-1631	158	29	surface	surface	NOUN
dpc-1631	158	30	,	,	PUNCT
dpc-1631	158	31	gut	gut	VERB
dpc-1631	158	32	microbiota	microbiota	NOUN
dpc-1631	158	33	dysbiosis	dysbiosis	NOUN
dpc-1631	158	34	,	,	PUNCT
dpc-1631	158	35	and	and	CCONJ
dpc-1631	158	36	decreased	decrease	VERB
dpc-1631	158	37	levels	level	NOUN
dpc-1631	158	38	of	of	ADP
dpc-1631	158	39	vitamin	vitamin	NOUN
dpc-1631	158	40	d	d	NOUN
dpc-1631	158	41	[	[	X
dpc-1631	158	42	5,29,44,45	5,29,44,45	NUM
dpc-1631	158	43	]	]	X
dpc-1631	158	44	.	.	PUNCT
dpc-1631	159	1	several	several	ADJ
dpc-1631	159	2	data	datum	NOUN
dpc-1631	159	3	were	be	AUX
dpc-1631	159	4	suggestive	suggestive	ADJ
dpc-1631	159	5	of	of	ADP
dpc-1631	159	6	an	an	DET
dpc-1631	159	7	inverse	inverse	NOUN
dpc-1631	159	8	association	association	NOUN
dpc-1631	159	9	between	between	ADP
dpc-1631	159	10	vitamin	vitamin	NOUN
dpc-1631	159	11	d	d	PROPN
dpc-1631	159	12	serum	serum	NOUN
dpc-1631	159	13	levels	level	NOUN
dpc-1631	159	14	and	and	CCONJ
dpc-1631	159	15	melanoma	melanoma	NOUN
dpc-1631	159	16	thickness	thickness	NOUN
dpc-1631	159	17	at	at	ADP
dpc-1631	159	18	diagnosis	diagnosis	NOUN
dpc-1631	159	19	[	[	X
dpc-1631	159	20	17,25,45,46	17,25,45,46	NUM
dpc-1631	159	21	]	]	PUNCT
dpc-1631	159	22	.	.	PUNCT
dpc-1631	160	1	a	a	DET
dpc-1631	160	2	recent	recent	ADJ
dpc-1631	160	3	study	study	NOUN
dpc-1631	160	4	reported	report	VERB
dpc-1631	160	5	that	that	SCONJ
dpc-1631	160	6	bmi	bmi	NOUN
dpc-1631	160	7	and	and	CCONJ
dpc-1631	160	8	low	low	ADJ
dpc-1631	160	9	vitamin	vitamin	NOUN
dpc-1631	160	10	d	d	NOUN
dpc-1631	160	11	levels	level	NOUN
dpc-1631	160	12	were	be	AUX
dpc-1631	160	13	independently	independently	ADV
dpc-1631	160	14	associated	associate	VERB
dpc-1631	160	15	with	with	ADP
dpc-1631	160	16	thicker	thick	ADJ
dpc-1631	160	17	tumors	tumor	NOUN
dpc-1631	160	18	[	[	X
dpc-1631	160	19	13	13	NUM
dpc-1631	160	20	]	]	PUNCT
dpc-1631	160	21	.	.	PUNCT
dpc-1631	161	1	moreover	moreover	ADV
dpc-1631	161	2	,	,	PUNCT
dpc-1631	161	3	moreno	moreno	PROPN
dpc-1631	161	4	-	-	PUNCT
dpc-1631	161	5	arrones	arrones	PROPN
dpc-1631	161	6	et	et	NOUN
dpc-1631	161	7	al	al	PROPN
dpc-1631	161	8	,	,	PUNCT
dpc-1631	161	9	while	while	SCONJ
dpc-1631	161	10	registering	register	VERB
dpc-1631	161	11	decreased	decrease	VERB
dpc-1631	161	12	vitamin	vitamin	NOUN
dpc-1631	161	13	d	d	NOUN
dpc-1631	161	14	serum	serum	NOUN
dpc-1631	161	15	levels	level	NOUN
dpc-1631	161	16	at	at	ADP
dpc-1631	161	17	melanoma	melanoma	ADJ
dpc-1631	161	18	diagnosis	diagnosis	NOUN
dpc-1631	161	19	,	,	PUNCT
dpc-1631	161	20	described	describe	VERB
dpc-1631	161	21	a	a	DET
dpc-1631	161	22	significant	significant	ADJ
dpc-1631	161	23	association	association	NOUN
dpc-1631	161	24	of	of	ADP
dpc-1631	161	25	this	this	DET
dpc-1631	161	26	finding	finding	NOUN
dpc-1631	161	27	with	with	ADP
dpc-1631	161	28	both	both	DET
dpc-1631	161	29	tumor	tumor	NOUN
dpc-1631	161	30	mitotic	mitotic	ADJ
dpc-1631	161	31	rate	rate	NOUN
dpc-1631	161	32	and	and	CCONJ
dpc-1631	161	33	ulceration	ulceration	NOUN
dpc-1631	161	34	and	and	CCONJ
dpc-1631	161	35	a	a	DET
dpc-1631	161	36	borderline	borderline	NOUN
dpc-1631	161	37	association	association	NOUN
dpc-1631	161	38	with	with	ADP
dpc-1631	161	39	breslow	breslow	ADJ
dpc-1631	161	40	thickness	thickness	NOUN
dpc-1631	161	41	and	and	CCONJ
dpc-1631	161	42	bmi	bmi	X
dpc-1631	162	1	[	[	X
dpc-1631	162	2	47	47	NUM
dpc-1631	162	3	]	]	PUNCT
dpc-1631	162	4	.	.	PUNCT
dpc-1631	163	1	genetic	genetic	ADJ
dpc-1631	163	2	mechanisms	mechanism	NOUN
dpc-1631	163	3	have	have	AUX
dpc-1631	163	4	also	also	ADV
dpc-1631	163	5	been	be	AUX
dpc-1631	163	6	implicated	implicate	VERB
dpc-1631	163	7	,	,	PUNCT
dpc-1631	163	8	although	although	SCONJ
dpc-1631	163	9	the	the	DET
dpc-1631	163	10	available	available	ADJ
dpc-1631	163	11	data	datum	NOUN
dpc-1631	163	12	are	be	AUX
dpc-1631	163	13	still	still	ADV
dpc-1631	163	14	inconclusive	inconclusive	ADJ
dpc-1631	163	15	.	.	PUNCT
dpc-1631	164	1	a	a	DET
dpc-1631	164	2	genetic	genetic	ADJ
dpc-1631	164	3	link	link	NOUN
dpc-1631	164	4	between	between	ADP
dpc-1631	164	5	obesity	obesity	NOUN
dpc-1631	164	6	and	and	CCONJ
dpc-1631	164	7	pigmentation	pigmentation	NOUN
dpc-1631	164	8	has	have	AUX
dpc-1631	164	9	been	be	AUX
dpc-1631	164	10	proposed	propose	VERB
dpc-1631	164	11	,	,	PUNCT
dpc-1631	164	12	as	as	ADV
dpc-1631	164	13	well	well	ADV
dpc-1631	164	14	as	as	ADP
dpc-1631	164	15	the	the	DET
dpc-1631	164	16	role	role	NOUN
dpc-1631	164	17	of	of	ADP
dpc-1631	164	18	obesity	obesity	NOUN
dpc-1631	164	19	susceptibility	susceptibility	NOUN
dpc-1631	164	20	loci	locus	NOUN
dpc-1631	164	21	in	in	ADP
dpc-1631	164	22	determining	determine	VERB
dpc-1631	164	23	the	the	DET
dpc-1631	164	24	risk	risk	NOUN
dpc-1631	164	25	and	and	CCONJ
dpc-1631	164	26	aggressiveness	aggressiveness	NOUN
dpc-1631	164	27	of	of	ADP
dpc-1631	164	28	melanoma	melanoma	NOUN
dpc-1631	164	29	,	,	PUNCT
dpc-1631	164	30	involving	involve	VERB
dpc-1631	164	31	,	,	PUNCT
dpc-1631	164	32	for	for	ADP
dpc-1631	164	33	instance	instance	NOUN
dpc-1631	164	34	,	,	PUNCT
dpc-1631	164	35	certain	certain	ADJ
dpc-1631	164	36	vitamin	vitamin	NOUN
dpc-1631	164	37	d	d	NOUN
dpc-1631	164	38	receptor	receptor	NOUN
dpc-1631	164	39	polymorphisms	polymorphism	NOUN
dpc-1631	164	40	and	and	CCONJ
dpc-1631	164	41	genetic	genetic	ADJ
dpc-1631	164	42	variations	variation	NOUN
dpc-1631	164	43	in	in	ADP
dpc-1631	164	44	igf-1	igf-1	NOUN
dpc-1631	164	45	or	or	CCONJ
dpc-1631	164	46	estrogen	estrogen	NOUN
dpc-1631	164	47	receptor	receptor	NOUN
dpc-1631	164	48	pathways	pathway	NOUN
dpc-1631	165	1	[	[	X
dpc-1631	165	2	5,45,48,49	5,45,48,49	NUM
dpc-1631	165	3	]	]	PUNCT
dpc-1631	165	4	.	.	PUNCT
dpc-1631	166	1	a	a	DET
dpc-1631	166	2	strong	strong	ADJ
dpc-1631	166	3	association	association	NOUN
dpc-1631	166	4	between	between	ADP
dpc-1631	166	5	breslow	breslow	NOUN
dpc-1631	166	6	index	index	NOUN
dpc-1631	166	7	and	and	CCONJ
dpc-1631	166	8	the	the	DET
dpc-1631	166	9	igf-1(ca)19	igf-1(ca)19	ADJ
dpc-1631	166	10	repeat	repeat	NOUN
dpc-1631	166	11	frequency	frequency	NOUN
dpc-1631	166	12	was	be	AUX
dpc-1631	166	13	found	find	VERB
dpc-1631	166	14	(	(	PUNCT
dpc-1631	166	15	p	p	X
dpc-1631	166	16	<	<	X
dpc-1631	166	17	0.001	0.001	NUM
dpc-1631	166	18	)	)	PUNCT
dpc-1631	166	19	in	in	ADP
dpc-1631	166	20	one	one	NUM
dpc-1631	166	21	study	study	NOUN
dpc-1631	166	22	[	[	X
dpc-1631	166	23	50	50	NUM
dpc-1631	166	24	]	]	PUNCT
dpc-1631	166	25	.	.	PUNCT
dpc-1631	167	1	fang	fang	PROPN
dpc-1631	167	2	et	et	PROPN
dpc-1631	167	3	al	al	PROPN
dpc-1631	167	4	investigated	investigate	VERB
dpc-1631	167	5	some	some	DET
dpc-1631	167	6	bmi	bmi	NOUN
dpc-1631	167	7	-	-	PUNCT
dpc-1631	167	8	associated	associate	VERB
dpc-1631	167	9	single	single	ADJ
dpc-1631	167	10	-	-	PUNCT
dpc-1631	167	11	nucleotide	nucleotide	NOUN
dpc-1631	167	12	polymorphisms	polymorphism	NOUN
dpc-1631	167	13	(	(	PUNCT
dpc-1631	167	14	snps	snps	PROPN
dpc-1631	167	15	)	)	PUNCT
dpc-1631	167	16	in	in	ADP
dpc-1631	167	17	relation	relation	NOUN
dpc-1631	167	18	with	with	ADP
dpc-1631	167	19	melanoma	melanoma	NOUN
dpc-1631	167	20	risk	risk	NOUN
dpc-1631	167	21	or	or	CCONJ
dpc-1631	167	22	outcome	outcome	NOUN
dpc-1631	167	23	.	.	PUNCT
dpc-1631	168	1	in	in	ADP
dpc-1631	168	2	particular	particular	ADJ
dpc-1631	168	3	,	,	PUNCT
dpc-1631	168	4	the	the	DET
dpc-1631	168	5	c	c	NOUN
dpc-1631	168	6	allele	allele	NOUN
dpc-1631	168	7	in	in	ADP
dpc-1631	168	8	the	the	DET
dpc-1631	168	9	rs17782313	rs17782313	PROPN
dpc-1631	168	10	snp	snp	NOUN
dpc-1631	168	11	(	(	PUNCT
dpc-1631	168	12	within	within	ADP
dpc-1631	168	13	the	the	DET
dpc-1631	168	14	melanocortin-4	melanocortin-4	NUM
dpc-1631	168	15	receptor	receptor	NOUN
dpc-1631	168	16	)	)	PUNCT
dpc-1631	168	17	was	be	AUX
dpc-1631	168	18	associated	associate	VERB
dpc-1631	168	19	with	with	ADP
dpc-1631	168	20	increased	increase	VERB
dpc-1631	168	21	bmi	bmi	NOUN
dpc-1631	168	22	and	and	CCONJ
dpc-1631	168	23	poorer	poor	ADJ
dpc-1631	168	24	overall	overall	ADJ
dpc-1631	168	25	and	and	CCONJ
dpc-1631	168	26	melanoma	melanoma	NOUN
dpc-1631	168	27	-	-	PUNCT
dpc-1631	168	28	specific	specific	ADJ
dpc-1631	168	29	survival	survival	NOUN
dpc-1631	168	30	among	among	ADP
dpc-1631	168	31	patients	patient	NOUN
dpc-1631	168	32	with	with	ADP
dpc-1631	168	33	stage	stage	NOUN
dpc-1631	168	34	i	i	PROPN
dpc-1631	168	35	/	/	SYM
dpc-1631	168	36	ii	ii	PROPN
dpc-1631	168	37	melanoma	melanoma	NOUN
dpc-1631	168	38	,	,	PUNCT
dpc-1631	168	39	showing	show	VERB
dpc-1631	168	40	a	a	DET
dpc-1631	168	41	trend	trend	NOUN
dpc-1631	168	42	towards	towards	ADP
dpc-1631	168	43	the	the	DET
dpc-1631	168	44	association	association	NOUN
dpc-1631	168	45	with	with	ADP
dpc-1631	168	46	elevated	elevated	ADJ
dpc-1631	168	47	crp	crp	NOUN
dpc-1631	169	1	[	[	X
dpc-1631	169	2	18	18	NUM
dpc-1631	169	3	]	]	PUNCT
dpc-1631	169	4	.	.	PUNCT
dpc-1631	170	1	beyond	beyond	ADP
dpc-1631	170	2	biological	biological	ADJ
dpc-1631	170	3	mechanisms	mechanism	NOUN
dpc-1631	170	4	underlying	underlie	VERB
dpc-1631	170	5	the	the	DET
dpc-1631	170	6	relationship	relationship	NOUN
dpc-1631	170	7	between	between	ADP
dpc-1631	170	8	bmi	bmi	NOUN
dpc-1631	170	9	and	and	CCONJ
dpc-1631	170	10	melanoma	melanoma	NOUN
dpc-1631	170	11	thickness	thickness	NOUN
dpc-1631	170	12	,	,	PUNCT
dpc-1631	170	13	stenehjem	stenehjem	VERB
dpc-1631	170	14	et	et	NOUN
dpc-1631	170	15	al	al	PROPN
dpc-1631	170	16	tried	try	VERB
dpc-1631	170	17	to	to	PART
dpc-1631	170	18	explain	explain	VERB
dpc-1631	170	19	their	their	PRON
dpc-1631	170	20	results	result	NOUN
dpc-1631	170	21	also	also	ADV
dpc-1631	170	22	based	base	VERB
dpc-1631	170	23	on	on	ADP
dpc-1631	170	24	behavioural	behavioural	ADJ
dpc-1631	170	25	mechanisms	mechanism	NOUN
dpc-1631	170	26	[	[	X
dpc-1631	170	27	24	24	NUM
dpc-1631	170	28	]	]	PUNCT
dpc-1631	170	29	.	.	PUNCT
dpc-1631	171	1	in	in	ADP
dpc-1631	171	2	particular	particular	ADJ
dpc-1631	171	3	,	,	PUNCT
dpc-1631	171	4	obesity	obesity	NOUN
dpc-1631	171	5	and	and	CCONJ
dpc-1631	171	6	body	body	NOUN
dpc-1631	171	7	dissatisfaction	dissatisfaction	NOUN
dpc-1631	171	8	have	have	AUX
dpc-1631	171	9	been	be	AUX
dpc-1631	171	10	associated	associate	VERB
dpc-1631	171	11	with	with	ADP
dpc-1631	171	12	reduced	reduce	VERB
dpc-1631	171	13	skin	skin	NOUN
dpc-1631	171	14	self	self	NOUN
dpc-1631	171	15	-	-	PUNCT
dpc-1631	171	16	examination	examination	NOUN
dpc-1631	171	17	and	and	CCONJ
dpc-1631	171	18	consequently	consequently	ADV
dpc-1631	171	19	with	with	ADP
dpc-1631	171	20	the	the	DET
dpc-1631	171	21	risk	risk	NOUN
dpc-1631	171	22	of	of	ADP
dpc-1631	171	23	delayed	delay	VERB
dpc-1631	171	24	detection	detection	NOUN
dpc-1631	171	25	of	of	ADP
dpc-1631	171	26	lesions	lesion	NOUN
dpc-1631	171	27	,	,	PUNCT
dpc-1631	171	28	whereas	whereas	SCONJ
dpc-1631	171	29	the	the	DET
dpc-1631	171	30	decline	decline	NOUN
dpc-1631	171	31	in	in	ADP
dpc-1631	171	32	adjusted	adjusted	ADJ
dpc-1631	171	33	mean	mean	ADJ
dpc-1631	171	34	breslow	breslow	ADJ
dpc-1631	171	35	thickness	thickness	NOUN
dpc-1631	171	36	for	for	ADP
dpc-1631	171	37	the	the	DET
dpc-1631	171	38	highest	high	ADJ
dpc-1631	171	39	anthropometric	anthropometric	ADJ
dpc-1631	171	40	values	value	NOUN
dpc-1631	171	41	observed	observe	VERB
dpc-1631	171	42	by	by	ADP
dpc-1631	171	43	those	those	DET
dpc-1631	171	44	authors	author	NOUN
dpc-1631	171	45	in	in	ADP
dpc-1631	171	46	their	their	PRON
dpc-1631	171	47	study	study	NOUN
dpc-1631	171	48	might	might	AUX
dpc-1631	171	49	reflect	reflect	VERB
dpc-1631	171	50	a	a	DET
dpc-1631	171	51	less	less	ADV
dpc-1631	171	52	sun	sun	NOUN
dpc-1631	171	53	-	-	PUNCT
dpc-1631	171	54	seeking	seek	VERB
dpc-1631	171	55	attitude	attitude	NOUN
dpc-1631	171	56	.	.	PUNCT
dpc-1631	172	1	moreover	moreover	ADV
dpc-1631	172	2	,	,	PUNCT
dpc-1631	172	3	according	accord	VERB
dpc-1631	172	4	to	to	ADP
dpc-1631	172	5	skowron	skowron	PROPN
dpc-1631	172	6	et	et	PROPN
dpc-1631	172	7	al	al	PROPN
dpc-1631	173	1	[	[	X
dpc-1631	173	2	23	23	NUM
dpc-1631	173	3	]	]	PUNCT
dpc-1631	173	4	,	,	PUNCT
dpc-1631	173	5	obese	obese	ADJ
dpc-1631	173	6	people	people	NOUN
dpc-1631	173	7	could	could	AUX
dpc-1631	173	8	be	be	AUX
dpc-1631	173	9	at	at	ADP
dpc-1631	173	10	higher	high	ADJ
dpc-1631	173	11	risk	risk	NOUN
dpc-1631	173	12	of	of	ADP
dpc-1631	173	13	hidden	hide	VERB
dpc-1631	173	14	melanomas	melanomas	NOUN
dpc-1631	173	15	because	because	SCONJ
dpc-1631	173	16	of	of	ADP
dpc-1631	173	17	their	their	PRON
dpc-1631	173	18	larger	large	ADJ
dpc-1631	173	19	skin	skin	NOUN
dpc-1631	173	20	surface	surface	NOUN
dpc-1631	173	21	and	and	CCONJ
dpc-1631	173	22	folds	fold	NOUN
dpc-1631	173	23	or	or	CCONJ
dpc-1631	173	24	may	may	AUX
dpc-1631	173	25	be	be	AUX
dpc-1631	173	26	reluctant	reluctant	ADJ
dpc-1631	173	27	to	to	PART
dpc-1631	173	28	undergo	undergo	VERB
dpc-1631	173	29	dermatological	dermatological	ADJ
dpc-1631	173	30	examinations	examination	NOUN
dpc-1631	173	31	.	.	PUNCT
dpc-1631	174	1	nevertheless	nevertheless	ADV
dpc-1631	174	2	,	,	PUNCT
dpc-1631	174	3	the	the	DET
dpc-1631	174	4	results	result	NOUN
dpc-1631	174	5	of	of	ADP
dpc-1631	174	6	the	the	DET
dpc-1631	174	7	study	study	NOUN
dpc-1631	174	8	performed	perform	VERB
dpc-1631	174	9	by	by	ADP
dpc-1631	174	10	skowron	skowron	PROPN
dpc-1631	174	11	et	et	PROPN
dpc-1631	174	12	al	al	PROPN
dpc-1631	174	13	did	do	AUX
dpc-1631	174	14	not	not	PART
dpc-1631	174	15	confirm	confirm	VERB
dpc-1631	174	16	any	any	DET
dpc-1631	174	17	association	association	NOUN
dpc-1631	174	18	between	between	ADP
dpc-1631	174	19	bmi	bmi	NOUN
dpc-1631	174	20	categorization	categorization	NOUN
dpc-1631	174	21	and	and	CCONJ
dpc-1631	174	22	either	either	CCONJ
dpc-1631	174	23	the	the	DET
dpc-1631	174	24	visibility	visibility	NOUN
dpc-1631	174	25	of	of	ADP
dpc-1631	174	26	melanoma	melanoma	NOUN
dpc-1631	174	27	or	or	CCONJ
dpc-1631	174	28	the	the	DET
dpc-1631	174	29	mode	mode	NOUN
dpc-1631	174	30	of	of	ADP
dpc-1631	174	31	melanoma	melanoma	NOUN
dpc-1631	174	32	identification	identification	NOUN
dpc-1631	174	33	[	[	X
dpc-1631	174	34	23	23	NUM
dpc-1631	174	35	]	]	PUNCT
dpc-1631	174	36	.	.	PUNCT
dpc-1631	175	1	conclusions	conclusion	NOUN
dpc-1631	175	2	there	there	PRON
dpc-1631	175	3	are	be	VERB
dpc-1631	175	4	several	several	ADJ
dpc-1631	175	5	hints	hint	NOUN
dpc-1631	175	6	suggesting	suggest	VERB
dpc-1631	175	7	the	the	DET
dpc-1631	175	8	potential	potential	ADJ
dpc-1631	175	9	influence	influence	NOUN
dpc-1631	175	10	of	of	ADP
dpc-1631	175	11	obesity	obesity	NOUN
dpc-1631	175	12	on	on	ADP
dpc-1631	175	13	malignancies	malignancy	NOUN
dpc-1631	175	14	,	,	PUNCT
dpc-1631	175	15	including	include	VERB
dpc-1631	175	16	melanoma	melanoma	NOUN
dpc-1631	175	17	.	.	PUNCT
dpc-1631	176	1	most	most	ADJ
dpc-1631	176	2	studies	study	NOUN
dpc-1631	176	3	defined	define	VERB
dpc-1631	176	4	obesity	obesity	NOUN
dpc-1631	176	5	based	base	VERB
dpc-1631	176	6	on	on	ADP
dpc-1631	176	7	bmi	bmi	NOUN
dpc-1631	176	8	,	,	PUNCT
dpc-1631	176	9	although	although	SCONJ
dpc-1631	176	10	this	this	PRON
dpc-1631	176	11	is	be	AUX
dpc-1631	176	12	considered	consider	VERB
dpc-1631	176	13	an	an	DET
dpc-1631	176	14	imperfect	imperfect	ADJ
dpc-1631	176	15	measure	measure	NOUN
dpc-1631	176	16	of	of	ADP
dpc-1631	176	17	body	body	NOUN
dpc-1631	176	18	composition	composition	NOUN
dpc-1631	176	19	.	.	PUNCT
dpc-1631	177	1	mixed	mixed	ADJ
dpc-1631	177	2	results	result	NOUN
dpc-1631	177	3	have	have	AUX
dpc-1631	177	4	been	be	AUX
dpc-1631	177	5	obtained	obtain	VERB
dpc-1631	177	6	from	from	ADP
dpc-1631	177	7	studies	study	NOUN
dpc-1631	177	8	assessing	assess	VERB
dpc-1631	177	9	clinical	clinical	ADJ
dpc-1631	177	10	outcomes	outcome	NOUN
dpc-1631	177	11	in	in	ADP
dpc-1631	177	12	patients	patient	NOUN
dpc-1631	177	13	with	with	ADP
dpc-1631	177	14	melanoma	melanoma	NOUN
dpc-1631	177	15	in	in	ADP
dpc-1631	177	16	relation	relation	NOUN
dpc-1631	177	17	to	to	PART
dpc-1631	177	18	bmi	bmi	VERB
dpc-1631	177	19	.	.	PUNCT
dpc-1631	178	1	more	more	ADV
dpc-1631	178	2	consistent	consistent	ADJ
dpc-1631	178	3	data	datum	NOUN
dpc-1631	178	4	seem	seem	VERB
dpc-1631	178	5	to	to	PART
dpc-1631	178	6	support	support	VERB
dpc-1631	178	7	the	the	DET
dpc-1631	178	8	relationship	relationship	NOUN
dpc-1631	178	9	between	between	ADP
dpc-1631	178	10	bmi	bmi	NOUN
dpc-1631	178	11	and	and	CCONJ
dpc-1631	178	12	breslow	breslow	ADJ
dpc-1631	178	13	thickness	thickness	NOUN
dpc-1631	178	14	.	.	PUNCT
dpc-1631	179	1	multiple	multiple	ADJ
dpc-1631	179	2	biological	biological	ADJ
dpc-1631	179	3	and	and	CCONJ
dpc-1631	179	4	behavioural	behavioural	ADJ
dpc-1631	179	5	mechanisms	mechanism	NOUN
dpc-1631	179	6	might	might	AUX
dpc-1631	179	7	contribute	contribute	VERB
dpc-1631	179	8	to	to	ADP
dpc-1631	179	9	the	the	DET
dpc-1631	179	10	effects	effect	NOUN
dpc-1631	179	11	of	of	ADP
dpc-1631	179	12	obesity	obesity	NOUN
dpc-1631	179	13	on	on	ADP
dpc-1631	179	14	melanoma	melanoma	NOUN
dpc-1631	179	15	progression	progression	NOUN
dpc-1631	179	16	and	and	CCONJ
dpc-1631	179	17	outcome	outcome	NOUN
dpc-1631	179	18	and	and	CCONJ
dpc-1631	179	19	some	some	PRON
dpc-1631	179	20	of	of	ADP
dpc-1631	179	21	these	these	PRON
dpc-1631	179	22	have	have	AUX
dpc-1631	179	23	been	be	AUX
dpc-1631	179	24	outlined	outline	VERB
dpc-1631	179	25	,	,	PUNCT
dpc-1631	179	26	although	although	SCONJ
dpc-1631	179	27	the	the	DET
dpc-1631	179	28	obesity	obesity	NOUN
dpc-1631	179	29	-	-	PUNCT
dpc-1631	179	30	melanoma	melanoma	NOUN
dpc-1631	179	31	relationship	relationship	NOUN
dpc-1631	179	32	deserves	deserve	VERB
dpc-1631	179	33	further	further	ADJ
dpc-1631	179	34	investigations	investigation	NOUN
dpc-1631	179	35	.	.	PUNCT
dpc-1631	180	1	references	reference	NOUN
dpc-1631	180	2	1	1	NUM
dpc-1631	180	3	.	.	PUNCT
dpc-1631	181	1	avgerinos	avgerinos	PROPN
dpc-1631	181	2	ki	ki	PROPN
dpc-1631	181	3	,	,	PUNCT
dpc-1631	181	4	spyrou	spyrou	NOUN
dpc-1631	181	5	n	n	CCONJ
dpc-1631	181	6	,	,	PUNCT
dpc-1631	181	7	mantzoros	mantzoros	PROPN
dpc-1631	181	8	cs	cs	PROPN
dpc-1631	181	9	,	,	PUNCT
dpc-1631	181	10	dalamaga	dalamaga	NOUN
dpc-1631	181	11	m.	m.	NOUN
dpc-1631	181	12	obesity	obesity	NOUN
dpc-1631	181	13	and	and	CCONJ
dpc-1631	181	14	cancer	cancer	NOUN
dpc-1631	181	15	risk	risk	NOUN
dpc-1631	181	16	:	:	PUNCT
dpc-1631	181	17	emerging	emerge	VERB
dpc-1631	181	18	biological	biological	ADJ
dpc-1631	181	19	mechanisms	mechanism	NOUN
dpc-1631	181	20	and	and	CCONJ
dpc-1631	181	21	perreview	perreview	VERB
dpc-1631	182	1	|	|	ADV
dpc-1631	182	2	dermatol	dermatol	ADJ
dpc-1631	182	3	pract	pract	NOUN
dpc-1631	182	4	concept	concept	NOUN
dpc-1631	182	5	.	.	PUNCT
dpc-1631	183	1	2021;11(4	2021;11(4	NUM
dpc-1631	183	2	):	):	PUNCT
dpc-1631	183	3	e2021106	e2021106	NOUN
dpc-1631	183	4	7	7	NUM
dpc-1631	183	5	spectives	spective	NOUN
dpc-1631	183	6	.	.	PUNCT
dpc-1631	184	1	metabolism	metabolism	NOUN
dpc-1631	184	2	.	.	PUNCT
dpc-1631	185	1	2019;92:121	2019;92:121	NUM
dpc-1631	185	2	-	-	SYM
dpc-1631	185	3	135	135	NUM
dpc-1631	185	4	.	.	PUNCT
dpc-1631	186	1	doi	doi	NOUN
dpc-1631	186	2	:	:	PUNCT
dpc-1631	186	3	10.1016	10.1016	NUM
dpc-1631	186	4	/	/	SYM
dpc-1631	186	5	j.metabol.2018.11.001	j.metabol.2018.11.001	PROPN
dpc-1631	186	6	.	.	PUNCT
dpc-1631	187	1	pmid	pmid	NOUN
dpc-1631	187	2	:	:	PUNCT
dpc-1631	187	3	30445141	30445141	NUM
dpc-1631	187	4	.	.	PUNCT
dpc-1631	188	1	2	2	X
dpc-1631	188	2	.	.	X
dpc-1631	188	3	bandera	bandera	PROPN
dpc-1631	188	4	ev	ev	PROPN
dpc-1631	188	5	,	,	PUNCT
dpc-1631	188	6	fay	fay	PROPN
dpc-1631	188	7	sh	sh	PROPN
dpc-1631	188	8	,	,	PUNCT
dpc-1631	188	9	giovannucci	giovannucci	PROPN
dpc-1631	188	10	e	e	PROPN
dpc-1631	188	11	,	,	PUNCT
dpc-1631	188	12	et	et	PROPN
dpc-1631	188	13	al	al	PROPN
dpc-1631	188	14	;	;	PUNCT
dpc-1631	188	15	world	world	NOUN
dpc-1631	188	16	cancer	cancer	PROPN
dpc-1631	188	17	research	research	PROPN
dpc-1631	188	18	fund	fund	PROPN
dpc-1631	188	19	international	international	ADJ
dpc-1631	188	20	continuous	continuous	ADJ
dpc-1631	188	21	update	update	NOUN
dpc-1631	188	22	project	project	NOUN
dpc-1631	188	23	panel	panel	NOUN
dpc-1631	188	24	.	.	PUNCT
dpc-1631	189	1	the	the	DET
dpc-1631	189	2	use	use	NOUN
dpc-1631	189	3	and	and	CCONJ
dpc-1631	189	4	interpretation	interpretation	NOUN
dpc-1631	189	5	of	of	ADP
dpc-1631	189	6	anthropometric	anthropometric	ADJ
dpc-1631	189	7	measures	measure	NOUN
dpc-1631	189	8	in	in	ADP
dpc-1631	189	9	cancer	cancer	NOUN
dpc-1631	189	10	epidemiology	epidemiology	NOUN
dpc-1631	189	11	:	:	PUNCT
dpc-1631	189	12	a	a	DET
dpc-1631	189	13	perspective	perspective	NOUN
dpc-1631	189	14	from	from	ADP
dpc-1631	189	15	the	the	DET
dpc-1631	189	16	world	world	NOUN
dpc-1631	189	17	cancer	cancer	PROPN
dpc-1631	189	18	research	research	PROPN
dpc-1631	189	19	fund	fund	PROPN
dpc-1631	189	20	international	international	ADJ
dpc-1631	189	21	continuous	continuous	ADJ
dpc-1631	189	22	update	update	NOUN
dpc-1631	189	23	project	project	NOUN
dpc-1631	189	24	.	.	PUNCT
dpc-1631	190	1	int	int	NOUN
dpc-1631	190	2	j	j	PROPN
dpc-1631	190	3	cancer	cancer	NOUN
dpc-1631	190	4	.	.	PUNCT
dpc-1631	191	1	2016;139(11):23912397	2016;139(11):23912397	NUM
dpc-1631	191	2	.	.	PUNCT
dpc-1631	192	1	doi	doi	NOUN
dpc-1631	192	2	:	:	PUNCT
dpc-1631	192	3	10.1002	10.1002	NUM
dpc-1631	192	4	/	/	SYM
dpc-1631	192	5	ijc.30248	ijc.30248	NUM
dpc-1631	192	6	.	.	PUNCT
dpc-1631	193	1	pmid	pmid	NOUN
dpc-1631	193	2	:	:	PUNCT
dpc-1631	193	3	27352197	27352197	NUM
dpc-1631	193	4	.	.	PUNCT
dpc-1631	194	1	3	3	X
dpc-1631	194	2	.	.	X
dpc-1631	194	3	hopkins	hopkins	PROPN
dpc-1631	194	4	bd	bd	PROPN
dpc-1631	194	5	,	,	PUNCT
dpc-1631	194	6	goncalves	goncalves	PROPN
dpc-1631	194	7	md	md	PROPN
dpc-1631	194	8	,	,	PUNCT
dpc-1631	194	9	cantley	cantley	PROPN
dpc-1631	194	10	lc	lc	PROPN
dpc-1631	194	11	.	.	PROPN
dpc-1631	194	12	obesity	obesity	NOUN
dpc-1631	194	13	and	and	CCONJ
dpc-1631	194	14	cancer	cancer	NOUN
dpc-1631	194	15	mechanisms	mechanism	NOUN
dpc-1631	194	16	:	:	PUNCT
dpc-1631	194	17	cancer	cancer	NOUN
dpc-1631	194	18	metabolism	metabolism	NOUN
dpc-1631	194	19	.	.	PUNCT
dpc-1631	195	1	j	j	PROPN
dpc-1631	195	2	clin	clin	PROPN
dpc-1631	195	3	oncol	oncol	PROPN
dpc-1631	195	4	.	.	PUNCT
dpc-1631	196	1	2016;34(35):42774283	2016;34(35):42774283	NUM
dpc-1631	196	2	.	.	X
dpc-1631	196	3	doi	doi	NOUN
dpc-1631	196	4	:	:	PUNCT
dpc-1631	196	5	10.1200	10.1200	NUM
dpc-1631	196	6	/	/	SYM
dpc-1631	196	7	jco.2016.67.9712	jco.2016.67.9712	NOUN
dpc-1631	196	8	.	.	PUNCT
dpc-1631	197	1	pmid	pmid	NOUN
dpc-1631	197	2	:	:	PUNCT
dpc-1631	197	3	27903152	27903152	NUM
dpc-1631	197	4	.	.	PUNCT
dpc-1631	198	1	4	4	X
dpc-1631	198	2	.	.	X
dpc-1631	198	3	smith	smith	PROPN
dpc-1631	198	4	lk	lk	PROPN
dpc-1631	198	5	,	,	PUNCT
dpc-1631	198	6	arabi	arabi	PROPN
dpc-1631	198	7	s	s	PART
dpc-1631	198	8	,	,	PUNCT
dpc-1631	198	9	lelliott	lelliott	VERB
dpc-1631	198	10	ej	ej	PROPN
dpc-1631	198	11	,	,	PUNCT
dpc-1631	198	12	mcarthur	mcarthur	PROPN
dpc-1631	198	13	ga	ga	PROPN
dpc-1631	198	14	,	,	PUNCT
dpc-1631	198	15	sheppard	sheppard	PROPN
dpc-1631	198	16	ke	ke	PROPN
dpc-1631	198	17	.	.	PUNCT
dpc-1631	199	1	obesity	obesity	NOUN
dpc-1631	199	2	and	and	CCONJ
dpc-1631	199	3	the	the	DET
dpc-1631	199	4	impact	impact	NOUN
dpc-1631	199	5	on	on	ADP
dpc-1631	199	6	cutaneous	cutaneous	ADJ
dpc-1631	199	7	melanoma	melanoma	NOUN
dpc-1631	199	8	:	:	PUNCT
dpc-1631	199	9	friend	friend	NOUN
dpc-1631	199	10	or	or	CCONJ
dpc-1631	199	11	foe	foe	NOUN
dpc-1631	199	12	?	?	PUNCT
dpc-1631	200	1	cancers	cancer	NOUN
dpc-1631	200	2	(	(	PUNCT
dpc-1631	200	3	basel	basel	PROPN
dpc-1631	200	4	)	)	PUNCT
dpc-1631	200	5	.	.	PUNCT
dpc-1631	201	1	2020;12(6):1583	2020;12(6):1583	NUM
dpc-1631	201	2	.	.	PUNCT
dpc-1631	202	1	doi	doi	NOUN
dpc-1631	202	2	:	:	PUNCT
dpc-1631	202	3	10.3390	10.3390	NUM
dpc-1631	202	4	/	/	SYM
dpc-1631	202	5	cancers12061583	cancers12061583	PROPN
dpc-1631	202	6	.	.	PUNCT
dpc-1631	203	1	pmid	pmid	NOUN
dpc-1631	203	2	:	:	PUNCT
dpc-1631	203	3	32549336	32549336	NUM
dpc-1631	203	4	.	.	PUNCT
dpc-1631	204	1	5	5	X
dpc-1631	204	2	.	.	X
dpc-1631	204	3	clement	clement	PROPN
dpc-1631	204	4	e	e	PROPN
dpc-1631	204	5	,	,	PUNCT
dpc-1631	204	6	lazar	lazar	PROPN
dpc-1631	204	7	i	i	PROPN
dpc-1631	204	8	,	,	PUNCT
dpc-1631	204	9	muller	muller	PROPN
dpc-1631	204	10	c	c	PROPN
dpc-1631	204	11	,	,	PUNCT
dpc-1631	204	12	nieto	nieto	PROPN
dpc-1631	204	13	l.	l.	PROPN
dpc-1631	204	14	obesity	obesity	PROPN
dpc-1631	204	15	and	and	CCONJ
dpc-1631	204	16	melanoma	melanoma	NOUN
dpc-1631	204	17	:	:	PUNCT
dpc-1631	204	18	could	could	AUX
dpc-1631	204	19	fat	fat	VERB
dpc-1631	204	20	be	be	AUX
dpc-1631	204	21	fueling	fuel	VERB
dpc-1631	204	22	malignancy	malignancy	NOUN
dpc-1631	204	23	?	?	PUNCT
dpc-1631	205	1	pigment	pigment	ADJ
dpc-1631	205	2	cell	cell	NOUN
dpc-1631	205	3	melanoma	melanoma	NOUN
dpc-1631	205	4	res	re	NOUN
dpc-1631	205	5	.	.	PUNCT
dpc-1631	206	1	2017;30(3):294	2017;30(3):294	NUM
dpc-1631	206	2	-	-	SYM
dpc-1631	206	3	306	306	NUM
dpc-1631	206	4	.	.	PUNCT
dpc-1631	207	1	doi	doi	NOUN
dpc-1631	207	2	:	:	PUNCT
dpc-1631	207	3	10.1111	10.1111	NUM
dpc-1631	207	4	/	/	SYM
dpc-1631	207	5	pcmr.12584	pcmr.12584	PROPN
dpc-1631	207	6	.	.	PUNCT
dpc-1631	208	1	pmid	pmid	NOUN
dpc-1631	208	2	:	:	PUNCT
dpc-1631	208	3	28222242	28222242	NUM
dpc-1631	208	4	.	.	PUNCT
dpc-1631	209	1	6	6	NUM
dpc-1631	209	2	.	.	PUNCT
dpc-1631	209	3	mcquade	mcquade	PROPN
dpc-1631	209	4	j	j	PROPN
dpc-1631	209	5	,	,	PUNCT
dpc-1631	209	6	daniel	daniel	PROPN
dpc-1631	209	7	c	c	PROPN
dpc-1631	209	8	,	,	PUNCT
dpc-1631	209	9	hess	hess	PROPN
dpc-1631	209	10	kr	kr	PROPN
dpc-1631	209	11	,	,	PUNCT
dpc-1631	209	12	et	et	PROPN
dpc-1631	209	13	al	al	PROPN
dpc-1631	209	14	.	.	PROPN
dpc-1631	209	15	association	association	PROPN
dpc-1631	209	16	of	of	ADP
dpc-1631	209	17	body	body	NOUN
dpc-1631	209	18	-	-	PUNCT
dpc-1631	209	19	mass	mass	NOUN
dpc-1631	209	20	index	index	NOUN
dpc-1631	209	21	and	and	CCONJ
dpc-1631	209	22	outcomes	outcome	NOUN
dpc-1631	209	23	in	in	ADP
dpc-1631	209	24	patients	patient	NOUN
dpc-1631	209	25	with	with	ADP
dpc-1631	209	26	metastatic	metastatic	ADJ
dpc-1631	209	27	melanoma	melanoma	NOUN
dpc-1631	209	28	treated	treat	VERB
dpc-1631	209	29	with	with	ADP
dpc-1631	209	30	targeted	target	VERB
dpc-1631	209	31	therapy	therapy	NOUN
dpc-1631	209	32	,	,	PUNCT
dpc-1631	209	33	immunotherapy	immunotherapy	NOUN
dpc-1631	209	34	,	,	PUNCT
dpc-1631	209	35	or	or	CCONJ
dpc-1631	209	36	chemotherapy	chemotherapy	NOUN
dpc-1631	209	37	:	:	PUNCT
dpc-1631	209	38	a	a	DET
dpc-1631	209	39	retrospective	retrospective	ADJ
dpc-1631	209	40	,	,	PUNCT
dpc-1631	209	41	multicohort	multicohort	VERB
dpc-1631	209	42	analysis	analysis	NOUN
dpc-1631	209	43	.	.	PUNCT
dpc-1631	210	1	lancet	lancet	PROPN
dpc-1631	210	2	oncol	oncol	PROPN
dpc-1631	210	3	.	.	PUNCT
dpc-1631	211	1	2018;19(3):310	2018;19(3):310	NUM
dpc-1631	211	2	–	–	PUNCT
dpc-1631	211	3	322	322	NUM
dpc-1631	211	4	.	.	PUNCT
dpc-1631	211	5	doi	doi	NOUN
dpc-1631	211	6	:	:	PUNCT
dpc-1631	211	7	10.1016	10.1016	NUM
dpc-1631	211	8	/	/	SYM
dpc-1631	211	9	s1470	s1470	PROPN
dpc-1631	211	10	-	-	PUNCT
dpc-1631	211	11	2045(18)30078	2045(18)30078	NUM
dpc-1631	211	12	-	-	PUNCT
dpc-1631	211	13	0	0	NUM
dpc-1631	211	14	.	.	NOUN
dpc-1631	212	1	7	7	NUM
dpc-1631	212	2	.	.	X
dpc-1631	213	1	wang	wang	PROPN
dpc-1631	213	2	z	z	PROPN
dpc-1631	213	3	,	,	PUNCT
dpc-1631	213	4	aguilar	aguilar	PROPN
dpc-1631	213	5	e	e	PROPN
dpc-1631	213	6	,	,	PUNCT
dpc-1631	213	7	luna	luna	PROPN
dpc-1631	213	8	j	j	PROPN
dpc-1631	213	9	,	,	PUNCT
dpc-1631	213	10	et	et	PROPN
dpc-1631	213	11	al	al	PROPN
dpc-1631	213	12	.	.	PUNCT
dpc-1631	214	1	paradoxical	paradoxical	ADJ
dpc-1631	214	2	effects	effect	NOUN
dpc-1631	214	3	of	of	ADP
dpc-1631	214	4	obesity	obesity	NOUN
dpc-1631	214	5	on	on	ADP
dpc-1631	214	6	t	t	PROPN
dpc-1631	214	7	cell	cell	NOUN
dpc-1631	214	8	function	function	NOUN
dpc-1631	214	9	during	during	ADP
dpc-1631	214	10	tumor	tumor	NOUN
dpc-1631	214	11	progression	progression	NOUN
dpc-1631	214	12	and	and	CCONJ
dpc-1631	214	13	pd-1	pd-1	ADV
dpc-1631	214	14	checkpoint	checkpoint	NOUN
dpc-1631	214	15	blockade	blockade	NOUN
dpc-1631	214	16	.	.	PUNCT
dpc-1631	215	1	nat	nat	PROPN
dpc-1631	215	2	med	med	PROPN
dpc-1631	215	3	.	.	PUNCT
dpc-1631	216	1	2019;25(1):141	2019;25(1):141	NUM
dpc-1631	216	2	-	-	PUNCT
dpc-1631	216	3	151	151	NUM
dpc-1631	216	4	.	.	PUNCT
dpc-1631	217	1	doi	doi	NOUN
dpc-1631	217	2	:	:	PUNCT
dpc-1631	217	3	10.1038	10.1038	NUM
dpc-1631	217	4	/	/	SYM
dpc-1631	217	5	s41591018	s41591018	NOUN
dpc-1631	217	6	-	-	PUNCT
dpc-1631	217	7	0221	0221	NUM
dpc-1631	217	8	-	-	PUNCT
dpc-1631	217	9	5	5	NUM
dpc-1631	217	10	.	.	NOUN
dpc-1631	217	11	8	8	NUM
dpc-1631	217	12	.	.	PUNCT
dpc-1631	218	1	donnelly	donnelly	PROPN
dpc-1631	218	2	d	d	PROPN
dpc-1631	218	3	,	,	PUNCT
dpc-1631	218	4	bajaj	bajaj	PROPN
dpc-1631	218	5	s	s	PROPN
dpc-1631	218	6	,	,	PUNCT
dpc-1631	218	7	yu	yu	PROPN
dpc-1631	218	8	j	j	PROPN
dpc-1631	218	9	,	,	PUNCT
dpc-1631	218	10	et	et	PROPN
dpc-1631	218	11	al	al	PROPN
dpc-1631	218	12	.	.	PUNCT
dpc-1631	219	1	the	the	DET
dpc-1631	219	2	complex	complex	ADJ
dpc-1631	219	3	relationship	relationship	NOUN
dpc-1631	219	4	between	between	ADP
dpc-1631	219	5	body	body	NOUN
dpc-1631	219	6	mass	mass	NOUN
dpc-1631	219	7	index	index	NOUN
dpc-1631	219	8	and	and	CCONJ
dpc-1631	219	9	response	response	NOUN
dpc-1631	219	10	to	to	ADP
dpc-1631	219	11	immune	immune	ADJ
dpc-1631	219	12	checkpoint	checkpoint	NOUN
dpc-1631	219	13	inhibition	inhibition	NOUN
dpc-1631	219	14	in	in	ADP
dpc-1631	219	15	metastatic	metastatic	ADJ
dpc-1631	219	16	melanoma	melanoma	NOUN
dpc-1631	219	17	patients	patient	NOUN
dpc-1631	219	18	.	.	PUNCT
dpc-1631	220	1	j	j	PROPN
dpc-1631	220	2	immunother	immunother	ADJ
dpc-1631	220	3	cancer	cancer	NOUN
dpc-1631	220	4	.	.	PUNCT
dpc-1631	221	1	2019;7(1):222	2019;7(1):222	X
dpc-1631	221	2	.	.	PUNCT
dpc-1631	222	1	doi	doi	NOUN
dpc-1631	222	2	:	:	PUNCT
dpc-1631	222	3	10.1186	10.1186	NUM
dpc-1631	222	4	/	/	SYM
dpc-1631	222	5	s40425	s40425	NOUN
dpc-1631	222	6	-	-	PUNCT
dpc-1631	222	7	019	019	NUM
dpc-1631	222	8	-	-	PUNCT
dpc-1631	222	9	0699	0699	NUM
dpc-1631	222	10	-	-	SYM
dpc-1631	222	11	5	5	NUM
dpc-1631	222	12	.	.	PUNCT
dpc-1631	223	1	pmid	pmid	NOUN
dpc-1631	223	2	:	:	PUNCT
dpc-1631	223	3	31426863	31426863	NUM
dpc-1631	223	4	.	.	PUNCT
dpc-1631	224	1	9	9	X
dpc-1631	224	2	.	.	X
dpc-1631	224	3	rutkowski	rutkowski	PROPN
dpc-1631	224	4	p	p	X
dpc-1631	224	5	,	,	PUNCT
dpc-1631	224	6	indini	indini	VERB
dpc-1631	224	7	a	a	PRON
dpc-1631	224	8	,	,	PUNCT
dpc-1631	224	9	de	de	X
dpc-1631	224	10	luca	luca	PROPN
dpc-1631	224	11	m	m	PROPN
dpc-1631	224	12	,	,	PUNCT
dpc-1631	224	13	et	et	PROPN
dpc-1631	224	14	al	al	PROPN
dpc-1631	224	15	.	.	PROPN
dpc-1631	224	16	body	body	PROPN
dpc-1631	224	17	mass	mass	PROPN
dpc-1631	224	18	index	index	NOUN
dpc-1631	224	19	(	(	PUNCT
dpc-1631	224	20	bmi	bmi	PROPN
dpc-1631	224	21	)	)	PUNCT
dpc-1631	224	22	and	and	CCONJ
dpc-1631	224	23	outcome	outcome	NOUN
dpc-1631	224	24	of	of	ADP
dpc-1631	224	25	metastatic	metastatic	ADJ
dpc-1631	224	26	melanoma	melanoma	NOUN
dpc-1631	224	27	patients	patient	NOUN
dpc-1631	224	28	receiving	receive	VERB
dpc-1631	224	29	targeted	target	VERB
dpc-1631	224	30	therapy	therapy	NOUN
dpc-1631	224	31	and	and	CCONJ
dpc-1631	224	32	immunotherapy	immunotherapy	NOUN
dpc-1631	224	33	:	:	PUNCT
dpc-1631	224	34	a	a	DET
dpc-1631	224	35	multicenter	multicenter	ADJ
dpc-1631	224	36	international	international	ADJ
dpc-1631	224	37	retrospective	retrospective	ADJ
dpc-1631	224	38	study	study	NOUN
dpc-1631	224	39	.	.	PUNCT
dpc-1631	225	1	j	j	PROPN
dpc-1631	225	2	immunother	immunother	ADJ
dpc-1631	225	3	cancer	cancer	NOUN
dpc-1631	225	4	.	.	PUNCT
dpc-1631	226	1	2020;8(2):e001117	2020;8(2):e001117	NUM
dpc-1631	226	2	.	.	PUNCT
dpc-1631	226	3	doi	doi	NOUN
dpc-1631	226	4	:	:	PUNCT
dpc-1631	226	5	10.1136	10.1136	NUM
dpc-1631	226	6	/	/	SYM
dpc-1631	226	7	jitc-2020	jitc-2020	NOUN
dpc-1631	226	8	-	-	PUNCT
dpc-1631	226	9	001117	001117	NUM
dpc-1631	226	10	.	.	PUNCT
dpc-1631	227	1	pmid	pmid	NOUN
dpc-1631	227	2	:	:	PUNCT
dpc-1631	227	3	33203662	33203662	NUM
dpc-1631	227	4	.	.	PUNCT
dpc-1631	228	1	10	10	NUM
dpc-1631	228	2	.	.	PUNCT
dpc-1631	229	1	reeves	reeves	PROPN
dpc-1631	229	2	gk	gk	PROPN
dpc-1631	229	3	,	,	PUNCT
dpc-1631	229	4	pirie	pirie	PROPN
dpc-1631	229	5	k	k	PROPN
dpc-1631	229	6	,	,	PUNCT
dpc-1631	229	7	beral	beral	ADJ
dpc-1631	229	8	v	v	NOUN
dpc-1631	229	9	,	,	PUNCT
dpc-1631	229	10	green	green	PROPN
dpc-1631	229	11	j	j	PROPN
dpc-1631	229	12	,	,	PUNCT
dpc-1631	229	13	spencer	spencer	PROPN
dpc-1631	229	14	e	e	PROPN
dpc-1631	229	15	,	,	PUNCT
dpc-1631	229	16	bull	bull	PROPN
dpc-1631	229	17	d	d	NOUN
dpc-1631	229	18	;	;	PUNCT
dpc-1631	229	19	million	million	NUM
dpc-1631	229	20	women	woman	NOUN
dpc-1631	229	21	study	study	VERB
dpc-1631	229	22	collaboration	collaboration	NOUN
dpc-1631	229	23	.	.	PUNCT
dpc-1631	230	1	cancer	cancer	NOUN
dpc-1631	230	2	incidence	incidence	NOUN
dpc-1631	230	3	and	and	CCONJ
dpc-1631	230	4	mortality	mortality	NOUN
dpc-1631	230	5	in	in	ADP
dpc-1631	230	6	relation	relation	NOUN
dpc-1631	230	7	to	to	ADP
dpc-1631	230	8	body	body	NOUN
dpc-1631	230	9	mass	mass	NOUN
dpc-1631	230	10	index	index	NOUN
dpc-1631	230	11	in	in	ADP
dpc-1631	230	12	the	the	DET
dpc-1631	230	13	million	million	NUM
dpc-1631	230	14	women	woman	NOUN
dpc-1631	230	15	study	study	NOUN
dpc-1631	230	16	:	:	PUNCT
dpc-1631	230	17	cohort	cohort	NOUN
dpc-1631	230	18	study	study	NOUN
dpc-1631	230	19	.	.	PUNCT
dpc-1631	231	1	bmj	bmj	PROPN
dpc-1631	231	2	.	.	PUNCT
dpc-1631	232	1	2007;335(7630):1134	2007;335(7630):1134	NUM
dpc-1631	232	2	.	.	PUNCT
dpc-1631	232	3	doi	doi	NOUN
dpc-1631	232	4	:	:	PUNCT
dpc-1631	232	5	10.1136/	10.1136/	NUM
dpc-1631	232	6	bmj.39367.495995.ae	bmj.39367.495995.ae	PROPN
dpc-1631	232	7	.	.	PUNCT
dpc-1631	233	1	pmid	pmid	NOUN
dpc-1631	233	2	:	:	PUNCT
dpc-1631	233	3	17986716	17986716	NUM
dpc-1631	233	4	.	.	PUNCT
dpc-1631	234	1	11	11	NUM
dpc-1631	234	2	.	.	PUNCT
dpc-1631	234	3	calle	calle	PROPN
dpc-1631	234	4	ee	ee	PROPN
dpc-1631	234	5	,	,	PUNCT
dpc-1631	234	6	rodriguez	rodriguez	PROPN
dpc-1631	234	7	c	c	PROPN
dpc-1631	234	8	,	,	PUNCT
dpc-1631	234	9	walker	walker	PROPN
dpc-1631	234	10	-	-	PUNCT
dpc-1631	234	11	thurmond	thurmond	PROPN
dpc-1631	234	12	k	k	PROPN
dpc-1631	234	13	,	,	PUNCT
dpc-1631	234	14	thun	thun	PROPN
dpc-1631	234	15	mj	mj	PROPN
dpc-1631	234	16	.	.	PROPN
dpc-1631	234	17	overweight	overweight	PROPN
dpc-1631	234	18	,	,	PUNCT
dpc-1631	234	19	obesity	obesity	NOUN
dpc-1631	234	20	,	,	PUNCT
dpc-1631	234	21	and	and	CCONJ
dpc-1631	234	22	mortality	mortality	NOUN
dpc-1631	234	23	from	from	ADP
dpc-1631	234	24	cancer	cancer	NOUN
dpc-1631	234	25	in	in	ADP
dpc-1631	234	26	a	a	DET
dpc-1631	234	27	prospectively	prospectively	ADV
dpc-1631	234	28	studied	study	VERB
dpc-1631	234	29	cohort	cohort	NOUN
dpc-1631	234	30	of	of	ADP
dpc-1631	234	31	u.s	u.s	PROPN
dpc-1631	234	32	.	.	PROPN
dpc-1631	234	33	adults	adult	NOUN
dpc-1631	234	34	.	.	PUNCT
dpc-1631	235	1	n	n	X
dpc-1631	235	2	engl	engl	PROPN
dpc-1631	235	3	j	j	PROPN
dpc-1631	235	4	med	med	PROPN
dpc-1631	235	5	.	.	PUNCT
dpc-1631	236	1	2003;348(17):16251638	2003;348(17):16251638	NUM
dpc-1631	236	2	.	.	PUNCT
dpc-1631	236	3	doi	doi	NOUN
dpc-1631	236	4	:	:	PUNCT
dpc-1631	236	5	10.1056	10.1056	NUM
dpc-1631	236	6	/	/	SYM
dpc-1631	236	7	nejmoa021423	nejmoa021423	PROPN
dpc-1631	236	8	.	.	PUNCT
dpc-1631	237	1	pmid	pmid	NOUN
dpc-1631	237	2	:	:	PUNCT
dpc-1631	237	3	12711737	12711737	NUM
dpc-1631	237	4	.	.	PUNCT
dpc-1631	238	1	12	12	NUM
dpc-1631	238	2	.	.	PUNCT
dpc-1631	239	1	moliterni	moliterni	PROPN
dpc-1631	239	2	e	e	PROPN
dpc-1631	239	3	,	,	PUNCT
dpc-1631	239	4	paolino	paolino	PROPN
dpc-1631	239	5	g	g	NOUN
dpc-1631	239	6	,	,	PUNCT
dpc-1631	239	7	veronese	veronese	ADJ
dpc-1631	239	8	n	n	CCONJ
dpc-1631	239	9	,	,	PUNCT
dpc-1631	239	10	et	et	PROPN
dpc-1631	239	11	al	al	PROPN
dpc-1631	239	12	.	.	PUNCT
dpc-1631	239	13	prognostic	prognostic	ADJ
dpc-1631	239	14	correlation	correlation	NOUN
dpc-1631	239	15	between	between	ADP
dpc-1631	239	16	vitamin	vitamin	NOUN
dpc-1631	239	17	d	d	NOUN
dpc-1631	239	18	serological	serological	ADJ
dpc-1631	239	19	levels	level	NOUN
dpc-1631	239	20	,	,	PUNCT
dpc-1631	239	21	body	body	NOUN
dpc-1631	239	22	mass	mass	NOUN
dpc-1631	239	23	index	index	NOUN
dpc-1631	239	24	and	and	CCONJ
dpc-1631	239	25	clinical	clinical	ADJ
dpc-1631	239	26	-	-	PUNCT
dpc-1631	239	27	pathological	pathological	ADJ
dpc-1631	239	28	features	feature	NOUN
dpc-1631	239	29	in	in	ADP
dpc-1631	239	30	melanoma	melanoma	NOUN
dpc-1631	239	31	patients	patient	NOUN
dpc-1631	239	32	.	.	PUNCT
dpc-1631	240	1	g	g	ADP
dpc-1631	240	2	ital	ital	ADJ
dpc-1631	240	3	dermatol	dermatol	NOUN
dpc-1631	240	4	venereol	venereol	NOUN
dpc-1631	240	5	.	.	PUNCT
dpc-1631	241	1	2018;153(5):732	2018;153(5):732	PROPN
dpc-1631	241	2	-	-	PUNCT
dpc-1631	241	3	733	733	NUM
dpc-1631	241	4	.	.	PUNCT
dpc-1631	242	1	doi	doi	NOUN
dpc-1631	242	2	:	:	PUNCT
dpc-1631	242	3	10.23736	10.23736	NUM
dpc-1631	242	4	/	/	SYM
dpc-1631	242	5	s03920488.17.05652	s03920488.17.05652	VERB
dpc-1631	242	6	-	-	SYM
dpc-1631	242	7	8	8	NUM
dpc-1631	242	8	.	.	PUNCT
dpc-1631	243	1	pmid	pmid	NOUN
dpc-1631	243	2	:	:	PUNCT
dpc-1631	243	3	30246955	30246955	NUM
dpc-1631	243	4	.	.	PUNCT
dpc-1631	244	1	13	13	NUM
dpc-1631	244	2	.	.	PUNCT
dpc-1631	244	3	hardie	hardie	PROPN
dpc-1631	244	4	cm	cm	PROPN
dpc-1631	244	5	,	,	PUNCT
dpc-1631	244	6	elliott	elliott	PROPN
dpc-1631	244	7	f	f	PROPN
dpc-1631	244	8	,	,	PUNCT
dpc-1631	244	9	chan	chan	PROPN
dpc-1631	244	10	m	m	PROPN
dpc-1631	244	11	,	,	PUNCT
dpc-1631	244	12	rogers	rogers	PROPN
dpc-1631	244	13	z	z	PROPN
dpc-1631	244	14	,	,	PUNCT
dpc-1631	244	15	bishop	bishop	PROPN
dpc-1631	244	16	dt	dt	PROPN
dpc-1631	244	17	,	,	PUNCT
dpc-1631	244	18	newton	newton	PROPN
dpc-1631	244	19	-	-	PUNCT
dpc-1631	244	20	bishop	bishop	PROPN
dpc-1631	244	21	ja	ja	PROPN
dpc-1631	244	22	.	.	PUNCT
dpc-1631	245	1	environmental	environmental	ADJ
dpc-1631	245	2	exposures	exposure	NOUN
dpc-1631	245	3	such	such	ADJ
dpc-1631	245	4	as	as	ADP
dpc-1631	245	5	smoking	smoking	NOUN
dpc-1631	245	6	and	and	CCONJ
dpc-1631	245	7	low	low	ADJ
dpc-1631	245	8	vitamin	vitamin	NOUN
dpc-1631	245	9	d	d	NOUN
dpc-1631	245	10	are	be	AUX
dpc-1631	245	11	predictive	predictive	ADJ
dpc-1631	245	12	of	of	ADP
dpc-1631	245	13	poor	poor	ADJ
dpc-1631	245	14	outcome	outcome	NOUN
dpc-1631	245	15	in	in	ADP
dpc-1631	245	16	cutaneous	cutaneous	ADJ
dpc-1631	245	17	melanoma	melanoma	NOUN
dpc-1631	245	18	rather	rather	ADV
dpc-1631	245	19	than	than	ADP
dpc-1631	245	20	other	other	ADJ
dpc-1631	245	21	deprivation	deprivation	NOUN
dpc-1631	245	22	measures	measure	NOUN
dpc-1631	245	23	.	.	PUNCT
dpc-1631	246	1	j	j	PROPN
dpc-1631	246	2	invest	invest	VERB
dpc-1631	246	3	dermatol	dermatol	NOUN
dpc-1631	246	4	.	.	PUNCT
dpc-1631	247	1	2020;140:327337.e2	2020;140:327337.e2	NUM
dpc-1631	247	2	.	.	PUNCT
dpc-1631	248	1	doi	doi	NOUN
dpc-1631	248	2	:	:	PUNCT
dpc-1631	248	3	10.1016	10.1016	NUM
dpc-1631	248	4	/	/	SYM
dpc-1631	248	5	j.jid.2019.05.033	j.jid.2019.05.033	PROPN
dpc-1631	248	6	.	.	PUNCT
dpc-1631	249	1	pmid	pmid	NOUN
dpc-1631	249	2	:	:	PUNCT
dpc-1631	249	3	31425707	31425707	NUM
dpc-1631	249	4	.	.	PUNCT
dpc-1631	250	1	14	14	NUM
dpc-1631	250	2	.	.	PUNCT
dpc-1631	251	1	beswick	beswick	PROPN
dpc-1631	251	2	s	s	PROPN
dpc-1631	251	3	,	,	PUNCT
dpc-1631	251	4	affleck	affleck	PROPN
dpc-1631	251	5	p	p	PROPN
dpc-1631	251	6	,	,	PUNCT
dpc-1631	251	7	elliott	elliott	PROPN
dpc-1631	251	8	f	f	PROPN
dpc-1631	251	9	,	,	PUNCT
dpc-1631	251	10	et	et	PROPN
dpc-1631	251	11	al	al	PROPN
dpc-1631	251	12	.	.	PROPN
dpc-1631	252	1	environmental	environmental	ADJ
dpc-1631	252	2	risk	risk	NOUN
dpc-1631	252	3	factors	factor	NOUN
dpc-1631	252	4	for	for	ADP
dpc-1631	252	5	relapse	relapse	NOUN
dpc-1631	252	6	of	of	ADP
dpc-1631	252	7	melanoma	melanoma	NOUN
dpc-1631	252	8	.	.	PUNCT
dpc-1631	253	1	eur	eur	PROPN
dpc-1631	253	2	j	j	PROPN
dpc-1631	253	3	cancer	cancer	NOUN
dpc-1631	253	4	.	.	PUNCT
dpc-1631	254	1	2008;44(12):1717	2008;44(12):1717	NUM
dpc-1631	254	2	-	-	SYM
dpc-1631	254	3	1725	1725	NUM
dpc-1631	254	4	.	.	PUNCT
dpc-1631	255	1	doi	doi	NOUN
dpc-1631	255	2	:	:	PUNCT
dpc-1631	255	3	10.1016	10.1016	NUM
dpc-1631	255	4	/	/	SYM
dpc-1631	255	5	j.ejca.2008.05.007	j.ejca.2008.05.007	NOUN
dpc-1631	255	6	.	.	PUNCT
dpc-1631	256	1	pmid	pmid	NOUN
dpc-1631	256	2	:	:	PUNCT
dpc-1631	256	3	18602256	18602256	NUM
dpc-1631	256	4	.	.	PUNCT
dpc-1631	257	1	15	15	NUM
dpc-1631	257	2	.	.	PUNCT
dpc-1631	257	3	oba	oba	PROPN
dpc-1631	257	4	j	j	PROPN
dpc-1631	257	5	,	,	PUNCT
dpc-1631	257	6	wei	wei	PROPN
dpc-1631	257	7	w	w	PROPN
dpc-1631	257	8	,	,	PUNCT
dpc-1631	257	9	gershenwald	gershenwald	PROPN
dpc-1631	257	10	je	je	PROPN
dpc-1631	257	11	,	,	PUNCT
dpc-1631	257	12	et	et	PROPN
dpc-1631	257	13	al	al	PROPN
dpc-1631	257	14	.	.	PROPN
dpc-1631	257	15	elevated	elevated	PROPN
dpc-1631	257	16	serum	serum	NOUN
dpc-1631	257	17	leptin	leptin	NOUN
dpc-1631	257	18	levels	level	NOUN
dpc-1631	257	19	are	be	AUX
dpc-1631	257	20	associated	associate	VERB
dpc-1631	257	21	with	with	ADP
dpc-1631	257	22	an	an	DET
dpc-1631	257	23	increased	increase	VERB
dpc-1631	257	24	risk	risk	NOUN
dpc-1631	257	25	of	of	ADP
dpc-1631	257	26	sentinel	sentinel	ADJ
dpc-1631	257	27	lymph	lymph	NOUN
dpc-1631	257	28	node	node	VERB
dpc-1631	257	29	metastasis	metastasis	NOUN
dpc-1631	257	30	in	in	ADP
dpc-1631	257	31	cutaneous	cutaneous	ADJ
dpc-1631	257	32	melanoma	melanoma	NOUN
dpc-1631	257	33	.	.	PUNCT
dpc-1631	258	1	medicine	medicine	NOUN
dpc-1631	258	2	(	(	PUNCT
dpc-1631	258	3	baltimore	baltimore	PROPN
dpc-1631	258	4	)	)	PUNCT
dpc-1631	258	5	.	.	PUNCT
dpc-1631	259	1	2016;95(11):e3073	2016;95(11):e3073	X
dpc-1631	259	2	.	.	PUNCT
dpc-1631	260	1	doi	doi	NOUN
dpc-1631	260	2	:	:	PUNCT
dpc-1631	260	3	10.1097	10.1097	NUM
dpc-1631	260	4	/	/	SYM
dpc-1631	260	5	md.0000000000003073	md.0000000000003073	PROPN
dpc-1631	260	6	.	.	PUNCT
dpc-1631	261	1	pmid	pmid	NOUN
dpc-1631	261	2	:	:	PUNCT
dpc-1631	261	3	26986135	26986135	NUM
dpc-1631	261	4	.	.	PUNCT
dpc-1631	262	1	16	16	NUM
dpc-1631	262	2	.	.	PUNCT
dpc-1631	263	1	newton	newton	PROPN
dpc-1631	263	2	-	-	PUNCT
dpc-1631	263	3	bishop	bishop	PROPN
dpc-1631	263	4	ja	ja	PROPN
dpc-1631	263	5	,	,	PUNCT
dpc-1631	263	6	davies	davies	PROPN
dpc-1631	263	7	jr	jr	PROPN
dpc-1631	263	8	,	,	PUNCT
dpc-1631	263	9	latheef	latheef	PROPN
dpc-1631	263	10	f	f	NUM
dpc-1631	263	11	,	,	PUNCT
dpc-1631	263	12	et	et	PROPN
dpc-1631	263	13	al	al	PROPN
dpc-1631	263	14	.	.	PROPN
dpc-1631	264	1	25	25	NUM
dpc-1631	264	2	-	-	PUNCT
dpc-1631	264	3	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1631	264	4	d2	d2	PROPN
dpc-1631	264	5	/d3	/d3	PROPN
dpc-1631	264	6	levels	level	NOUN
dpc-1631	264	7	and	and	CCONJ
dpc-1631	264	8	factors	factor	NOUN
dpc-1631	264	9	associated	associate	VERB
dpc-1631	264	10	with	with	ADP
dpc-1631	264	11	systemic	systemic	ADJ
dpc-1631	264	12	inflammation	inflammation	NOUN
dpc-1631	264	13	and	and	CCONJ
dpc-1631	264	14	melanoma	melanoma	NOUN
dpc-1631	264	15	survival	survival	NOUN
dpc-1631	264	16	in	in	ADP
dpc-1631	264	17	the	the	DET
dpc-1631	264	18	leeds	leeds	PROPN
dpc-1631	264	19	melanoma	melanoma	PROPN
dpc-1631	264	20	cohort	cohort	NOUN
dpc-1631	264	21	.	.	PUNCT
dpc-1631	265	1	int	int	NOUN
dpc-1631	265	2	j	j	PROPN
dpc-1631	265	3	cancer	cancer	NOUN
dpc-1631	265	4	.	.	PUNCT
dpc-1631	266	1	2015;136(12):2890	2015;136(12):2890	NOUN
dpc-1631	266	2	-	-	NOUN
dpc-1631	266	3	2899	2899	NUM
dpc-1631	266	4	.	.	PUNCT
dpc-1631	267	1	doi	doi	NOUN
dpc-1631	267	2	:	:	PUNCT
dpc-1631	267	3	10.1002	10.1002	NUM
dpc-1631	267	4	/	/	SYM
dpc-1631	267	5	ijc.29334	ijc.29334	PROPN
dpc-1631	267	6	.	.	PUNCT
dpc-1631	268	1	pmid	pmid	NOUN
dpc-1631	268	2	:	:	PUNCT
dpc-1631	268	3	25403087	25403087	NUM
dpc-1631	268	4	.	.	PUNCT
dpc-1631	269	1	17	17	NUM
dpc-1631	269	2	.	.	PUNCT
dpc-1631	270	1	newton	newton	PROPN
dpc-1631	270	2	-	-	PUNCT
dpc-1631	270	3	bishop	bishop	PROPN
dpc-1631	270	4	ja	ja	PROPN
dpc-1631	270	5	,	,	PUNCT
dpc-1631	270	6	beswick	beswick	PROPN
dpc-1631	270	7	s	s	PROPN
dpc-1631	270	8	,	,	PUNCT
dpc-1631	270	9	randerson	randerson	NOUN
dpc-1631	270	10	-	-	PUNCT
dpc-1631	270	11	moor	moor	PROPN
dpc-1631	270	12	j	j	PROPN
dpc-1631	270	13	,	,	PUNCT
dpc-1631	270	14	et	et	PROPN
dpc-1631	270	15	al	al	PROPN
dpc-1631	270	16	.	.	PROPN
dpc-1631	271	1	serum	serum	PROPN
dpc-1631	271	2	25	25	NUM
dpc-1631	271	3	-	-	PUNCT
dpc-1631	271	4	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1631	271	5	d3	d3	PROPN
dpc-1631	271	6	levels	level	NOUN
dpc-1631	271	7	are	be	AUX
dpc-1631	271	8	associated	associate	VERB
dpc-1631	271	9	with	with	ADP
dpc-1631	271	10	breslow	breslow	ADJ
dpc-1631	271	11	thickness	thickness	NOUN
dpc-1631	271	12	at	at	ADP
dpc-1631	271	13	presentation	presentation	NOUN
dpc-1631	271	14	and	and	CCONJ
dpc-1631	271	15	survival	survival	NOUN
dpc-1631	271	16	from	from	ADP
dpc-1631	271	17	melanoma	melanoma	NOUN
dpc-1631	271	18	.	.	PUNCT
dpc-1631	272	1	j	j	PROPN
dpc-1631	272	2	clin	clin	PROPN
dpc-1631	272	3	oncol	oncol	PROPN
dpc-1631	272	4	.	.	PUNCT
dpc-1631	273	1	2009;27(32):5439	2009;27(32):5439	NUM
dpc-1631	273	2	-	-	SYM
dpc-1631	273	3	5444	5444	NUM
dpc-1631	273	4	.	.	PUNCT
dpc-1631	274	1	doi	doi	NOUN
dpc-1631	274	2	:	:	PUNCT
dpc-1631	274	3	10.1200	10.1200	NUM
dpc-1631	274	4	/	/	SYM
dpc-1631	274	5	jco.2009.22.1135	jco.2009.22.1135	PROPN
dpc-1631	274	6	.	.	PUNCT
dpc-1631	275	1	pmid	pmid	NOUN
dpc-1631	275	2	:	:	PUNCT
dpc-1631	275	3	19770375	19770375	NUM
dpc-1631	275	4	.	.	PUNCT
dpc-1631	276	1	18	18	NUM
dpc-1631	276	2	.	.	X
dpc-1631	276	3	fang	fang	PROPN
dpc-1631	276	4	s	s	PROPN
dpc-1631	276	5	,	,	PUNCT
dpc-1631	276	6	wang	wang	PROPN
dpc-1631	276	7	y	y	PROPN
dpc-1631	276	8	,	,	PUNCT
dpc-1631	276	9	dang	dang	INTJ
dpc-1631	276	10	y	y	PROPN
dpc-1631	276	11	,	,	PUNCT
dpc-1631	276	12	et	et	PROPN
dpc-1631	276	13	al	al	PROPN
dpc-1631	276	14	.	.	PROPN
dpc-1631	276	15	association	association	PROPN
dpc-1631	276	16	between	between	ADP
dpc-1631	276	17	body	body	NOUN
dpc-1631	276	18	mass	mass	PROPN
dpc-1631	276	19	index	index	NOUN
dpc-1631	276	20	,	,	PUNCT
dpc-1631	276	21	c	c	NOUN
dpc-1631	276	22	-	-	PUNCT
dpc-1631	276	23	reactive	reactive	ADJ
dpc-1631	276	24	protein	protein	NOUN
dpc-1631	276	25	levels	level	NOUN
dpc-1631	276	26	,	,	PUNCT
dpc-1631	276	27	and	and	CCONJ
dpc-1631	276	28	melanoma	melanoma	NOUN
dpc-1631	276	29	patient	patient	ADJ
dpc-1631	276	30	outcomes	outcome	NOUN
dpc-1631	276	31	.	.	PUNCT
dpc-1631	277	1	j	j	PROPN
dpc-1631	277	2	invest	invest	VERB
dpc-1631	277	3	dermatol	dermatol	NOUN
dpc-1631	277	4	.	.	PUNCT
dpc-1631	278	1	2017;137(8):1792	2017;137(8):1792	NUM
dpc-1631	278	2	-	-	SYM
dpc-1631	278	3	1795	1795	NUM
dpc-1631	278	4	.	.	PUNCT
dpc-1631	279	1	doi	doi	NOUN
dpc-1631	279	2	:	:	PUNCT
dpc-1631	279	3	10.1016	10.1016	NUM
dpc-1631	279	4	/	/	SYM
dpc-1631	279	5	j.	j.	PROPN
dpc-1631	279	6	jid.2017.04.007	jid.2017.04.007	PROPN
dpc-1631	279	7	.	.	PUNCT
dpc-1631	280	1	pmid	pmid	NOUN
dpc-1631	280	2	:	:	PUNCT
dpc-1631	280	3	28442307	28442307	NUM
dpc-1631	280	4	.	.	PUNCT
dpc-1631	281	1	19	19	NUM
dpc-1631	281	2	.	.	PUNCT
dpc-1631	282	1	kim	kim	PROPN
dpc-1631	282	2	je	je	PROPN
dpc-1631	282	3	,	,	PUNCT
dpc-1631	282	4	chung	chung	VERB
dpc-1631	282	5	by	by	ADV
dpc-1631	282	6	,	,	PUNCT
dpc-1631	282	7	sim	sim	ADJ
dpc-1631	282	8	cy	cy	PROPN
dpc-1631	282	9	,	,	PUNCT
dpc-1631	282	10	et	et	PROPN
dpc-1631	282	11	al	al	PROPN
dpc-1631	282	12	.	.	PUNCT
dpc-1631	282	13	clinicopathologic	clinicopathologic	ADJ
dpc-1631	282	14	features	feature	NOUN
dpc-1631	282	15	and	and	CCONJ
dpc-1631	282	16	prognostic	prognostic	ADJ
dpc-1631	282	17	factors	factor	NOUN
dpc-1631	282	18	of	of	ADP
dpc-1631	282	19	primary	primary	ADJ
dpc-1631	282	20	cutaneous	cutaneous	ADJ
dpc-1631	282	21	melanoma	melanoma	NOUN
dpc-1631	282	22	:	:	PUNCT
dpc-1631	282	23	a	a	DET
dpc-1631	282	24	multicenter	multicenter	ADJ
dpc-1631	282	25	study	study	NOUN
dpc-1631	282	26	in	in	ADP
dpc-1631	282	27	korea	korea	PROPN
dpc-1631	282	28	.	.	PUNCT
dpc-1631	283	1	j	j	PROPN
dpc-1631	283	2	korean	korean	PROPN
dpc-1631	283	3	med	med	PROPN
dpc-1631	283	4	sci	sci	PROPN
dpc-1631	283	5	.	.	PUNCT
dpc-1631	284	1	2019;34(16):e126	2019;34(16):e126	NUM
dpc-1631	284	2	.	.	PUNCT
dpc-1631	285	1	doi	doi	NOUN
dpc-1631	285	2	:	:	PUNCT
dpc-1631	285	3	10.3346	10.3346	NUM
dpc-1631	285	4	/	/	SYM
dpc-1631	285	5	jkms.2019.34.e126	jkms.2019.34.e126	PROPN
dpc-1631	285	6	.	.	PUNCT
dpc-1631	286	1	pmid	pmid	NOUN
dpc-1631	286	2	:	:	PUNCT
dpc-1631	286	3	31020815	31020815	NUM
dpc-1631	286	4	.	.	PUNCT
dpc-1631	287	1	20	20	NUM
dpc-1631	287	2	.	.	PUNCT
dpc-1631	288	1	world	world	PROPN
dpc-1631	288	2	health	health	PROPN
dpc-1631	288	3	organization	organization	NOUN
dpc-1631	288	4	iotf	iotf	VERB
dpc-1631	288	5	.	.	PUNCT
dpc-1631	289	1	the	the	DET
dpc-1631	289	2	asian	asian	ADJ
dpc-1631	289	3	-	-	PUNCT
dpc-1631	289	4	pacific	pacific	NOUN
dpc-1631	289	5	perspective	perspective	NOUN
dpc-1631	289	6	:	:	PUNCT
dpc-1631	289	7	redefining	redefine	VERB
dpc-1631	289	8	obesity	obesity	NOUN
dpc-1631	289	9	and	and	CCONJ
dpc-1631	289	10	its	its	PRON
dpc-1631	289	11	treatment	treatment	NOUN
dpc-1631	289	12	.	.	PUNCT
dpc-1631	290	1	geneva	geneva	PROPN
dpc-1631	290	2	:	:	PUNCT
dpc-1631	290	3	who	who	PRON
dpc-1631	290	4	western	western	ADJ
dpc-1631	290	5	pacific	pacific	PROPN
dpc-1631	290	6	region	region	NOUN
dpc-1631	290	7	,	,	PUNCT
dpc-1631	290	8	2000	2000	NUM
dpc-1631	290	9	.	.	PUNCT
dpc-1631	291	1	21	21	NUM
dpc-1631	291	2	.	.	X
dpc-1631	291	3	de	de	PROPN
dpc-1631	291	4	giorgi	giorgi	PROPN
dpc-1631	291	5	v	v	PROPN
dpc-1631	291	6	,	,	PUNCT
dpc-1631	291	7	gori	gori	PROPN
dpc-1631	291	8	a	a	X
dpc-1631	291	9	,	,	PUNCT
dpc-1631	291	10	papi	papi	NOUN
dpc-1631	291	11	f	f	PROPN
dpc-1631	291	12	,	,	PUNCT
dpc-1631	291	13	et	et	PROPN
dpc-1631	291	14	al	al	PROPN
dpc-1631	291	15	.	.	PUNCT
dpc-1631	291	16	excess	excess	ADJ
dpc-1631	291	17	body	body	NOUN
dpc-1631	291	18	weight	weight	NOUN
dpc-1631	291	19	and	and	CCONJ
dpc-1631	291	20	increased	increase	VERB
dpc-1631	291	21	breslow	breslow	ADJ
dpc-1631	291	22	thickness	thickness	NOUN
dpc-1631	291	23	in	in	ADP
dpc-1631	291	24	melanoma	melanoma	NOUN
dpc-1631	291	25	patients	patient	NOUN
dpc-1631	291	26	:	:	PUNCT
dpc-1631	291	27	a	a	DET
dpc-1631	291	28	retrospective	retrospective	ADJ
dpc-1631	291	29	study	study	NOUN
dpc-1631	291	30	.	.	PUNCT
dpc-1631	292	1	eur	eur	PROPN
dpc-1631	292	2	j	j	PROPN
dpc-1631	292	3	cancer	cancer	NOUN
dpc-1631	292	4	prev	prev	X
dpc-1631	292	5	.	.	PUNCT
dpc-1631	293	1	2013;22(5):480	2013;22(5):480	NUM
dpc-1631	293	2	-	-	PUNCT
dpc-1631	293	3	485	485	NUM
dpc-1631	293	4	.	.	PUNCT
dpc-1631	294	1	doi	doi	NOUN
dpc-1631	294	2	:	:	PUNCT
dpc-1631	294	3	10.1097/	10.1097/	NUM
dpc-1631	294	4	cej.0b013e32835f3b5d	cej.0b013e32835f3b5d	PROPN
dpc-1631	294	5	.	.	PUNCT
dpc-1631	295	1	pmid	pmid	NOUN
dpc-1631	295	2	:	:	PUNCT
dpc-1631	295	3	23462459	23462459	NUM
dpc-1631	295	4	.	.	PUNCT
dpc-1631	296	1	22	22	NUM
dpc-1631	296	2	.	.	PUNCT
dpc-1631	297	1	gandini	gandini	PROPN
dpc-1631	297	2	s	s	PROPN
dpc-1631	297	3	,	,	PUNCT
dpc-1631	297	4	montella	montella	NOUN
dpc-1631	297	5	m	m	PROPN
dpc-1631	297	6	,	,	PUNCT
dpc-1631	297	7	ayala	ayala	PROPN
dpc-1631	297	8	f	f	PROPN
dpc-1631	297	9	,	,	PUNCT
dpc-1631	297	10	et	et	PROPN
dpc-1631	297	11	al	al	PROPN
dpc-1631	297	12	;	;	PUNCT
dpc-1631	297	13	clinical	clinical	ADJ
dpc-1631	297	14	national	national	ADJ
dpc-1631	297	15	melanoma	melanoma	PROPN
dpc-1631	297	16	registry	registry	PROPN
dpc-1631	297	17	group	group	NOUN
dpc-1631	297	18	.	.	PUNCT
dpc-1631	298	1	sun	sun	NOUN
dpc-1631	298	2	exposure	exposure	NOUN
dpc-1631	298	3	and	and	CCONJ
dpc-1631	298	4	melanoma	melanoma	NOUN
dpc-1631	298	5	prognostic	prognostic	ADJ
dpc-1631	298	6	factors	factor	NOUN
dpc-1631	298	7	.	.	PUNCT
dpc-1631	299	1	oncol	oncol	ADJ
dpc-1631	299	2	lett	lett	PROPN
dpc-1631	299	3	.	.	PUNCT
dpc-1631	300	1	2016;11(4):2706	2016;11(4):2706	PROPN
dpc-1631	300	2	-	-	PUNCT
dpc-1631	300	3	2714	2714	NUM
dpc-1631	300	4	.	.	PUNCT
dpc-1631	301	1	doi	doi	NOUN
dpc-1631	301	2	:	:	PUNCT
dpc-1631	301	3	10.3892/	10.3892/	NUM
dpc-1631	301	4	ol.2016.4292	ol.2016.4292	NOUN
dpc-1631	301	5	.	.	PUNCT
dpc-1631	302	1	pmid	pmid	NOUN
dpc-1631	302	2	:	:	PUNCT
dpc-1631	302	3	27073541	27073541	NUM
dpc-1631	302	4	.	.	PUNCT
dpc-1631	303	1	23	23	NUM
dpc-1631	303	2	.	.	PUNCT
dpc-1631	304	1	skowron	skowron	PROPN
dpc-1631	304	2	f	f	PROPN
dpc-1631	304	3	,	,	PUNCT
dpc-1631	304	4	bérard	bérard	NOUN
dpc-1631	304	5	f	f	PROPN
dpc-1631	304	6	,	,	PUNCT
dpc-1631	304	7	balme	balme	ADJ
dpc-1631	304	8	b	b	NOUN
dpc-1631	304	9	,	,	PUNCT
dpc-1631	304	10	maucort	maucort	NOUN
dpc-1631	304	11	-	-	PUNCT
dpc-1631	304	12	boulch	boulch	PROPN
dpc-1631	304	13	d.	d.	PROPN
dpc-1631	304	14	role	role	NOUN
dpc-1631	304	15	of	of	ADP
dpc-1631	304	16	obesity	obesity	NOUN
dpc-1631	304	17	on	on	ADP
dpc-1631	304	18	the	the	DET
dpc-1631	304	19	thickness	thickness	NOUN
dpc-1631	304	20	of	of	ADP
dpc-1631	304	21	primary	primary	ADJ
dpc-1631	304	22	cutaneous	cutaneous	ADJ
dpc-1631	304	23	melanoma	melanoma	NOUN
dpc-1631	304	24	.	.	PUNCT
dpc-1631	305	1	j	j	PROPN
dpc-1631	305	2	eur	eur	PROPN
dpc-1631	305	3	acad	acad	PROPN
dpc-1631	305	4	dermatol	dermatol	NOUN
dpc-1631	305	5	venereol	venereol	NOUN
dpc-1631	305	6	.	.	PUNCT
dpc-1631	306	1	2015;29(2):262	2015;29(2):262	NOUN
dpc-1631	306	2	-	-	PUNCT
dpc-1631	306	3	269	269	NUM
dpc-1631	306	4	.	.	PUNCT
dpc-1631	306	5	doi	doi	NOUN
dpc-1631	306	6	:	:	PUNCT
dpc-1631	306	7	10.1111/	10.1111/	NUM
dpc-1631	306	8	jdv.12515	jdv.12515	PROPN
dpc-1631	306	9	.	.	PUNCT
dpc-1631	307	1	pmid	pmid	NOUN
dpc-1631	307	2	:	:	PUNCT
dpc-1631	307	3	24750303	24750303	NUM
dpc-1631	307	4	.	.	PUNCT
dpc-1631	308	1	24	24	NUM
dpc-1631	308	2	.	.	PUNCT
dpc-1631	308	3	stenehjem	stenehjem	NOUN
dpc-1631	308	4	js	js	PROPN
dpc-1631	308	5	,	,	PUNCT
dpc-1631	308	6	veierød	veierød	VERB
dpc-1631	308	7	mb	mb	ADP
dpc-1631	308	8	,	,	PUNCT
dpc-1631	308	9	nilsen	nilsen	PROPN
dpc-1631	308	10	lt	lt	PROPN
dpc-1631	308	11	,	,	PUNCT
dpc-1631	308	12	et	et	PROPN
dpc-1631	308	13	al	al	PROPN
dpc-1631	308	14	.	.	PROPN
dpc-1631	309	1	anthropometric	anthropometric	ADJ
dpc-1631	309	2	factors	factor	NOUN
dpc-1631	309	3	and	and	CCONJ
dpc-1631	309	4	breslow	breslow	ADJ
dpc-1631	309	5	thickness	thickness	NOUN
dpc-1631	309	6	:	:	PUNCT
dpc-1631	309	7	prospective	prospective	ADJ
dpc-1631	309	8	data	datum	NOUN
dpc-1631	309	9	on	on	ADP
dpc-1631	309	10	2570	2570	NUM
dpc-1631	309	11	cases	case	NOUN
dpc-1631	309	12	of	of	ADP
dpc-1631	309	13	cutaneous	cutaneous	ADJ
dpc-1631	309	14	melanoma	melanoma	NOUN
dpc-1631	309	15	in	in	ADP
dpc-1631	309	16	the	the	DET
dpc-1631	309	17	population	population	NOUN
dpc-1631	309	18	-	-	PUNCT
dpc-1631	309	19	based	base	VERB
dpc-1631	309	20	janus	janus	PROPN
dpc-1631	309	21	cohort	cohort	NOUN
dpc-1631	309	22	.	.	PUNCT
dpc-1631	310	1	br	br	PROPN
dpc-1631	310	2	j	j	PROPN
dpc-1631	310	3	dermatol	dermatol	NOUN
dpc-1631	310	4	.	.	PUNCT
dpc-1631	311	1	2018;179(3):632	2018;179(3):632	NUM
dpc-1631	311	2	-	-	SYM
dpc-1631	311	3	641	641	NUM
dpc-1631	311	4	.	.	PUNCT
dpc-1631	311	5	doi	doi	NOUN
dpc-1631	311	6	:	:	PUNCT
dpc-1631	311	7	10.1111	10.1111	NUM
dpc-1631	311	8	/	/	SYM
dpc-1631	311	9	bjd.16825	bjd.16825	PROPN
dpc-1631	311	10	.	.	PUNCT
dpc-1631	312	1	pmid	pmid	NOUN
dpc-1631	312	2	:	:	PUNCT
dpc-1631	312	3	29858512	29858512	NUM
dpc-1631	312	4	.	.	PUNCT
dpc-1631	313	1	25	25	NUM
dpc-1631	313	2	.	.	PUNCT
dpc-1631	314	1	wyatt	wyatt	PROPN
dpc-1631	314	2	c	c	PROPN
dpc-1631	314	3	,	,	PUNCT
dpc-1631	314	4	lucas	lucas	PROPN
dpc-1631	314	5	rm	rm	PROPN
dpc-1631	314	6	,	,	PUNCT
dpc-1631	314	7	hurst	hurst	PROPN
dpc-1631	314	8	c	c	PROPN
dpc-1631	314	9	,	,	PUNCT
dpc-1631	314	10	et	et	PROPN
dpc-1631	314	11	al	al	PROPN
dpc-1631	314	12	.	.	PUNCT
dpc-1631	315	1	vitamin	vitamin	NOUN
dpc-1631	315	2	d	d	NOUN
dpc-1631	315	3	deficiency	deficiency	NOUN
dpc-1631	315	4	at	at	ADP
dpc-1631	315	5	melanoma	melanoma	ADJ
dpc-1631	315	6	diagnosis	diagnosis	NOUN
dpc-1631	315	7	is	be	AUX
dpc-1631	315	8	associated	associate	VERB
dpc-1631	315	9	with	with	ADP
dpc-1631	315	10	higher	high	ADJ
dpc-1631	315	11	breslow	breslow	NOUN
dpc-1631	315	12	thickness	thickness	NOUN
dpc-1631	315	13	.	.	PUNCT
dpc-1631	316	1	plos	plos	PROPN
dpc-1631	316	2	one	one	NUM
dpc-1631	316	3	.	.	PUNCT
dpc-1631	317	1	2015;10(5):e0126394	2015;10(5):e0126394	NUM
dpc-1631	317	2	.	.	PUNCT
dpc-1631	317	3	doi	doi	NOUN
dpc-1631	317	4	:	:	PUNCT
dpc-1631	317	5	10.1371	10.1371	NUM
dpc-1631	317	6	/	/	SYM
dpc-1631	317	7	journal	journal	NOUN
dpc-1631	317	8	.	.	PUNCT
dpc-1631	318	1	pone.0126394	pone.0126394	PROPN
dpc-1631	318	2	.	.	PROPN
dpc-1631	318	3	pmid	pmid	PROPN
dpc-1631	318	4	:	:	PUNCT
dpc-1631	318	5	25970336	25970336	NUM
dpc-1631	318	6	.	.	PUNCT
dpc-1631	319	1	26	26	NUM
dpc-1631	319	2	.	.	PUNCT
dpc-1631	319	3	von	von	PROPN
dpc-1631	319	4	schuckmann	schuckmann	PROPN
dpc-1631	319	5	la	la	PROPN
dpc-1631	319	6	,	,	PUNCT
dpc-1631	319	7	smith	smith	PROPN
dpc-1631	319	8	d	d	PROPN
dpc-1631	319	9	,	,	PUNCT
dpc-1631	319	10	hughes	hughes	PROPN
dpc-1631	319	11	mcb	mcb	PROPN
dpc-1631	319	12	,	,	PUNCT
dpc-1631	319	13	et	et	PROPN
dpc-1631	319	14	al	al	PROPN
dpc-1631	319	15	.	.	PROPN
dpc-1631	319	16	associations	association	NOUN
dpc-1631	319	17	of	of	ADP
dpc-1631	319	18	statins	statin	NOUN
dpc-1631	319	19	and	and	CCONJ
dpc-1631	319	20	diabetes	diabetes	NOUN
dpc-1631	319	21	with	with	ADP
dpc-1631	319	22	diagnosis	diagnosis	NOUN
dpc-1631	319	23	of	of	ADP
dpc-1631	319	24	ulcerated	ulcerated	ADJ
dpc-1631	319	25	cutaneous	cutaneous	ADJ
dpc-1631	319	26	melanoma	melanoma	NOUN
dpc-1631	319	27	.	.	PUNCT
dpc-1631	320	1	j	j	PROPN
dpc-1631	320	2	invest	invest	VERB
dpc-1631	320	3	dermatol	dermatol	NOUN
dpc-1631	320	4	.	.	PUNCT
dpc-1631	321	1	2017;137(12):2599	2017;137(12):2599	NUM
dpc-1631	321	2	-	-	SYM
dpc-1631	321	3	2605	2605	NUM
dpc-1631	321	4	.	.	PUNCT
dpc-1631	322	1	doi	doi	NOUN
dpc-1631	322	2	:	:	PUNCT
dpc-1631	322	3	10.1016	10.1016	NUM
dpc-1631	322	4	/	/	SYM
dpc-1631	322	5	j.jid.2017.07.836	j.jid.2017.07.836	NOUN
dpc-1631	322	6	.	.	PUNCT
dpc-1631	323	1	pmid	pmid	NOUN
dpc-1631	323	2	:	:	PUNCT
dpc-1631	323	3	28842323	28842323	NUM
dpc-1631	323	4	.	.	PUNCT
dpc-1631	324	1	27	27	NUM
dpc-1631	324	2	.	.	PUNCT
dpc-1631	324	3	cauci	cauci	PROPN
dpc-1631	324	4	s	s	PROPN
dpc-1631	324	5	,	,	PUNCT
dpc-1631	324	6	maione	maione	NOUN
dpc-1631	324	7	v	v	NOUN
dpc-1631	324	8	,	,	PUNCT
dpc-1631	324	9	buligan	buligan	VERB
dpc-1631	324	10	c	c	NOUN
dpc-1631	324	11	,	,	PUNCT
dpc-1631	324	12	linussio	linussio	NOUN
dpc-1631	324	13	m	m	PROPN
dpc-1631	324	14	,	,	PUNCT
dpc-1631	324	15	serraino	serraino	NOUN
dpc-1631	324	16	d	d	NOUN
dpc-1631	324	17	,	,	PUNCT
dpc-1631	324	18	stinco	stinco	PROPN
dpc-1631	324	19	g.	g.	PROPN
dpc-1631	324	20	bsmi	bsmi	PROPN
dpc-1631	324	21	(	(	PUNCT
dpc-1631	324	22	rs1544410	rs1544410	PROPN
dpc-1631	324	23	)	)	PUNCT
dpc-1631	324	24	and	and	CCONJ
dpc-1631	324	25	foki	foki	NOUN
dpc-1631	324	26	(	(	PUNCT
dpc-1631	324	27	rs2228570	rs2228570	NOUN
dpc-1631	324	28	)	)	PUNCT
dpc-1631	324	29	vitamin	vitamin	NOUN
dpc-1631	324	30	d	d	NOUN
dpc-1631	324	31	receptor	receptor	NOUN
dpc-1631	324	32	polymorphisms	polymorphism	NOUN
dpc-1631	324	33	,	,	PUNCT
dpc-1631	324	34	smoking	smoking	NOUN
dpc-1631	324	35	,	,	PUNCT
dpc-1631	324	36	and	and	CCONJ
dpc-1631	324	37	body	body	NOUN
dpc-1631	324	38	mass	mass	NOUN
dpc-1631	324	39	index	index	NOUN
dpc-1631	324	40	as	as	ADP
dpc-1631	324	41	risk	risk	NOUN
dpc-1631	324	42	factors	factor	NOUN
dpc-1631	324	43	of	of	ADP
dpc-1631	324	44	cutaneous	cutaneous	ADJ
dpc-1631	324	45	malignant	malignant	ADJ
dpc-1631	324	46	melanoma	melanoma	NOUN
dpc-1631	324	47	in	in	ADP
dpc-1631	324	48	northeast	northeast	PROPN
dpc-1631	324	49	italy	italy	PROPN
dpc-1631	324	50	.	.	PUNCT
dpc-1631	325	1	cancer	cancer	NOUN
dpc-1631	325	2	biol	biol	PROPN
dpc-1631	325	3	med	me	VERB
dpc-1631	325	4	.	.	PUNCT
dpc-1631	326	1	2017;14(3):302	2017;14(3):302	NUM
dpc-1631	326	2	-	-	PUNCT
dpc-1631	326	3	318	318	NUM
dpc-1631	326	4	.	.	PUNCT
dpc-1631	327	1	doi	doi	NOUN
dpc-1631	327	2	:	:	PUNCT
dpc-1631	327	3	10.20892	10.20892	NUM
dpc-1631	327	4	/	/	SYM
dpc-1631	327	5	j.issn.20953941.2017.0064	j.issn.20953941.2017.0064	NOUN
dpc-1631	327	6	.	.	PUNCT
dpc-1631	328	1	pmid	pmid	NOUN
dpc-1631	328	2	:	:	PUNCT
dpc-1631	328	3	28884047	28884047	NUM
dpc-1631	328	4	.	.	PUNCT
dpc-1631	329	1	28	28	NUM
dpc-1631	329	2	.	.	PUNCT
dpc-1631	329	3	renehan	renehan	PROPN
dpc-1631	329	4	ag	ag	PROPN
dpc-1631	329	5	,	,	PUNCT
dpc-1631	329	6	tyson	tyson	PROPN
dpc-1631	329	7	m	m	PROPN
dpc-1631	329	8	,	,	PUNCT
dpc-1631	329	9	egger	egger	NOUN
dpc-1631	329	10	m	m	PROPN
dpc-1631	329	11	,	,	PUNCT
dpc-1631	329	12	heller	heller	NOUN
dpc-1631	329	13	rf	rf	NOUN
dpc-1631	329	14	,	,	PUNCT
dpc-1631	329	15	zwahlen	zwahlen	PROPN
dpc-1631	329	16	m.	m.	NOUN
dpc-1631	329	17	body	body	NOUN
dpc-1631	329	18	-	-	PUNCT
dpc-1631	329	19	mass	mass	NOUN
dpc-1631	329	20	index	index	NOUN
dpc-1631	329	21	and	and	CCONJ
dpc-1631	329	22	incidence	incidence	NOUN
dpc-1631	329	23	of	of	ADP
dpc-1631	329	24	cancer	cancer	NOUN
dpc-1631	329	25	:	:	PUNCT
dpc-1631	329	26	a	a	DET
dpc-1631	329	27	systematic	systematic	ADJ
dpc-1631	329	28	review	review	NOUN
dpc-1631	329	29	and	and	CCONJ
dpc-1631	329	30	meta	meta	ADJ
dpc-1631	329	31	-	-	PUNCT
dpc-1631	329	32	analysis	analysis	NOUN
dpc-1631	329	33	of	of	ADP
dpc-1631	329	34	prospective	prospective	ADJ
dpc-1631	329	35	observational	observational	ADJ
dpc-1631	329	36	studies	study	NOUN
dpc-1631	329	37	.	.	PUNCT
dpc-1631	330	1	8	8	NUM
dpc-1631	330	2	review	review	NOUN
dpc-1631	330	3	|	|	ADV
dpc-1631	330	4	dermatol	dermatol	ADJ
dpc-1631	330	5	pract	pract	NOUN
dpc-1631	330	6	concept	concept	NOUN
dpc-1631	330	7	.	.	PUNCT
dpc-1631	331	1	2021;11(4	2021;11(4	NUM
dpc-1631	331	2	):	):	PUNCT
dpc-1631	331	3	e2021106	e2021106	NOUN
dpc-1631	331	4	lancet	lancet	NOUN
dpc-1631	331	5	.	.	PUNCT
dpc-1631	332	1	2008;371(9612):569	2008;371(9612):569	NUM
dpc-1631	332	2	-	-	SYM
dpc-1631	332	3	578	578	NUM
dpc-1631	332	4	.	.	PUNCT
dpc-1631	333	1	doi	doi	NOUN
dpc-1631	333	2	:	:	PUNCT
dpc-1631	333	3	10.1016	10.1016	NUM
dpc-1631	333	4	/	/	SYM
dpc-1631	333	5	s01406736(08)60269	s01406736(08)60269	NOUN
dpc-1631	333	6	-	-	PUNCT
dpc-1631	333	7	x.	x.	NOUN
dpc-1631	333	8	29	29	NUM
dpc-1631	333	9	.	.	PUNCT
dpc-1631	334	1	sergentanis	sergentanis	PROPN
dpc-1631	334	2	tn	tn	PROPN
dpc-1631	334	3	,	,	PUNCT
dpc-1631	334	4	antoniadis	antoniadis	PROPN
dpc-1631	334	5	ag	ag	PROPN
dpc-1631	334	6	,	,	PUNCT
dpc-1631	334	7	gogas	gogas	PROPN
dpc-1631	334	8	hj	hj	PROPN
dpc-1631	334	9	,	,	PUNCT
dpc-1631	334	10	et	et	PROPN
dpc-1631	334	11	al	al	PROPN
dpc-1631	334	12	.	.	PROPN
dpc-1631	334	13	obesity	obesity	NOUN
dpc-1631	334	14	and	and	CCONJ
dpc-1631	334	15	risk	risk	NOUN
dpc-1631	334	16	of	of	ADP
dpc-1631	334	17	malignant	malignant	ADJ
dpc-1631	334	18	melanoma	melanoma	NOUN
dpc-1631	334	19	:	:	PUNCT
dpc-1631	334	20	a	a	DET
dpc-1631	334	21	meta	meta	ADJ
dpc-1631	334	22	-	-	PUNCT
dpc-1631	334	23	analysis	analysis	NOUN
dpc-1631	334	24	of	of	ADP
dpc-1631	334	25	cohort	cohort	NOUN
dpc-1631	334	26	and	and	CCONJ
dpc-1631	334	27	case	case	NOUN
dpc-1631	334	28	-	-	PUNCT
dpc-1631	334	29	control	control	NOUN
dpc-1631	334	30	studies	study	NOUN
dpc-1631	334	31	.	.	PUNCT
dpc-1631	335	1	eur	eur	PROPN
dpc-1631	335	2	j	j	PROPN
dpc-1631	335	3	cancer	cancer	NOUN
dpc-1631	335	4	.	.	PUNCT
dpc-1631	336	1	2013;49(3):642	2013;49(3):642	PROPN
dpc-1631	336	2	-	-	PUNCT
dpc-1631	336	3	657	657	NUM
dpc-1631	336	4	.	.	PUNCT
dpc-1631	337	1	doi	doi	NOUN
dpc-1631	337	2	:	:	PUNCT
dpc-1631	337	3	10.1016	10.1016	NUM
dpc-1631	337	4	/	/	SYM
dpc-1631	337	5	j.	j.	PROPN
dpc-1631	337	6	ejca.2012.08.028	ejca.2012.08.028	PROPN
dpc-1631	337	7	.	.	PUNCT
dpc-1631	338	1	pmid	pmid	NOUN
dpc-1631	338	2	:	:	PUNCT
dpc-1631	338	3	23200191	23200191	NUM
dpc-1631	338	4	.	.	PUNCT
dpc-1631	339	1	30	30	NUM
dpc-1631	339	2	.	.	PUNCT
dpc-1631	340	1	dobbins	dobbins	PROPN
dpc-1631	340	2	m	m	PROPN
dpc-1631	340	3	,	,	PUNCT
dpc-1631	340	4	decorby	decorby	PROPN
dpc-1631	340	5	k	k	PROPN
dpc-1631	340	6	,	,	PUNCT
dpc-1631	340	7	choi	choi	PROPN
dpc-1631	340	8	bc	bc	PROPN
dpc-1631	340	9	.	.	PUNCT
dpc-1631	341	1	the	the	DET
dpc-1631	341	2	association	association	NOUN
dpc-1631	341	3	between	between	ADP
dpc-1631	341	4	obesity	obesity	NOUN
dpc-1631	341	5	and	and	CCONJ
dpc-1631	341	6	cancer	cancer	NOUN
dpc-1631	341	7	risk	risk	NOUN
dpc-1631	341	8	:	:	PUNCT
dpc-1631	341	9	a	a	DET
dpc-1631	341	10	meta	meta	ADJ
dpc-1631	341	11	-	-	PUNCT
dpc-1631	341	12	analysis	analysis	NOUN
dpc-1631	341	13	of	of	ADP
dpc-1631	341	14	observational	observational	ADJ
dpc-1631	341	15	studies	study	NOUN
dpc-1631	341	16	from	from	ADP
dpc-1631	341	17	1985	1985	NUM
dpc-1631	341	18	to	to	ADP
dpc-1631	341	19	2011	2011	NUM
dpc-1631	341	20	.	.	PUNCT
dpc-1631	342	1	isrn	isrn	PROPN
dpc-1631	342	2	prev	prev	PROPN
dpc-1631	342	3	med	med	PROPN
dpc-1631	342	4	.	.	PUNCT
dpc-1631	343	1	2013:680536	2013:680536	X
dpc-1631	343	2	.	.	PUNCT
dpc-1631	343	3	doi	doi	NOUN
dpc-1631	343	4	:	:	PUNCT
dpc-1631	343	5	10.5402/2013/680536	10.5402/2013/680536	NUM
dpc-1631	343	6	.	.	PUNCT
dpc-1631	344	1	pmid	pmid	NOUN
dpc-1631	344	2	:	:	PUNCT
dpc-1631	344	3	24977095	24977095	NUM
dpc-1631	344	4	.	.	PUNCT
dpc-1631	345	1	31	31	NUM
dpc-1631	345	2	.	.	PUNCT
dpc-1631	346	1	præstegaard	præstegaard	PROPN
dpc-1631	346	2	c	c	PROPN
dpc-1631	346	3	,	,	PUNCT
dpc-1631	346	4	kjær	kjær	NOUN
dpc-1631	346	5	sk	sk	VERB
dpc-1631	346	6	,	,	PUNCT
dpc-1631	346	7	christensen	christensen	PROPN
dpc-1631	346	8	j	j	PROPN
dpc-1631	346	9	,	,	PUNCT
dpc-1631	346	10	tjønneland	tjønneland	PROPN
dpc-1631	346	11	a	a	NOUN
dpc-1631	346	12	,	,	PUNCT
dpc-1631	346	13	halkjær	halkjær	PROPN
dpc-1631	346	14	j	j	PROPN
dpc-1631	346	15	,	,	PUNCT
dpc-1631	346	16	jensen	jensen	PROPN
dpc-1631	346	17	a.	a.	NOUN
dpc-1631	346	18	obesity	obesity	NOUN
dpc-1631	346	19	and	and	CCONJ
dpc-1631	346	20	risks	risk	NOUN
dpc-1631	346	21	for	for	ADP
dpc-1631	346	22	malignant	malignant	ADJ
dpc-1631	346	23	melanoma	melanoma	NOUN
dpc-1631	346	24	and	and	CCONJ
dpc-1631	346	25	non	non	ADJ
dpc-1631	346	26	-	-	ADJ
dpc-1631	346	27	melanoma	melanoma	ADJ
dpc-1631	346	28	skin	skin	NOUN
dpc-1631	346	29	cancer	cancer	NOUN
dpc-1631	346	30	:	:	PUNCT
dpc-1631	346	31	results	result	NOUN
dpc-1631	346	32	from	from	ADP
dpc-1631	346	33	a	a	DET
dpc-1631	346	34	large	large	ADJ
dpc-1631	346	35	danish	danish	ADJ
dpc-1631	346	36	prospective	prospective	ADJ
dpc-1631	346	37	cohort	cohort	NOUN
dpc-1631	346	38	study	study	NOUN
dpc-1631	346	39	.	.	PUNCT
dpc-1631	347	1	j	j	PROPN
dpc-1631	347	2	invest	invest	VERB
dpc-1631	347	3	dermatol	dermatol	NOUN
dpc-1631	347	4	.	.	PUNCT
dpc-1631	348	1	2015;135(3):901	2015;135(3):901	NUM
dpc-1631	348	2	-	-	SYM
dpc-1631	348	3	904	904	NUM
dpc-1631	348	4	.	.	PUNCT
dpc-1631	349	1	doi	doi	NOUN
dpc-1631	349	2	:	:	PUNCT
dpc-1631	349	3	10.1038	10.1038	NUM
dpc-1631	349	4	/	/	SYM
dpc-1631	349	5	jid.2014.438	jid.2014.438	PROPN
dpc-1631	349	6	.	.	PUNCT
dpc-1631	350	1	pmid	pmid	NOUN
dpc-1631	350	2	:	:	PUNCT
dpc-1631	350	3	25290686	25290686	NUM
dpc-1631	350	4	.	.	PUNCT
dpc-1631	351	1	32	32	NUM
dpc-1631	351	2	.	.	PUNCT
dpc-1631	352	1	choi	choi	PROPN
dpc-1631	352	2	ek	ek	PROPN
dpc-1631	352	3	,	,	PUNCT
dpc-1631	352	4	park	park	NOUN
dpc-1631	352	5	hb	hb	PROPN
dpc-1631	352	6	,	,	PUNCT
dpc-1631	352	7	lee	lee	PROPN
dpc-1631	352	8	kh	kh	PROPN
dpc-1631	352	9	,	,	PUNCT
dpc-1631	352	10	et	et	PROPN
dpc-1631	352	11	al	al	PROPN
dpc-1631	352	12	.	.	PROPN
dpc-1631	352	13	body	body	PROPN
dpc-1631	352	14	mass	mass	PROPN
dpc-1631	352	15	index	index	NOUN
dpc-1631	352	16	and	and	CCONJ
dpc-1631	352	17	20	20	NUM
dpc-1631	352	18	specific	specific	ADJ
dpc-1631	352	19	cancers	cancer	NOUN
dpc-1631	352	20	:	:	PUNCT
dpc-1631	352	21	re	re	NOUN
dpc-1631	352	22	-	-	NOUN
dpc-1631	352	23	analyses	analysis	NOUN
dpc-1631	352	24	of	of	ADP
dpc-1631	352	25	dose	dose	NOUN
dpc-1631	352	26	-	-	PUNCT
dpc-1631	352	27	response	response	NOUN
dpc-1631	352	28	meta	meta	NOUN
dpc-1631	352	29	-	-	PUNCT
dpc-1631	352	30	analyses	analysis	NOUN
dpc-1631	352	31	of	of	ADP
dpc-1631	352	32	observational	observational	ADJ
dpc-1631	352	33	studies	study	NOUN
dpc-1631	352	34	.	.	PUNCT
dpc-1631	353	1	ann	ann	PROPN
dpc-1631	353	2	oncol	oncol	PROPN
dpc-1631	353	3	.	.	PUNCT
dpc-1631	354	1	2018;29(3):749	2018;29(3):749	NUM
dpc-1631	354	2	-	-	PUNCT
dpc-1631	354	3	757	757	PROPN
dpc-1631	354	4	.	.	PUNCT
dpc-1631	355	1	doi	doi	NOUN
dpc-1631	355	2	:	:	PUNCT
dpc-1631	355	3	10.1093/	10.1093/	NUM
dpc-1631	355	4	annonc	annonc	VERB
dpc-1631	355	5	/	/	SYM
dpc-1631	355	6	mdx819	mdx819	NOUN
dpc-1631	355	7	.	.	PUNCT
dpc-1631	356	1	pmid	pmid	NOUN
dpc-1631	356	2	:	:	PUNCT
dpc-1631	356	3	29300814	29300814	NUM
dpc-1631	356	4	.	.	PUNCT
dpc-1631	357	1	33	33	NUM
dpc-1631	357	2	.	.	PUNCT
dpc-1631	358	1	gershenwald	gershenwald	PROPN
dpc-1631	358	2	je	je	PROPN
dpc-1631	358	3	,	,	PUNCT
dpc-1631	358	4	scolyer	scolyer	PROPN
dpc-1631	358	5	ra	ra	PROPN
dpc-1631	358	6	,	,	PUNCT
dpc-1631	358	7	hess	hess	PROPN
dpc-1631	358	8	kr	kr	PROPN
dpc-1631	358	9	,	,	PUNCT
dpc-1631	358	10	et	et	PROPN
dpc-1631	358	11	al	al	PROPN
dpc-1631	358	12	.	.	PUNCT
dpc-1631	358	13	melanoma	melanoma	PROPN
dpc-1631	358	14	staging	staging	NOUN
dpc-1631	358	15	:	:	PUNCT
dpc-1631	358	16	evidence	evidence	NOUN
dpc-1631	358	17	-	-	PUNCT
dpc-1631	358	18	based	base	VERB
dpc-1631	358	19	changes	change	NOUN
dpc-1631	358	20	in	in	ADP
dpc-1631	358	21	the	the	DET
dpc-1631	358	22	american	american	PROPN
dpc-1631	358	23	joint	joint	PROPN
dpc-1631	358	24	committee	committee	PROPN
dpc-1631	358	25	on	on	ADP
dpc-1631	358	26	cancer	cancer	NOUN
dpc-1631	358	27	eighth	eighth	PROPN
dpc-1631	358	28	edition	edition	NOUN
dpc-1631	358	29	cancer	cancer	NOUN
dpc-1631	358	30	staging	staging	NOUN
dpc-1631	358	31	manual	manual	NOUN
dpc-1631	358	32	.	.	PUNCT
dpc-1631	359	1	ca	can	AUX
dpc-1631	359	2	cancer	cancer	PROPN
dpc-1631	359	3	j	j	PROPN
dpc-1631	359	4	clin	clin	PROPN
dpc-1631	359	5	.	.	PUNCT
dpc-1631	360	1	2017;67(6):472	2017;67(6):472	NUM
dpc-1631	360	2	-	-	SYM
dpc-1631	360	3	492	492	NUM
dpc-1631	360	4	.	.	PUNCT
dpc-1631	361	1	doi	doi	NOUN
dpc-1631	361	2	:	:	PUNCT
dpc-1631	361	3	10.3322	10.3322	NUM
dpc-1631	361	4	/	/	SYM
dpc-1631	361	5	caac.21409	caac.21409	PROPN
dpc-1631	361	6	.	.	PUNCT
dpc-1631	362	1	pmid	pmid	NOUN
dpc-1631	362	2	:	:	PUNCT
dpc-1631	362	3	29028110	29028110	NUM
dpc-1631	362	4	.	.	PUNCT
dpc-1631	363	1	34	34	NUM
dpc-1631	363	2	.	.	PUNCT
dpc-1631	363	3	mcquade	mcquade	PROPN
dpc-1631	363	4	jl	jl	PROPN
dpc-1631	363	5	,	,	PUNCT
dpc-1631	363	6	daniel	daniel	PROPN
dpc-1631	363	7	cr	cr	PROPN
dpc-1631	363	8	,	,	PUNCT
dpc-1631	363	9	davies	davies	PROPN
dpc-1631	363	10	ma	ma	PROPN
dpc-1631	363	11	.	.	PROPN
dpc-1631	363	12	body	body	NOUN
dpc-1631	363	13	-	-	PUNCT
dpc-1631	363	14	mass	mass	NOUN
dpc-1631	363	15	index	index	NOUN
dpc-1631	363	16	and	and	CCONJ
dpc-1631	363	17	metastatic	metastatic	ADJ
dpc-1631	363	18	melanoma	melanoma	NOUN
dpc-1631	363	19	outcomes	outcome	NOUN
dpc-1631	363	20	authors	author	NOUN
dpc-1631	363	21	’	'	PUNCT
dpc-1631	363	22	reply	reply	NOUN
dpc-1631	363	23	.	.	PUNCT
dpc-1631	364	1	lancet	lancet	PROPN
dpc-1631	364	2	oncol	oncol	PROPN
dpc-1631	364	3	.	.	PUNCT
dpc-1631	365	1	2018;19(5):e227	2018;19(5):e227	PROPN
dpc-1631	365	2	-	-	PUNCT
dpc-1631	365	3	e228	e228	PROPN
dpc-1631	365	4	.	.	PUNCT
dpc-1631	365	5	doi	doi	PROPN
dpc-1631	365	6	:	:	PUNCT
dpc-1631	365	7	10.1016	10.1016	NUM
dpc-1631	365	8	/	/	SYM
dpc-1631	365	9	s1470	s1470	PROPN
dpc-1631	365	10	-	-	PUNCT
dpc-1631	365	11	2045(18)30266	2045(18)30266	NUM
dpc-1631	365	12	-	-	PUNCT
dpc-1631	365	13	3	3	NUM
dpc-1631	365	14	.	.	PUNCT
dpc-1631	366	1	pmid	pmid	NOUN
dpc-1631	366	2	:	:	PUNCT
dpc-1631	366	3	35	35	NUM
dpc-1631	366	4	.	.	PUNCT
dpc-1631	367	1	kushiro	kushiro	PROPN
dpc-1631	367	2	k	k	PROPN
dpc-1631	367	3	,	,	PUNCT
dpc-1631	367	4	chu	chu	PROPN
dpc-1631	367	5	ra	ra	PROPN
dpc-1631	367	6	,	,	PUNCT
dpc-1631	367	7	verma	verma	PROPN
dpc-1631	367	8	a	a	PROPN
dpc-1631	367	9	,	,	PUNCT
dpc-1631	367	10	núñez	núñez	PROPN
dpc-1631	367	11	np	np	INTJ
dpc-1631	367	12	.	.	PUNCT
dpc-1631	367	13	adipocytes	adipocyte	NOUN
dpc-1631	367	14	promote	promote	VERB
dpc-1631	367	15	b16bl6	b16bl6	NOUN
dpc-1631	367	16	melanoma	melanoma	NOUN
dpc-1631	367	17	cell	cell	NOUN
dpc-1631	367	18	invasion	invasion	NOUN
dpc-1631	367	19	and	and	CCONJ
dpc-1631	367	20	the	the	DET
dpc-1631	367	21	epithelial	epithelial	NOUN
dpc-1631	367	22	-	-	PUNCT
dpc-1631	367	23	to	to	ADP
dpc-1631	367	24	-	-	PUNCT
dpc-1631	367	25	mesenchymal	mesenchymal	NOUN
dpc-1631	367	26	transition	transition	NOUN
dpc-1631	367	27	.	.	PUNCT
dpc-1631	368	1	cancer	cancer	NOUN
dpc-1631	368	2	microenviron	microenviron	PROPN
dpc-1631	368	3	.	.	PUNCT
dpc-1631	369	1	2012;5(1):73	2012;5(1):73	NUM
dpc-1631	369	2	-	-	SYM
dpc-1631	369	3	82	82	NUM
dpc-1631	369	4	.	.	PUNCT
dpc-1631	369	5	doi	doi	NOUN
dpc-1631	369	6	:	:	PUNCT
dpc-1631	369	7	10.1007	10.1007	NUM
dpc-1631	369	8	/	/	SYM
dpc-1631	369	9	s12307	s12307	NOUN
dpc-1631	369	10	-	-	PUNCT
dpc-1631	369	11	011	011	NUM
dpc-1631	369	12	-	-	PUNCT
dpc-1631	369	13	0087	0087	NUM
dpc-1631	369	14	-	-	SYM
dpc-1631	369	15	2	2	NUM
dpc-1631	369	16	.	.	PUNCT
dpc-1631	370	1	pmid	pmid	NOUN
dpc-1631	370	2	:	:	PUNCT
dpc-1631	370	3	21892698	21892698	NUM
dpc-1631	370	4	.	.	PUNCT
dpc-1631	371	1	36	36	NUM
dpc-1631	371	2	.	.	PUNCT
dpc-1631	372	1	lazar	lazar	PROPN
dpc-1631	372	2	i	i	PROPN
dpc-1631	372	3	,	,	PUNCT
dpc-1631	372	4	clement	clement	PROPN
dpc-1631	372	5	e	e	PROPN
dpc-1631	372	6	,	,	PUNCT
dpc-1631	372	7	dauvillier	dauvillier	NOUN
dpc-1631	372	8	s	s	PROPN
dpc-1631	372	9	,	,	PUNCT
dpc-1631	372	10	et	et	PROPN
dpc-1631	372	11	al	al	PROPN
dpc-1631	372	12	.	.	PUNCT
dpc-1631	373	1	adipocyte	adipocyte	ADJ
dpc-1631	373	2	exosomes	exosome	NOUN
dpc-1631	373	3	promote	promote	VERB
dpc-1631	373	4	melanoma	melanoma	NOUN
dpc-1631	373	5	aggressiveness	aggressiveness	NOUN
dpc-1631	373	6	through	through	ADP
dpc-1631	373	7	fatty	fatty	NOUN
dpc-1631	373	8	acid	acid	NOUN
dpc-1631	373	9	oxidation	oxidation	NOUN
dpc-1631	373	10	:	:	PUNCT
dpc-1631	373	11	a	a	DET
dpc-1631	373	12	novel	novel	ADJ
dpc-1631	373	13	mechanism	mechanism	NOUN
dpc-1631	373	14	linking	link	VERB
dpc-1631	373	15	obesity	obesity	NOUN
dpc-1631	373	16	and	and	CCONJ
dpc-1631	373	17	cancer	cancer	NOUN
dpc-1631	373	18	.	.	PUNCT
dpc-1631	374	1	cancer	cancer	NOUN
dpc-1631	374	2	res	re	NOUN
dpc-1631	374	3	.	.	PUNCT
dpc-1631	375	1	2016;76(14):4051	2016;76(14):4051	NUM
dpc-1631	375	2	-	-	NOUN
dpc-1631	375	3	4057	4057	NUM
dpc-1631	375	4	.	.	PUNCT
dpc-1631	376	1	doi	doi	NOUN
dpc-1631	376	2	:	:	PUNCT
dpc-1631	376	3	10.1158/0008	10.1158/0008	NUM
dpc-1631	376	4	-	-	SYM
dpc-1631	376	5	5472.can-160651	5472.can-160651	NUM
dpc-1631	376	6	.	.	PUNCT
dpc-1631	377	1	pmid	pmid	NOUN
dpc-1631	377	2	:	:	PUNCT
dpc-1631	377	3	27216185	27216185	NUM
dpc-1631	377	4	.	.	PUNCT
dpc-1631	378	1	37	37	NUM
dpc-1631	378	2	.	.	PUNCT
dpc-1631	379	1	coelho	coelho	PROPN
dpc-1631	379	2	p	p	PROPN
dpc-1631	379	3	,	,	PUNCT
dpc-1631	379	4	almeida	almeida	PROPN
dpc-1631	379	5	j	j	PROPN
dpc-1631	379	6	,	,	PUNCT
dpc-1631	379	7	prudêncio	prudêncio	PROPN
dpc-1631	379	8	c	c	NOUN
dpc-1631	379	9	,	,	PUNCT
dpc-1631	379	10	fernandes	fernande	NOUN
dpc-1631	379	11	,	,	PUNCT
dpc-1631	379	12	r	r	PROPN
dpc-1631	379	13	,	,	PUNCT
dpc-1631	379	14	soares	soares	PROPN
dpc-1631	379	15	r.	r.	PROPN
dpc-1631	379	16	effect	effect	NOUN
dpc-1631	379	17	of	of	ADP
dpc-1631	379	18	adipocyte	adipocyte	ADJ
dpc-1631	379	19	secretome	secretome	NOUN
dpc-1631	379	20	in	in	ADP
dpc-1631	379	21	melanoma	melanoma	NOUN
dpc-1631	379	22	progression	progression	NOUN
dpc-1631	379	23	and	and	CCONJ
dpc-1631	379	24	vasculogenic	vasculogenic	ADJ
dpc-1631	379	25	mimicry	mimicry	NOUN
dpc-1631	379	26	.	.	PUNCT
dpc-1631	380	1	j	j	PROPN
dpc-1631	380	2	cell	cell	PROPN
dpc-1631	380	3	biochem	biochem	PROPN
dpc-1631	380	4	.	.	PUNCT
dpc-1631	381	1	2016;117(7):1697	2016;117(7):1697	NUM
dpc-1631	381	2	-	-	SYM
dpc-1631	381	3	1706	1706	NUM
dpc-1631	381	4	.	.	PUNCT
dpc-1631	382	1	doi	doi	NOUN
dpc-1631	382	2	:	:	PUNCT
dpc-1631	382	3	10.1002	10.1002	NUM
dpc-1631	382	4	/	/	SYM
dpc-1631	382	5	jcb.25463	jcb.25463	PROPN
dpc-1631	382	6	.	.	PUNCT
dpc-1631	383	1	pmid	pmid	NOUN
dpc-1631	383	2	:	:	PUNCT
dpc-1631	383	3	26666522	26666522	NUM
dpc-1631	383	4	.	.	PUNCT
dpc-1631	384	1	38	38	NUM
dpc-1631	384	2	.	.	PUNCT
dpc-1631	384	3	robado	robado	PROPN
dpc-1631	384	4	de	de	ADP
dpc-1631	384	5	lope	lope	PROPN
dpc-1631	384	6	l	l	PROPN
dpc-1631	384	7	,	,	PUNCT
dpc-1631	384	8	alcíbar	alcíbar	NOUN
dpc-1631	384	9	ol	ol	ADJ
dpc-1631	384	10	,	,	PUNCT
dpc-1631	384	11	amor	amor	PROPN
dpc-1631	384	12	lópez	lópez	PROPN
dpc-1631	384	13	a	a	DET
dpc-1631	384	14	,	,	PUNCT
dpc-1631	384	15	hergueta	hergueta	NOUN
dpc-1631	384	16	-	-	PUNCT
dpc-1631	384	17	redondo	redondo	PROPN
dpc-1631	384	18	m	m	PROPN
dpc-1631	384	19	,	,	PUNCT
dpc-1631	384	20	peinado	peinado	PROPN
dpc-1631	384	21	h.	h.	PROPN
dpc-1631	384	22	tumour	tumour	PROPN
dpc-1631	384	23	-	-	PUNCT
dpc-1631	384	24	adipose	adipose	NOUN
dpc-1631	384	25	tissue	tissue	NOUN
dpc-1631	384	26	crosstalk	crosstalk	NOUN
dpc-1631	384	27	:	:	PUNCT
dpc-1631	384	28	fuelling	fuel	VERB
dpc-1631	384	29	tumour	tumour	ADJ
dpc-1631	384	30	metastasis	metastasis	NOUN
dpc-1631	384	31	by	by	ADP
dpc-1631	384	32	extracellular	extracellular	ADJ
dpc-1631	384	33	vesicles	vesicle	NOUN
dpc-1631	384	34	.	.	PUNCT
dpc-1631	385	1	philos	philos	PROPN
dpc-1631	385	2	trans	trans	PROPN
dpc-1631	385	3	r	r	PROPN
dpc-1631	385	4	soc	soc	PROPN
dpc-1631	385	5	lond	lond	PROPN
dpc-1631	385	6	b	b	PROPN
dpc-1631	385	7	biol	biol	PROPN
dpc-1631	385	8	sci	sci	PROPN
dpc-1631	385	9	.	.	PROPN
dpc-1631	385	10	2018;373(1737	2018;373(1737	NUM
dpc-1631	385	11	)	)	PUNCT
dpc-1631	385	12	.	.	PUNCT
dpc-1631	386	1	doi	doi	NOUN
dpc-1631	386	2	:	:	PUNCT
dpc-1631	386	3	10.1098	10.1098	NUM
dpc-1631	386	4	/	/	SYM
dpc-1631	386	5	rstb.2016.0485	rstb.2016.0485	PROPN
dpc-1631	386	6	.	.	PUNCT
dpc-1631	387	1	pmid	pmid	NOUN
dpc-1631	387	2	:	:	PUNCT
dpc-1631	387	3	29158314	29158314	NUM
dpc-1631	387	4	.	.	PUNCT
dpc-1631	388	1	39	39	NUM
dpc-1631	388	2	.	.	PUNCT
dpc-1631	389	1	zhang	zhang	PROPN
dpc-1631	389	2	m	m	PROPN
dpc-1631	389	3	,	,	PUNCT
dpc-1631	389	4	di	di	PROPN
dpc-1631	389	5	martino	martino	PROPN
dpc-1631	389	6	js	js	PROPN
dpc-1631	389	7	,	,	PUNCT
dpc-1631	389	8	bowman	bowman	PROPN
dpc-1631	389	9	rl	rl	PROPN
dpc-1631	389	10	,	,	PUNCT
dpc-1631	389	11	et	et	PROPN
dpc-1631	389	12	al	al	PROPN
dpc-1631	389	13	.	.	PUNCT
dpc-1631	389	14	adipocyte	adipocyte	NOUN
dpc-1631	389	15	-	-	PUNCT
dpc-1631	389	16	derived	derive	VERB
dpc-1631	389	17	lipids	lipid	NOUN
dpc-1631	389	18	mediate	mediate	ADJ
dpc-1631	389	19	melanoma	melanoma	NOUN
dpc-1631	389	20	progression	progression	NOUN
dpc-1631	389	21	via	via	ADP
dpc-1631	389	22	fatp	fatp	ADJ
dpc-1631	389	23	proteins	protein	NOUN
dpc-1631	389	24	.	.	PUNCT
dpc-1631	390	1	cancer	cancer	NOUN
dpc-1631	390	2	discov	discov	NOUN
dpc-1631	390	3	.	.	PUNCT
dpc-1631	391	1	2018;8(8):1006	2018;8(8):1006	NUM
dpc-1631	391	2	-	-	SYM
dpc-1631	391	3	1025	1025	NUM
dpc-1631	391	4	.	.	PUNCT
dpc-1631	392	1	doi	doi	NOUN
dpc-1631	392	2	:	:	PUNCT
dpc-1631	392	3	10.1158/2159	10.1158/2159	NUM
dpc-1631	392	4	-	-	SYM
dpc-1631	392	5	8290.cd-171371	8290.cd-171371	NUM
dpc-1631	392	6	.	.	PUNCT
dpc-1631	393	1	pmid	pmid	NOUN
dpc-1631	393	2	:	:	PUNCT
dpc-1631	393	3	29903879	29903879	NUM
dpc-1631	393	4	.	.	PUNCT
dpc-1631	394	1	40	40	NUM
dpc-1631	394	2	.	.	PUNCT
dpc-1631	395	1	clement	clement	PROPN
dpc-1631	395	2	e	e	PROPN
dpc-1631	395	3	,	,	PUNCT
dpc-1631	395	4	lazar	lazar	PROPN
dpc-1631	395	5	i	i	PROPN
dpc-1631	395	6	,	,	PUNCT
dpc-1631	395	7	attané	attané	VERB
dpc-1631	395	8	c	c	AUX
dpc-1631	395	9	,	,	PUNCT
dpc-1631	395	10	et	et	PROPN
dpc-1631	395	11	al	al	PROPN
dpc-1631	395	12	.	.	PUNCT
dpc-1631	396	1	adipocyte	adipocyte	ADJ
dpc-1631	396	2	extracellular	extracellular	ADJ
dpc-1631	396	3	vesicles	vesicle	NOUN
dpc-1631	396	4	carry	carry	VERB
dpc-1631	396	5	enzymes	enzyme	NOUN
dpc-1631	396	6	and	and	CCONJ
dpc-1631	396	7	fatty	fatty	NOUN
dpc-1631	396	8	acids	acid	NOUN
dpc-1631	396	9	that	that	PRON
dpc-1631	396	10	stimulate	stimulate	VERB
dpc-1631	396	11	mitochondrial	mitochondrial	ADJ
dpc-1631	396	12	metabolism	metabolism	NOUN
dpc-1631	396	13	and	and	CCONJ
dpc-1631	396	14	remodeling	remodeling	NOUN
dpc-1631	396	15	in	in	ADP
dpc-1631	396	16	tumor	tumor	NOUN
dpc-1631	396	17	cells	cell	NOUN
dpc-1631	396	18	.	.	PUNCT
dpc-1631	397	1	embo	embo	PROPN
dpc-1631	397	2	j.	j.	PROPN
dpc-1631	397	3	2020;39(3):e102525	2020;39(3):e102525	PROPN
dpc-1631	397	4	.	.	PUNCT
dpc-1631	398	1	doi	doi	NOUN
dpc-1631	398	2	:	:	PUNCT
dpc-1631	398	3	10.15252	10.15252	NUM
dpc-1631	398	4	/	/	SYM
dpc-1631	398	5	embj.2019102525	embj.2019102525	PROPN
dpc-1631	398	6	.	.	PUNCT
dpc-1631	399	1	pmid	pmid	NOUN
dpc-1631	399	2	:	:	PUNCT
dpc-1631	399	3	31919869	31919869	NUM
dpc-1631	399	4	.	.	PUNCT
dpc-1631	400	1	41	41	NUM
dpc-1631	400	2	.	.	PUNCT
dpc-1631	401	1	chen	chen	PROPN
dpc-1631	401	2	j	j	PROPN
dpc-1631	401	3	,	,	PUNCT
dpc-1631	401	4	chi	chi	PROPN
dpc-1631	401	5	m	m	PROPN
dpc-1631	401	6	,	,	PUNCT
dpc-1631	401	7	chen	chen	PROPN
dpc-1631	401	8	c	c	PROPN
dpc-1631	401	9	,	,	PUNCT
dpc-1631	401	10	zhang	zhang	PROPN
dpc-1631	401	11	xd	xd	PROPN
dpc-1631	401	12	.	.	PUNCT
dpc-1631	401	13	obesity	obesity	NOUN
dpc-1631	401	14	and	and	CCONJ
dpc-1631	401	15	melanoma	melanoma	NOUN
dpc-1631	401	16	:	:	PUNCT
dpc-1631	401	17	exploring	explore	VERB
dpc-1631	401	18	molecular	molecular	ADJ
dpc-1631	401	19	links	link	NOUN
dpc-1631	401	20	.	.	PUNCT
dpc-1631	402	1	j	j	PROPN
dpc-1631	402	2	cell	cell	PROPN
dpc-1631	402	3	biochem	biochem	PROPN
dpc-1631	402	4	.	.	PUNCT
dpc-1631	403	1	2013;114(9):1955	2013;114(9):1955	NUM
dpc-1631	403	2	-	-	SYM
dpc-1631	403	3	1961	1961	NUM
dpc-1631	403	4	.	.	PUNCT
dpc-1631	404	1	doi	doi	NOUN
dpc-1631	404	2	:	:	PUNCT
dpc-1631	404	3	10.1002	10.1002	NUM
dpc-1631	404	4	/	/	SYM
dpc-1631	404	5	jcb.24549	jcb.24549	PROPN
dpc-1631	404	6	.	.	PUNCT
dpc-1631	405	1	pmid	pmid	NOUN
dpc-1631	405	2	:	:	PUNCT
dpc-1631	405	3	23554059	23554059	NUM
dpc-1631	405	4	.	.	PUNCT
dpc-1631	406	1	42	42	NUM
dpc-1631	406	2	.	.	PUNCT
dpc-1631	407	1	pandey	pandey	PROPN
dpc-1631	407	2	v	v	PROPN
dpc-1631	407	3	,	,	PUNCT
dpc-1631	407	4	vijayakumar	vijayakumar	PROPN
dpc-1631	407	5	mv	mv	PROPN
dpc-1631	407	6	,	,	PUNCT
dpc-1631	407	7	ajay	ajay	PROPN
dpc-1631	407	8	ak	ak	PROPN
dpc-1631	407	9	,	,	PUNCT
dpc-1631	407	10	malvi	malvi	VERB
dpc-1631	407	11	p	p	PRON
dpc-1631	407	12	,	,	PUNCT
dpc-1631	407	13	bhat	bhat	PROPN
dpc-1631	407	14	mk	mk	PROPN
dpc-1631	407	15	.	.	PUNCT
dpc-1631	408	1	diet	diet	NOUN
dpc-1631	408	2	-	-	PUNCT
dpc-1631	408	3	induced	induce	VERB
dpc-1631	408	4	obesity	obesity	NOUN
dpc-1631	408	5	increases	increase	VERB
dpc-1631	408	6	melanoma	melanoma	ADJ
dpc-1631	408	7	progression	progression	NOUN
dpc-1631	408	8	:	:	PUNCT
dpc-1631	408	9	involvement	involvement	NOUN
dpc-1631	408	10	of	of	ADP
dpc-1631	408	11	cav-1	cav-1	PUNCT
dpc-1631	408	12	and	and	CCONJ
dpc-1631	408	13	fasn	fasn	NOUN
dpc-1631	408	14	.	.	PUNCT
dpc-1631	409	1	int	int	PROPN
dpc-1631	409	2	j	j	PROPN
dpc-1631	409	3	cancer	cancer	NOUN
dpc-1631	409	4	.	.	PUNCT
dpc-1631	410	1	2012;130(3):497	2012;130(3):497	NUM
dpc-1631	410	2	-	-	SYM
dpc-1631	410	3	508	508	NUM
dpc-1631	410	4	.	.	PUNCT
dpc-1631	411	1	doi	doi	NOUN
dpc-1631	411	2	:	:	PUNCT
dpc-1631	411	3	10.1002	10.1002	NUM
dpc-1631	411	4	/	/	SYM
dpc-1631	411	5	ijc.26048	ijc.26048	PROPN
dpc-1631	411	6	.	.	PUNCT
dpc-1631	412	1	pmid	pmid	NOUN
dpc-1631	412	2	:	:	PUNCT
dpc-1631	412	3	21387314	21387314	NUM
dpc-1631	412	4	.	.	PUNCT
dpc-1631	413	1	43	43	NUM
dpc-1631	413	2	.	.	PUNCT
dpc-1631	413	3	malvi	malvi	VERB
dpc-1631	413	4	p	p	NOUN
dpc-1631	413	5	,	,	PUNCT
dpc-1631	413	6	chaube	chaube	NOUN
dpc-1631	413	7	b	b	PROPN
dpc-1631	413	8	,	,	PUNCT
dpc-1631	413	9	pandey	pandey	PROPN
dpc-1631	413	10	v	v	PROPN
dpc-1631	413	11	,	,	PUNCT
dpc-1631	414	1	et	et	PROPN
dpc-1631	414	2	al	al	PROPN
dpc-1631	414	3	.	.	PROPN
dpc-1631	414	4	obesity	obesity	PROPN
dpc-1631	414	5	induced	induce	VERB
dpc-1631	414	6	rapid	rapid	ADJ
dpc-1631	414	7	melanoma	melanoma	NOUN
dpc-1631	414	8	progression	progression	NOUN
dpc-1631	414	9	is	be	AUX
dpc-1631	414	10	reversed	reverse	VERB
dpc-1631	414	11	by	by	ADP
dpc-1631	414	12	orlistat	orlistat	NOUN
dpc-1631	414	13	treatment	treatment	NOUN
dpc-1631	414	14	and	and	CCONJ
dpc-1631	414	15	dietary	dietary	ADJ
dpc-1631	414	16	intervention	intervention	NOUN
dpc-1631	414	17	:	:	PUNCT
dpc-1631	414	18	role	role	NOUN
dpc-1631	414	19	of	of	ADP
dpc-1631	414	20	adipokines	adipokine	NOUN
dpc-1631	414	21	.	.	PUNCT
dpc-1631	415	1	mol	mol	ADP
dpc-1631	415	2	oncol	oncol	ADJ
dpc-1631	415	3	.	.	PUNCT
dpc-1631	416	1	2015;9(3):689	2015;9(3):689	X
dpc-1631	416	2	-	-	SYM
dpc-1631	416	3	703	703	NUM
dpc-1631	416	4	.	.	PUNCT
dpc-1631	417	1	doi	doi	NOUN
dpc-1631	417	2	:	:	PUNCT
dpc-1631	417	3	10.1016	10.1016	NUM
dpc-1631	417	4	/	/	SYM
dpc-1631	417	5	j.molonc.2014.11.006	j.molonc.2014.11.006	PROPN
dpc-1631	417	6	.	.	PUNCT
dpc-1631	418	1	pmid	pmid	NOUN
dpc-1631	418	2	:	:	PUNCT
dpc-1631	418	3	25499031	25499031	NUM
dpc-1631	418	4	.	.	PUNCT
dpc-1631	419	1	44	44	NUM
dpc-1631	419	2	.	.	PUNCT
dpc-1631	419	3	antoniadis	antoniadis	PROPN
dpc-1631	419	4	ag	ag	PROPN
dpc-1631	419	5	,	,	PUNCT
dpc-1631	419	6	petridou	petridou	NOUN
dpc-1631	419	7	et	et	NOUN
dpc-1631	419	8	,	,	PUNCT
dpc-1631	419	9	antonopoulos	antonopoulos	PROPN
dpc-1631	419	10	cn	cn	PROPN
dpc-1631	419	11	,	,	PUNCT
dpc-1631	419	12	et	et	PROPN
dpc-1631	419	13	al	al	PROPN
dpc-1631	419	14	.	.	PUNCT
dpc-1631	420	1	insulin	insulin	NOUN
dpc-1631	420	2	resistance	resistance	NOUN
dpc-1631	420	3	in	in	ADP
dpc-1631	420	4	relation	relation	NOUN
dpc-1631	420	5	to	to	ADP
dpc-1631	420	6	melanoma	melanoma	VERB
dpc-1631	420	7	risk	risk	NOUN
dpc-1631	420	8	.	.	PUNCT
dpc-1631	421	1	melanoma	melanoma	NOUN
dpc-1631	421	2	res	re	NOUN
dpc-1631	421	3	.	.	PUNCT
dpc-1631	422	1	2011;21(6):541	2011;21(6):541	NUM
dpc-1631	422	2	-	-	SYM
dpc-1631	422	3	546	546	NUM
dpc-1631	422	4	.	.	PUNCT
dpc-1631	423	1	doi	doi	NOUN
dpc-1631	423	2	:	:	PUNCT
dpc-1631	423	3	10.1097	10.1097	NUM
dpc-1631	423	4	/	/	SYM
dpc-1631	423	5	cmr.0b013e32834b0eeb	cmr.0b013e32834b0eeb	PROPN
dpc-1631	423	6	.	.	PUNCT
dpc-1631	424	1	pmid	pmid	NOUN
dpc-1631	424	2	:	:	PUNCT
dpc-1631	424	3	21946019	21946019	NUM
dpc-1631	424	4	.	.	PUNCT
dpc-1631	425	1	45	45	NUM
dpc-1631	425	2	.	.	PUNCT
dpc-1631	425	3	randerson	randerson	PROPN
dpc-1631	425	4	-	-	PUNCT
dpc-1631	425	5	moor	moor	PROPN
dpc-1631	425	6	ja	ja	PROPN
dpc-1631	425	7	,	,	PUNCT
dpc-1631	425	8	taylor	taylor	PROPN
dpc-1631	425	9	jc	jc	PROPN
dpc-1631	425	10	,	,	PUNCT
dpc-1631	425	11	elliott	elliott	PROPN
dpc-1631	425	12	f	f	PROPN
dpc-1631	425	13	,	,	PUNCT
dpc-1631	425	14	et	et	PROPN
dpc-1631	425	15	al	al	PROPN
dpc-1631	425	16	.	.	PUNCT
dpc-1631	426	1	vitamin	vitamin	NOUN
dpc-1631	426	2	d	d	NOUN
dpc-1631	426	3	receptor	receptor	NOUN
dpc-1631	426	4	gene	gene	NOUN
dpc-1631	426	5	polymorphisms	polymorphism	NOUN
dpc-1631	426	6	,	,	PUNCT
dpc-1631	426	7	serum	serum	NOUN
dpc-1631	426	8	25	25	NUM
dpc-1631	426	9	-	-	PUNCT
dpc-1631	426	10	hydroxyvitamin	hydroxyvitamin	NOUN
dpc-1631	426	11	d	d	NOUN
dpc-1631	426	12	levels	level	NOUN
dpc-1631	426	13	,	,	PUNCT
dpc-1631	426	14	and	and	CCONJ
dpc-1631	426	15	melanoma	melanoma	NOUN
dpc-1631	426	16	:	:	PUNCT
dpc-1631	426	17	uk	uk	PROPN
dpc-1631	426	18	case	case	NOUN
dpc-1631	426	19	–	–	PUNCT
dpc-1631	426	20	control	control	NOUN
dpc-1631	426	21	comparisons	comparison	NOUN
dpc-1631	426	22	and	and	CCONJ
dpc-1631	426	23	a	a	DET
dpc-1631	426	24	meta	meta	ADJ
dpc-1631	426	25	-	-	PUNCT
dpc-1631	426	26	analysis	analysis	NOUN
dpc-1631	426	27	of	of	ADP
dpc-1631	426	28	published	publish	VERB
dpc-1631	426	29	vdr	vdr	NOUN
dpc-1631	426	30	data	datum	NOUN
dpc-1631	426	31	.	.	PUNCT
dpc-1631	427	1	eur	eur	PROPN
dpc-1631	427	2	j	j	PROPN
dpc-1631	427	3	cancer	cancer	NOUN
dpc-1631	427	4	.	.	PUNCT
dpc-1631	428	1	2009;45(18):3271	2009;45(18):3271	NUM
dpc-1631	428	2	-	-	SYM
dpc-1631	428	3	3281	3281	NUM
dpc-1631	428	4	.	.	PUNCT
dpc-1631	429	1	doi	doi	NOUN
dpc-1631	429	2	:	:	PUNCT
dpc-1631	429	3	10.1016	10.1016	NUM
dpc-1631	429	4	/	/	SYM
dpc-1631	429	5	j.ejca.2009.06.011	j.ejca.2009.06.011	PROPN
dpc-1631	429	6	.	.	PUNCT
dpc-1631	430	1	pmid	pmid	NOUN
dpc-1631	430	2	:	:	PUNCT
dpc-1631	430	3	19615888	19615888	NUM
dpc-1631	430	4	.	.	PUNCT
dpc-1631	431	1	46	46	NUM
dpc-1631	431	2	.	.	X
dpc-1631	431	3	fang	fang	PROPN
dpc-1631	431	4	s	s	PROPN
dpc-1631	431	5	,	,	PUNCT
dpc-1631	431	6	sui	sui	PROPN
dpc-1631	431	7	d	d	PROPN
dpc-1631	431	8	,	,	PUNCT
dpc-1631	431	9	wang	wang	PROPN
dpc-1631	431	10	y	y	PROPN
dpc-1631	431	11	,	,	PUNCT
dpc-1631	431	12	et	et	PROPN
dpc-1631	431	13	al	al	PROPN
dpc-1631	431	14	.	.	PROPN
dpc-1631	431	15	association	association	PROPN
dpc-1631	431	16	of	of	ADP
dpc-1631	431	17	vitamin	vitamin	NOUN
dpc-1631	431	18	d	d	PROPN
dpc-1631	431	19	levels	level	NOUN
dpc-1631	431	20	with	with	ADP
dpc-1631	431	21	outcome	outcome	NOUN
dpc-1631	431	22	in	in	ADP
dpc-1631	431	23	patients	patient	NOUN
dpc-1631	431	24	with	with	ADP
dpc-1631	431	25	melanoma	melanoma	NOUN
dpc-1631	431	26	after	after	ADP
dpc-1631	431	27	adjustment	adjustment	NOUN
dpc-1631	431	28	for	for	ADP
dpc-1631	431	29	c	c	NOUN
dpc-1631	431	30	-	-	PUNCT
dpc-1631	431	31	reactive	reactive	ADJ
dpc-1631	431	32	protein	protein	NOUN
dpc-1631	431	33	.	.	PUNCT
dpc-1631	432	1	j	j	PROPN
dpc-1631	432	2	clin	clin	PROPN
dpc-1631	432	3	oncol	oncol	PROPN
dpc-1631	432	4	.	.	PUNCT
dpc-1631	433	1	2016;34(15):1741–1747	2016;34(15):1741–1747	X
dpc-1631	433	2	.	.	PUNCT
dpc-1631	433	3	doi	doi	NOUN
dpc-1631	433	4	:	:	PUNCT
dpc-1631	433	5	10.1200	10.1200	NUM
dpc-1631	433	6	/	/	SYM
dpc-1631	433	7	jco.2015.64.1357	jco.2015.64.1357	PROPN
dpc-1631	433	8	.	.	PUNCT
dpc-1631	434	1	pmid	pmid	NOUN
dpc-1631	434	2	:	:	PUNCT
dpc-1631	434	3	27001565	27001565	NUM
dpc-1631	434	4	.	.	PUNCT
dpc-1631	435	1	47	47	NUM
dpc-1631	435	2	.	.	PUNCT
dpc-1631	435	3	moreno	moreno	PROPN
dpc-1631	435	4	-	-	PUNCT
dpc-1631	435	5	arrones	arrones	PROPN
dpc-1631	435	6	om	om	PROPN
dpc-1631	435	7	,	,	PUNCT
dpc-1631	435	8	zegeer	zegeer	PROPN
dpc-1631	435	9	j	j	PROPN
dpc-1631	435	10	,	,	PUNCT
dpc-1631	435	11	et	et	PROPN
dpc-1631	435	12	al	al	PROPN
dpc-1631	435	13	.	.	PROPN
dpc-1631	435	14	decreased	decrease	VERB
dpc-1631	435	15	vitamin	vitamin	NOUN
dpc-1631	435	16	d	d	PROPN
dpc-1631	435	17	serum	serum	NOUN
dpc-1631	435	18	levels	level	NOUN
dpc-1631	435	19	at	at	ADP
dpc-1631	435	20	melanoma	melanoma	ADJ
dpc-1631	435	21	diagnosis	diagnosis	NOUN
dpc-1631	435	22	are	be	AUX
dpc-1631	435	23	associated	associate	VERB
dpc-1631	435	24	with	with	ADP
dpc-1631	435	25	tumor	tumor	NOUN
dpc-1631	435	26	ulceration	ulceration	NOUN
dpc-1631	435	27	and	and	CCONJ
dpc-1631	435	28	high	high	ADJ
dpc-1631	435	29	tumor	tumor	NOUN
dpc-1631	435	30	mitotic	mitotic	ADJ
dpc-1631	435	31	rate	rate	NOUN
dpc-1631	435	32	.	.	PUNCT
dpc-1631	436	1	melanoma	melanoma	NOUN
dpc-1631	436	2	res	re	NOUN
dpc-1631	436	3	.	.	PUNCT
dpc-1631	437	1	2019;29:664	2019;29:664	X
dpc-1631	437	2	-	-	SYM
dpc-1631	437	3	667	667	NUM
dpc-1631	437	4	.	.	PUNCT
dpc-1631	438	1	doi	doi	NOUN
dpc-1631	438	2	:	:	PUNCT
dpc-1631	438	3	10.1097	10.1097	NUM
dpc-1631	438	4	/	/	SYM
dpc-1631	438	5	cmr.0000000000000638	cmr.0000000000000638	NOUN
dpc-1631	438	6	.	.	PUNCT
dpc-1631	439	1	pmid	pmid	NOUN
dpc-1631	439	2	:	:	PUNCT
dpc-1631	439	3	31469708	31469708	NUM
dpc-1631	439	4	.	.	PUNCT
dpc-1631	440	1	48	48	NUM
dpc-1631	440	2	.	.	PUNCT
dpc-1631	441	1	li	li	PROPN
dpc-1631	441	2	x	x	PROPN
dpc-1631	441	3	,	,	PUNCT
dpc-1631	441	4	liang	liang	PROPN
dpc-1631	441	5	lm	lm	PROPN
dpc-1631	441	6	,	,	PUNCT
dpc-1631	441	7	zhang	zhang	PROPN
dpc-1631	441	8	mf	mf	PROPN
dpc-1631	441	9	,	,	PUNCT
dpc-1631	441	10	et	et	PROPN
dpc-1631	441	11	al	al	PROPN
dpc-1631	441	12	.	.	PUNCT
dpc-1631	441	13	obesity	obesity	NOUN
dpc-1631	441	14	-	-	PUNCT
dpc-1631	441	15	related	relate	VERB
dpc-1631	441	16	genetic	genetic	ADJ
dpc-1631	441	17	variants	variant	NOUN
dpc-1631	441	18	,	,	PUNCT
dpc-1631	441	19	human	human	ADJ
dpc-1631	441	20	pigmentation	pigmentation	NOUN
dpc-1631	441	21	,	,	PUNCT
dpc-1631	441	22	and	and	CCONJ
dpc-1631	441	23	risk	risk	NOUN
dpc-1631	441	24	of	of	ADP
dpc-1631	441	25	melanoma	melanoma	NOUN
dpc-1631	441	26	.	.	PUNCT
dpc-1631	442	1	hum	hum	PROPN
dpc-1631	442	2	genet	genet	PROPN
dpc-1631	442	3	.	.	PUNCT
dpc-1631	443	1	2013;132(7):793	2013;132(7):793	NUM
dpc-1631	443	2	-	-	SYM
dpc-1631	443	3	801	801	NUM
dpc-1631	443	4	.	.	PUNCT
dpc-1631	444	1	doi	doi	NOUN
dpc-1631	444	2	:	:	PUNCT
dpc-1631	444	3	10.1007	10.1007	NUM
dpc-1631	444	4	/	/	SYM
dpc-1631	444	5	s00439	s00439	NOUN
dpc-1631	444	6	-	-	PUNCT
dpc-1631	444	7	013	013	NUM
dpc-1631	444	8	-	-	PUNCT
dpc-1631	444	9	1293	1293	NUM
dpc-1631	444	10	-	-	SYM
dpc-1631	444	11	4	4	NUM
dpc-1631	444	12	.	.	PUNCT
dpc-1631	445	1	pmid	pmid	NOUN
dpc-1631	445	2	:	:	PUNCT
dpc-1631	445	3	23539184	23539184	NUM
dpc-1631	445	4	.	.	PUNCT
dpc-1631	446	1	49	49	NUM
dpc-1631	446	2	.	.	PUNCT
dpc-1631	447	1	de	de	PROPN
dpc-1631	447	2	giorgi	giorgi	PROPN
dpc-1631	447	3	v	v	NOUN
dpc-1631	447	4	,	,	PUNCT
dpc-1631	447	5	sestini	sestini	NOUN
dpc-1631	447	6	s	s	PROPN
dpc-1631	447	7	,	,	PUNCT
dpc-1631	447	8	gori	gori	X
dpc-1631	447	9	a	a	X
dpc-1631	447	10	,	,	PUNCT
dpc-1631	447	11	et	et	PROPN
dpc-1631	447	12	al	al	PROPN
dpc-1631	447	13	.	.	PUNCT
dpc-1631	447	14	polymorphisms	polymorphism	NOUN
dpc-1631	447	15	of	of	ADP
dpc-1631	447	16	estrogen	estrogen	NOUN
dpc-1631	447	17	receptors	receptor	NOUN
dpc-1631	447	18	:	:	PUNCT
dpc-1631	447	19	risk	risk	NOUN
dpc-1631	447	20	factors	factor	NOUN
dpc-1631	447	21	for	for	ADP
dpc-1631	447	22	invasive	invasive	ADJ
dpc-1631	447	23	melanoma	melanoma	NOUN
dpc-1631	447	24	a	a	DET
dpc-1631	447	25	prospective	prospective	ADJ
dpc-1631	447	26	study	study	NOUN
dpc-1631	447	27	.	.	PUNCT
dpc-1631	448	1	oncology	oncology	NOUN
dpc-1631	448	2	.	.	PUNCT
dpc-1631	449	1	2011;80(3	2011;80(3	X
dpc-1631	449	2	-	-	PUNCT
dpc-1631	449	3	4):232	4):232	NUM
dpc-1631	449	4	-	-	PUNCT
dpc-1631	449	5	237	237	NUM
dpc-1631	449	6	.	.	PUNCT
dpc-1631	450	1	doi	doi	NOUN
dpc-1631	450	2	:	:	PUNCT
dpc-1631	450	3	10.1159/000328321	10.1159/000328321	NUM
dpc-1631	450	4	.	.	PUNCT
dpc-1631	451	1	pmid	pmid	NOUN
dpc-1631	451	2	:	:	PUNCT
dpc-1631	451	3	21734414	21734414	NUM
dpc-1631	451	4	.	.	PUNCT
dpc-1631	452	1	50	50	NUM
dpc-1631	452	2	.	.	PUNCT
dpc-1631	453	1	santonocito	santonocito	PROPN
dpc-1631	453	2	c	c	PROPN
dpc-1631	453	3	,	,	PUNCT
dpc-1631	453	4	paradisi	paradisi	VERB
dpc-1631	453	5	a	a	DET
dpc-1631	453	6	,	,	PUNCT
dpc-1631	453	7	capizzi	capizzi	NOUN
dpc-1631	453	8	r	r	NOUN
dpc-1631	453	9	,	,	PUNCT
dpc-1631	453	10	et	et	PROPN
dpc-1631	453	11	al	al	PROPN
dpc-1631	453	12	.	.	PUNCT
dpc-1631	454	1	insulin	insulin	NOUN
dpc-1631	454	2	-	-	PUNCT
dpc-1631	454	3	like	like	ADJ
dpc-1631	454	4	growth	growth	NOUN
dpc-1631	454	5	factor	factor	NOUN
dpc-1631	454	6	i	i	PRON
dpc-1631	454	7	(	(	PUNCT
dpc-1631	454	8	ca	ca	NOUN
dpc-1631	454	9	)	)	PUNCT
dpc-1631	454	10	repeats	repeat	NOUN
dpc-1631	454	11	are	be	AUX
dpc-1631	454	12	associated	associate	VERB
dpc-1631	454	13	with	with	ADP
dpc-1631	454	14	higher	high	ADJ
dpc-1631	454	15	melanoma	melanoma	PROPN
dpc-1631	454	16	’s	’s	PART
dpc-1631	454	17	breslow	breslow	ADJ
dpc-1631	454	18	index	index	NOUN
dpc-1631	454	19	but	but	CCONJ
dpc-1631	454	20	not	not	PART
dpc-1631	454	21	associated	associate	VERB
dpc-1631	454	22	with	with	ADP
dpc-1631	454	23	the	the	DET
dpc-1631	454	24	presence	presence	NOUN
dpc-1631	454	25	of	of	ADP
dpc-1631	454	26	the	the	DET
dpc-1631	454	27	melanoma	melanoma	NOUN
dpc-1631	454	28	.	.	PUNCT
dpc-1631	455	1	a	a	DET
dpc-1631	455	2	pilot	pilot	NOUN
dpc-1631	455	3	study	study	NOUN
dpc-1631	455	4	.	.	PUNCT
dpc-1631	456	1	clin	clin	PROPN
dpc-1631	456	2	chim	chim	PROPN
dpc-1631	456	3	acta	acta	PROPN
dpc-1631	456	4	.	.	PUNCT
dpc-1631	457	1	2008;390(1	2008;390(1	NUM
dpc-1631	457	2	-	-	PUNCT
dpc-1631	457	3	2):104	2):104	NUM
dpc-1631	457	4	-	-	PUNCT
dpc-1631	457	5	9	9	NUM
dpc-1631	457	6	.	.	PUNCT
dpc-1631	457	7	doi	doi	NOUN
dpc-1631	457	8	:	:	PUNCT
dpc-1631	457	9	10.1016	10.1016	NUM
dpc-1631	457	10	/	/	SYM
dpc-1631	457	11	j.cca.2008.01.006	j.cca.2008.01.006	PROPN
dpc-1631	457	12	.	.	PUNCT
dpc-1631	458	1	pmid	pmid	NOUN
dpc-1631	458	2	:	:	PUNCT
dpc-1631	458	3	18237549	18237549	NUM
dpc-1631	458	4	.	.	PUNCT